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"Something has changed within me, 
something is not the same. 
I'm through with playing by 
the rules of someone else's game! 
Too late for second-guessing, 
too late to go back to sleep. 
It's time to trust my instincts, 
close my eyes 
and leap... 
 
It's time to try defying gravity, 
I think I'll try defying gravity... 
and you can't pull me down!" 
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and 
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I love you!	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Melanoma	   is	   the	   most	   aggressive	   skin	   cancer	   with	   very	   limited	   treatment	   options.	   Upon	  
appearance	   of	   metastases	   chemotherapeutics	   are	   used	   to	   either	   kill	   or	   slow	   down	   the	  
growth	  of	  cancer	  cells	  by	   inducing	  apoptosis	  or	  senescence,	   respectively.	  With	  melanomas	  
originating	   from	   melanocytes,	   it	   is	   vital	   to	   elucidate	   the	   mechanisms	   that	   distinguish	  
senescence	  induction	  from	  proliferation	  and	  tumourigenicity.	  	  
Xmrk	  (Xiphophorus	  melanoma	  receptor	  kinase),	  the	  fish	  orthologue	  of	  the	  human	  epidermal	  
growth	  factor	  receptor	  (EGFR),	  causes	  highly	  aggressive	  melanoma	  in	  fish.	  Using	  an	  inducible	  
variant,	   HERmrk,	   I	   showed	   that	   high	   receptor	   levels	   result	   in	   melanocyte	   senescence,	  
whereas	   low	   and	   medium	   expression	   allows	   for	   cell	   proliferation	   and	   tumourigenicity.	  
Mechanistically,	   HERmrk	   leads	   to	   increased	   reactive	   oxygen	   species	   (ROS)	   levels,	   which	  
trigger	  a	  DNA	  damage	  response.	  Consequently,	  multinucleated,	  senescent	  cells	  develop	  by	  
both	   endomitosis	   and	   fusion.	   Furthermore,	   oncogenic	   N-­‐RAS	   (N-­‐RAS61K)	   induces	   a	   similar	  
multinucleated	  phenotype	  in	  melanocytes.	  
In	  addition,	   I	   found	  that	  both	  overexpression	  of	  C-­‐MYC	  and	  the	  knockdown	  of	  miz-­‐1	   (Myc-­‐
interacting	   zinc	   finger	   protein	   1)	   diminished	   HERmrk-­‐induced	   senescence	   entry.	   C-­‐MYC	  
prevent	   ROS	   induction,	   DNA	   damage	   and	   senescence,	   while	   acting	   synergistically	   with	  
HERmrk	   in	   conveying	   tumourigenic	   features	   to	   melanocytes.	   Further	   analyses	   identified	  
cystathionase	   (CTH)	   as	   a	   novel	   target	   gene	   of	   Myc	   and	   Miz-­‐1	   crucial	   for	   senescence	  
prevention.	  CTH	  encodes	  an	  enzyme	  involved	  in	  the	  synthesis	  of	  cysteine	  from	  methionine,	  
thereby	  allowing	  for	  increased	  ROS	  detoxification.	  	  
Even	   though	   senescence	   was	   thought	   to	   be	   irreversible	   and	   hence	   tumour	   protective,	   I	  
demonstrated	   that	   prolonged	   expression	   of	   the	  melanoma	  oncogene	  N-­‐RAS61K	   in	   pigment	  
cells	  overcomes	  initial	  OIS	  by	  triggering	  the	  emergence	  of	  tumour-­‐initiating,	  mononucleated	  
stem-­‐like	  cells	  from	  multinucleated	  senescent	  cells.	  This	  progeny	  is	  dedifferentiated,	  highly	  
proliferative,	   anoikis-­‐resistant	   and	   induces	   fast-­‐growing,	   metastatic	   tumours	   upon	  
transplantation	   into	   nude	  mice.	  Our	   data	   demonstrate	   that	   induction	   of	  OIS	   is	   not	   only	   a	  
cellular	   failsafe	   mechanism,	   but	   also	   carries	   the	   potential	   to	   provide	   a	   source	   for	   highly	  




Das	   Melanom	   ist	   der	   aggressivste	   Hautkrebstyp	   mit	   äußerst	   begrenzten	  
Therapiemöglichkeiten.	   Sobald	   Metastasen	   diagnostiziert	   werden,	   kommen	  
Chemotherapeutika	   zum	   Einsatz,	   deren	   Aufgabe	   darin	   besteht,	   die	   Krebszellen	   durch	  
Apotoseinduktion	   zu	   töten	   oder	   ihre	   Verbreitung	   mittels	   Seneszenz	   zu	   verlangsamen.	   Da	  
Melanome	  aus	  Melanozyten	  hervorgehen,	  ist	  es	  essentiell,	  die	  Mechanismen	  zu	  analysieren,	  
die	  entscheiden,	  ob	  Zellen	  seneszent	  oder	  tumorigen	  werden.	  	  
Xmrk,	   die	   Xiphophorus-­‐Melanom-­‐Rezeptor-­‐Kinase	   und	   Fischortholog	   des	   humanen	  
epidermalen	  Wachstumsfaktors	   (EGFR),	  verursacht	  aggressive	  Melanome	   in	  Fischen.	  Durch	  
den	  Einsatz	  von	  HERmrk,	  einer	  induzierbaren	  Variante	  des	  Rezeptors,	  konnte	  ich	  zeigen,	  dass	  
hohe	  Expressionslevel	  Seneszenz	  in	  Melanozyten	  zur	  Folge	  haben,	  wohingegen	  niedrige	  oder	  
mittlere	   Rezeptorlevel	   mit	   erhöhter	   Zellproliferation	   und	   Tumorigenität	   der	   Zellen	  
einhergehen.	   Mechanistisch	   gesehen,	   führt	   die	   Aktivierung	   von	   HERmrk	   zu	   gesteigerten	  
Level	   an	   reaktiven	   Sauerstoffspezies	   (ROS),	   die	   wiederum	   DNA-­‐Schäden	   verursachen	   und	  
dadurch	   bestimmte	   Signalwege	   auslösen.	   Durch	   Endomitose	   und	   Fusion	   entstehen	  
letztendlich	  multinukleäre,	  seneszente	  Zellen.	  Interessanterweise,	  führte	  die	  Expression	  von	  
onkogenem	  N-­‐RAS	  (N-­‐RAS61K)	  in	  Melanozyten	  zu	  einem	  	  sehr	  ähnlichen	  Phänotyp.	  
Des	  Weiteren	   konnte	   ich	   zeigen,	   dass	   sowohl	   die	  Überexpression	   von	  C-­‐MYC	  als	   auch	  der	  
Knockdown	   von	  miz-­‐1	   (Myc-­‐interagierendes	   Zinkfingerprotein	   1)	   der	   HER-­‐mrk-­‐induzierten	  
Seneszenz	   entgegenwirkten.	   C-­‐MYC	   verhindert	   einerseits	   die	   Entstehung	   von	   ROS,	   die	  
dadurch	   verursachten	   DNA-­‐Schäden	   und	   damit	   die	   Seneszenz	   und	   wirkt	   andererseits	  
synergistisch	  mit	  HERmrk,	  indem	  es	  den	  Melanozyten	  tumorigene	  Eigenschaften	  verleiht.	  In	  
weiteren	   Analysen	   wurde	   Cystathionase	   (CTH)	   als	   neues	   Zielgen	   von	   Myc	   und	   Miz-­‐1	  
identifiziert,	  dem	  eine	  zentrale	  Rolle	   in	  der	  Seneszenzverhinderung	  zukommt.	   	  CTH	  kodiert	  
für	  ein	  Enzym,	  das	  die	  Synthese	  von	  Cystein	  aus	  Methionin	  und	  damit	  die	  Entsorgung	  von	  
ROS	  ermöglicht.	  	  
Obwohl	  man	  davon	  ausgeht,	  dass	  Seneszenz	  einen	  irreversiblen	  Mechanismus	  darstellt,	  der	  
die	   Tumorentstehung	   verhindert,	   konnte	   ich	   zeigen,	   dass	   die	   langfristige	   Expression	   des	  
Melanomonkogens	   N-­‐RAS61K	   die	   initiale	   Seneszenzinduktion	   durchbricht.	   Dabei	   gehen	  
mononukleäre,	  tumorigene,	  stammzellähnliche	  Zellen	  aus	  seneszenten	  Zellen	  hervor.	  Diese	  
Tochterzellen	   sind	   dedifferenziert,	   hochproliferativ,	   Anoikis-­‐resistent	   und	   induzieren	  
schnellwachsende,	  metastasierende	  Tumoren	  in	  Nacktmäusen.	  Damit	  machen	  meine	  Daten	  
deutlich,	  dass	  Seneszenz	  nicht	  nur	  als	  zellulärer	  Schadensbegrenzungsmechanismus	  fungiert,	  





Malignant	   melanoma	   is	   the	   most	   aggressive	   form	   of	   skin	   cancer	   with	   the	   number	   of	  
melanoma	   cases	   worldwide	   increasing	   faster	   than	   that	   of	   any	   other	   type	   of	   cancer	   1.	  
Estimates	   even	   suggest	   a	   doubling	   of	  melanoma	   incidence	   every	   10–20	   years	   2.	   Although	  
melanoma	  only	  accounts	  for	  about	  4%	  of	  skin	  cancer	  cases,	  it	  does	  so	  for	  as	  many	  as	  74%	  of	  
all	   related	  deaths.	   In	   2002,	   the	  World	  Health	  Organization	   (WHO)	  estimated	  160.000	  new	  
cases	   of	   malignant	   melanoma	   worldwide	   and	   reported	   41.000	   deaths	   caused	   by	   this	  
dreadful	  disease	  3.	  Even	  though	  there	  is	  a	  good	  chance	  for	  the	  recovery	  of	  patients	  suffering	  
from	  melanoma	   if	   the	   primary	   lesion	   is	   detected	   and	   excised	   very	   early	   (more	   than	   90%	  
survival	  in	  stage	  I	  melanomas),	  prognosis	  for	  5-­‐year	  survival	  for	  more	  advanced	  melanomas	  
drops	   to	   approximately	   60%	   of	   cases	   (stage	   II)	   and	   to	   as	   low	   as	   10%	   (stage	   III)	   before	  
reaching	  almost	  complete	  fatality	  (stage	  IV)	  usually	  within	  less	  than	  6-­‐8	  months	  4–6.	  Notably,	  
melanomas	   of	   as	   little	   as	   4	   millimeters	   in	   diameter	   are	   usually	   associated	   with	   distant	  
metastases.	   Hence,	   metastasis	   occurs	   very	   early	   in	   the	   progression	   of	   the	   disease.	   Once	  
melanomas	  have	  metastasized	   to	  distant	  organs,	   they	  are	  classified	  as	   stage	   IV	  melanoma	  
(Figure	   1)	   7.	   These	   data	   underline	   the	   current	   lack	   of	   therapeutic	   approaches	   to	   treat	  
advanced	   melanoma.	   Beyond	   an	   early	   surgical	   removal	   of	   the	   primary	   tumour	   after	  
diagnosis,	   there	   is	   currently	   no	   promising	   standard	   therapy	   available	   for	   treatment	   of	  
advanced	  melanomas.	  	  
Hence,	   it	   is	  not	  surprising	  that	  malignant	  melanoma	  is	  one	  of	  the	  most	  aggressive	  types	  of	  
human	  cancers	  8.	  Most	  frequently	  arising	  in	  the	  skin,	  melanomas	  can	  evolve	  from	  benign	  or	  
pre-­‐malignant	   aggregations	   of	  melanocytes,	   termed	   nevi	   9.	   It	   is	   noteworthy	   that	   nevi	   are	  
considered	   permanently	   growth-­‐arrested	   (or	   “senescent”)	   and	   are	   thought	   to	   rarely	  
progress	   into	  melanoma.	   Indeed,	   studies	   showed	   that	   human	   nevi,	  most	   of	  which	   bear	   a	  
BRAFV600E	  mutation,	  are	  invariably	  positive	  for	  senescence-­‐associated-­‐β-­‐galactosidase	  (SA-­‐β-­‐
Gal),	  one	  of	   the	   classical	   senescence	  markers	   10–12.	  Nevertheless,	   traditionally,	   five	  distinct	  
steps	  of	  melanoma	  development	  and	  progression	  are	  distinguished:	  A	  dysplastic	  nevus	   (2)	  
showing	  a	  high	  level	  of	  structural	  and	  architectural	  changes	  arises	  from	  a	  common	  nevus	  (1).	  
The	  subsequent	  radial	  growth	  phase	  (RGP)	  primary	  melanoma	  (3;	  stage	  I	  melanoma)	  is	  the	  
first	  recognizable	  malignant	  stage	  in	  which	  cells	  do	  not	  yet	  possess	  metastatic	  potential	  but	  
are	   already	   locally	   invasive.	   This	   means	   that	   the	   epidermis	   that	   covers	   a	   portion	   of	   the	  
primary	   tumour	   might	   no	   longer	   be	   intact.	   The	   RGP	   can	   be	   followed	   by	   a	   VGP	   (vertical	  
growth	  phase)	   leading	   to	  primary	  melanoma	   lesions	   (4)	   in	  which	  melanoma	  cells	   infiltrate	  
and	  invade	  the	  dermis	  and	  finally	  the	  subcutis	  (late	  stage	  I	  melanoma).	  Besides,	  the	  tumour	  
cells	  bear	  metastatic	  potential	  even	   though	   they	  have	  not	  metastasized	   to	   local	  or	  distant	  
lymph	   nodes	   (stage	   II	  melanoma).	   Once	   the	  melanoma	   has	  metastasized	   to	   local	   but	   not	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distant	   lymph	   nodes,	   it	   is	   classified	   as	   stage	   III	   melanoma.	   This	   process	   finally	   results	   in	  
metastasis	  to	  distant	  lymph	  nodes	  and	  organs	  (5;	  stage	  IV	  melanoma;	  Figure	  1	  and	  2)	  13.	  	  
	  
Figure	  1:	  Characteristics	  of	  melanoma	  stages	  and	  the	  corresponding	  5-­‐year	  survival	  rates	  
Melanomas	  are	  staged	  (I-­‐IV)	  according	  to	  tumour	  size,	  localization,	  recurrence	  and	  metastasis	  risk	  level	  as	  well	  
as	   the	   presence	   and	   location	   of	  metastases.	   The	   corresponding	   5-­‐year	   survival	   rates	   for	  melanoma	  patients	  





Figure	  2:	  Five	  steps	  of	  melanoma	  development	  
Traditionally,	   five	   steps	   of	  melanoma	   development	   are	   distinguished:	   the	   dysplastic	   nevus	   (2)	   arises	   from	   a	  
benign	   nevus	   (1),	   followed	   by	   a	   subsequent	   radial	   growth	   phase	   melanoma	   (RGP).	   Then	   the	   tumour	   cells	  
become	  locally	  invasive	  forming	  a	  vertical	  growth	  phase	  melanoma	  (VGP)	  before	  metastasizing	  to	  regional	  and	  
distant	  sites	  of	  the	  body.	  
The	  neoplastic	  transformation	  of	  melanocytes	  often	  involves	  onco-­‐proteins	  that	  up-­‐regulate	  
the	   mitogen-­‐activated	   kinase	   pathway	   9.	   In	   particular,	   activating	   mutations	   of	   BRAF	   (e.g.	  
V600E)	  or	  NRAS	  (e.g.	  Q61K	  or	  Q61R)	  are	  found	  in	  approximately	  60%	  and	  20%	  of	  melanomas	  
from	  non-­‐chronically	  sun-­‐damaged	  skin,	  respectively	  14–16.	  However,	  BRAFV600E	  mutations	  in	  
adapted	  from	  435	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melanomas	  from	  chronically	  sun-­‐damaged	  skin	  or	  from	  skin	  relatively	  unexposed	  to	  sun	  are	  
less	  common	  14.	  Intriguingly,	  BRAFV600E	  mutations	  are	  detected	  at	  even	  higher	  frequencies	  in	  
benign	  acquired	  nevi	  (82%)	  17,	  whereas	  81%	  of	  benign	  congenital	  nevi	  harbour	  mutations	  in	  
the	  NRAS	  gene	  18.	  Besides,	   inducing	  NRAS	  point	  mutations	  are	  detected	   in	  33%	  of	  primary	  
melanomas	   and	   26%	   of	   metastatic	   melanoma	   samples	   19.	   Moreover,	   activating	   HRas	  
mutations	   (H-­‐rasG12V)	   in	  mouse	  melanocytes	   in	   cooperation	  with	   inactivating	  mutations	   in	  
tumour	   suppressors	   like	   CDKN2A	   (cyclin	   dependent	   kinase	   inhibitor	   2A)	   or	   TP53	   (tumour	  
protein	  53)	  can	  lead	  to	  cell	  transformation	  20,21.	  Apart	  from	  oncogenic	  mutations	  in	  RAS	  or	  B-­‐
RAF,	   the	  hyperactivation	  of	   upstream-­‐acting	   receptor	   tyrosine	   kinases	   (RTKs)	   is	   frequently	  
observed	  in	  melanoma	  22–26.	  In	  murine	  H-­‐RASV12-­‐driven	  melanoma,	  transcriptional	  induction	  
of	   epidermal	   growth	   factor	   receptor	   (EGFR)	   ligands	   is	   observed,	   resulting	   in	   an	   autocrine	  
EGFR-­‐stimulating	  loop	  important	  for	  melanomagenesis	  27.	  Moreover,	  the	  RTK	  Xmrk	  induces	  
highly	   malignant	   melanoma	   in	   several	   backcross	   hybrids	   of	   the	   fish	   Xiphophorus	   28,29.	  
Besides,	   a	   forward	  genetic	   screen	   in	  benign	  and	  malignant	  human	  melanocytic	  neoplasms	  
lacking	   a	   BRAF	   or	   NRAS	  mutation	   identified	   the	   oncogenic	  mutation	   GNAQQ209L	   in	   83%	   of	  
blue	   naevi	   (n=529),	   50%	   of	   ‘malignant	   blue	   naevi’	   (n=52)	   and	   46%	   of	   uveal	   melanomas	  
(n=548)	   30.	  Even	   though	  GNAQQ209L	  was	   long	  ago	  demonstrated	   to	   transform	  3T3cells	   31,	   it	  
has	   only	   recently	   been	   shown	   that	   Q209L	   or	   R183C	  mutations	   in	   GNA11,	   a	   paralogue	   of	  
GNAQ,	  are	  capable	  of	  transforming	  melan-­‐a	  cells	  and	  induce	  tumours	  in	  non-­‐obese	  diabetic	  
mice	  with	  severe	  combined	  immunodeficiency	  and	  depletion	  of	  the	  interleukin-­‐2	  receptor	  γ	  
chain	   32.	   Furthermore,	   in	  about	  45%	  of	  melanomas,	   the	   lipid	  phosphatase	  PTEN	   is	  deleted	  
and	  the	  downstream	  Akt3	  gene	  is	  amplified	  33,34,	  with	  both	  mutations	  resulting	  in	  aberrant	  
Akt	  activity	  34.	  
The	  most	   significant	   risk	   factor	   for	   melanoma	   is	   a	   strong	   family	   history	   of	   this	   cancer.	   A	  
meta-­‐analysis	  of	  family	  history	  found	  that	  the	  presence	  of	  at	   least	  one	  first-­‐degree	  relative	  
with	  melanoma	  increases	  the	  risk	  by	  2.24-­‐fold	  35,36.	  Genetic	  studies	  of	  this	  heritable	  trait	  in	  
large	   melanoma-­‐prone	   families	   finally	   led	   to	   the	   initial	   identification	   of	   CDKN2A	   as	   the	  
familial	   melanoma	   gene.	   Located	   on	   chromosome	   9p21,	   LOH	   (loss	   of	   heterozygosity)	   or	  
mutation	  at	  this	  locus	  goes	  along	  with	  increased	  melanoma	  susceptibility	  37,38.	  Interestingly,	  
9p21	   homozygous	   deletions	   on	   CDKN2A	   were	   frequently	   observed	   in	   various	   cancer	   cell	  
lines	   39,40	   and	   somatic	  mutations	   in	   this	   gene	   are	   also	   found	   in	  most	   sporadic	  melanomas	  
41,42.	  Furthermore,	  several	  physical	  characteristics	  have	  been	  shown	  to	  increase	  the	  risk	  for	  
melanoma	  development,	  e.g.	  fair	  skin,	  an	  inability	  to	  tan,	  red	  hair,	  and	  blue	  eyes	  43.	  Likewise,	  
the	  presence	  of	  multiple	  pigmented	  lesions,	  including	  freckles	  and	  banal	  or	  clinically	  atypical	  
moles,	  is	  associated	  with	  increased	  melanoma	  risk	  44.	  	  	  
To	   date,	   the	   failure	   of	   current	   approaches	   to	   provide	   successful	   melanoma	   treatment	  
reflects	   an	   underlying	   problem,	   which	   is	   only	   poorly	   understood	   at	   the	   molecular	   level:	  
cancer	   cell	   population	  heterogeneity.	   Increasing	   evidence	   suggests	   that	   tumours	   comprise	  
multiple	   subpopulations	   of	   cancer	   cells,	   some	   of	  which	  may	   be	   resistant	   to	   therapy.	   Two	  
models	   that	   aim	   at	   explaining	   tumour	   heterogeneity	   and	   treatment	   failure	   are	   being	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discussed:	   the	  melanoma	  stem	  cell	  and	   the	  melanoma	  switch	  model.	  The	  melanoma	  stem	  
cell	  model	   claims	   that	  cancers	  develop	   from	  a	   small,	   therapy-­‐resistant	   subset	  of	   cells	  with	  
self-­‐renewal	   properties	   analogous	   to	   organ	   stem	   cells	   45.	   Several	   melanoma	   stem	   cell	  
markers	   have	   been	   suggested,	   e.g.	   the	   rhodamine	   efflux	   transporter	  ABCB5	   46,	   the	   neural	  
crest	  nerve	  growth	  factor	  receptor	  CD271	  (Ngfr	  ⁄	  p75)	  47,	  the	  H3K4	  demethylase	  JARID1B	  48	  
or	   the	   stem	   cell	   marker	   combination	   CD34+CD271-­‐	   49.	   However,	   contradictory	   results	  
concerning	  the	  tumour-­‐initiating	  potential	  of	  the	  marker-­‐bearing	  versus	  the	  marker-­‐negative	  
subpopulations	   50,	   the	   expression	   of	   differentiation	   markers	   on	   subsets	   of	   apparent	  
melanoma	  stem	  cells,	   the	   impact	  of	   technical	   issues	   (e.g.	   the	  prior	  embedding	   in	  matrigel)	  
and	   the	   fact	   that	   25%	   of	   single	   melanoma	   cells	   isolated	   from	   patients	   initiated	  
tumourigenesis	  51	  have	  caused	  some	  debate	  concerning	  these	  findings.	  That	  is	  probably	  the	  
reason	  why	   the	  melanoma	   switch	   theory	   is	   gaining	   recognition.	   This	  model	   suggests	   that	  
metastasis	  and	  phenotypic	  heterogeneity	  is	  driven	  by	  specific	  gene	  expression	  programs	  that	  
might	   be	   imposed	   by	   the	   cellular	   microenvironment	   rather	   than	   by	   the	   accumulation	   of	  
genetic	  events.	  Thereby,	  the	  changing	  microenvironmental	  conditions,	   to	  which	  melanoma	  
cells	   themselves	   also	   contribute,	   are	   suggested	   to	   allow	   virtually	   every	  melanoma	   cell	   to	  
switch	   back-­‐and-­‐forth	   between	   proliferative	   or	   migratory	   phenotypes.	   The	   phenotype-­‐
switch	   model	   theory	   is	   e.g.	   supported	   by	   the	   reversible	   E-­‐cadherin	   expression	   during	  
melanoma	  development	  52,	  an	  intrinsic	  migratory	  capacity	  switch	  53	  and	  the	  fact	  that	  matrix-­‐
modifying	   components	   secreted	   by	   metastatic	   melanoma	   cells	   can	   reprogram	   normal	  
melanocytes	   to	  a	   reversible	   invasive	  phenotype	  54.	  On	  top,	  gene	  expression	  profiling	  of	  86	  
melanoma	   cell	   lines	   in	   culture	   identified	   two	   major	   expression	   signatures,	   namely	   the	  
proliferative	   and	   the	   invasive	   one	   55,	   all	   of	   which	   generated	   heterogenous	   tumours	  
containing	   cells	   with	   both	   kinds	   of	   expression	   profiles	   when	   transplanted	   into	   mice	   56.	  
Furthermore,	   the	   expression	   of	   the	   transcription	   factor	   Brn-­‐2	   revealed	   a	   striking	  
heterogeneity	   in	   melanoma	   57.	   Brn-­‐2	   expression	   is	   positively	   associated	   with	   melanoma	  
proliferation,	  up-­‐regulated	  by	  BRAF	  and	  β-­‐catenin	  and	  associated	  with	  invasiveness.	  Besides,	  
Brn-­‐2	   actively	   represses	   the	   microphthalmia-­‐associated	   transcription	   factor	   Mitf,	   which	  
controls	  survival,	  differentiation,	  proliferation	  and	  migration	   in	  melanocytes	   58.	  Hence,	   it	   is	  
not	  surprising	  that	  motile	  cells	  in	  the	  primary	  tumour	  tend	  to	  express	  higher	  levels	  of	  Brn-­‐2	  
while	  showing	  low	  Mitf	  levels	  and	  pigmentation,	  whereas	  low	  Brn-­‐2	  cells	  predominate	  in	  the	  
resulting	  lung	  metastases	  57.	  	  
Regardless	  of	  which	  model	  one	  favours,	  animal	  models	  are	  considered	  a	  helpful	  and	  often	  
necessary	   tool	   to	   more	   deeply	   and	   relevantly	   investigate	   the	   mechanisms	   underlying	  
melanoma	   formation.	   One	   of	   the	   oldest	   ones	   for	   human	   cancer	   are	   Xiphophorus	   fish,	   in	  




3.2 The	  Xiphophorus	  melanoma	  model	  	  
Xmrk	  is	  the	  acronym	  for	  Xiphophorus	  melanoma	  receptor	  kinase	  (Xmrk)	  that	  acts	  as	  a	  very	  
strong	   oncogene	   when	   overexpressed	   in	   Xiphophorus	   melanoma.	   It	   is	   a	   transmembrane	  
glycoprotein	  belonging	  to	  the	  receptor	  tyrosine	  kinases	  (RTKs)	  that	  is	  permanently	  dimerized	  
due	   to	   disulfide	   bridges	   in	   the	   extracellular	   domain.	   Xmrk	   shows	   full	   transformation	  
potential	   as	   it	   is	   not	   only	   involved	   in	   proliferation	   and	   resistance	   to	   apoptosis	   but	   also	  
interferes	  with	  differentiation	  and	  induces	  migration	  59.	  	  
 
Figure	  3:	  Gordon/Kosswig/Anders	  melanoma	  model	  
Fish	   of	   the	   species	   Xiphophorus	   maculatus	   and	   Xiphophorus	   hellerii	   very	   rarely	   develop	   neoplastic	   lesions.	  
Nevertheless,	   certain	  backcross	  hybrids	   (highlighted	  by	   a	   red	  ellipse)	   develop	  highly	  malignant	  melanoma	  at	  
high	   frequency	  due	  to	   the	  presence	  of	   the	  dominant	  oncogene	   locus	  Tu.	  This	  Tu	   locus	  encodes	  Xmrk	  and	   its	  
expression	  is	  presumably	  repressed	  by	  the	  presence	  of	  the	  regulator	  R	  in	  the	  platyfish	  Xiphophorus	  maculatus.	  
The	   closely	   related	   swordtail	   Xiphophorus	   hellerii	   contains	   neither	   of	   these	   genes.	   Crossing	   conditioned	  
elimination	  of	  R	  leads	  to	  the	  development	  of	  highly	  malignant	  melanoma.	  
As	   Xmrk	   is	   one	   fish	   orthologue	   of	   the	   well-­‐studied	   mammalian	   epidermal	   growth	   factor	  
receptor	   (EGFR),	   its	   dimerization	   results	   in	   autophosphorylation	   and	   activation	   of	   various	  
pathways	   that	   are	   largely	   identical	   to	   those	   mapped	   for	   EGFR	   signalling	   (Figure	   4)	   60.	  
Phosphatidyl-­‐inositol	  3-­‐kinase	  (PI3K)	   is	  one	  of	  the	  downstream	  proteins	  activated	  by	  Xmrk.	  
Alone,	  or	   in	  combination	  with	  the	  src-­‐kinase	  fyn,	   it	  results	   in	  activation	  of	  the	  PI3K/protein	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kinase	  B	  (PKB/Akt)	  signalling	  pathway	  and	  consequently	  in	  protection	  from	  apoptosis	  28,59,61.	  
Furthermore,	  Xmrk	  activation	  leads	  to	  an	  increase	  in	  cell	  motility	  via	  interactions	  with	  focal	  
adhesion	  kinase	  (FAK)	  and	  fyn	  62	  .	  Changes	  in	  FAK	  activity	  are	  then	  followed	  by	  modulation	  of	  
focal	   adhesions	   and	   appearance	   of	   stress	   fibres	   63.	  Moreover,	   Xmrk	   expressing	   cells	   show	  
continuous	   binding	   and	   phosphorylation	   of	   the	   signal	   transducer	   and	   activator	   of	  
transcription	  5	   (STAT5)	   60.	  Phosphorylated	  STAT5	   translocates	   to	   the	  nucleus	  and	  activates	  
specific	   target	   genes	   resulting	   in	   proliferation	   signals	   and	   the	   expression	   of	   the	   anti-­‐
apoptotic	   protein	   bcl-­‐x	   64.	   Importantly,	   the	   Xmrk	   receptor	   was	   found	   to	   bind	   to	   growth	  
factor	   receptor	   binding	   protein	   2	   (GRB2),	   which	   initiates	   the	   activation	   of	   the	   mitogen-­‐
activated-­‐protein-­‐kinase	  (MAPK)	  through	  Ras	  and	  Raf,	  resulting	  in	  a	  strong	  activation	  of	  the	  
MAP	  kinases’	  extracellular	  signal-­‐regulated	  kinases	  1	  and	  2	  (ERK1	  and	  ERK2)	  65.	  This	  pathway	  
is	   not	   only	   essential	   for	   proliferation,	   but	   also	   for	   cell	   survival	   in	   3D-­‐matrices	   as	   it	   up-­‐
regulates	  the	  RNA	  and	  protein	  levels	  of	  the	  secreted	  protein	  osteopontin	  (Opn)	  29.	  Opn	  binds	  
to	  αVβ3	  integrins	  on	  the	  cell	  surface,	  which	  is	  in	  turn	  associated	  with	  neoplastic	  progression	  
and	   tumourigenicity	   in	   melanoma	   66,67.	   Besides,	   the	   MAPK-­‐dependent	   induction	   of	   the	  
matrix	  metalloprotease	  MMP13	  enhances	   proliferation	  while	   decreasing	   the	  pigmentation	  
of	   melanocytes	   68.	   As	   Xmrk	   is	   known	   to	   be	   a	   potent	   inducer	   of	   all	   three	   proteins,	  
understanding	   the	   effects	   of	   Xmrk	   on	   transformation	   serves	   as	   an	   important	   step	   in	  
melanomagenesis	  comprehension.	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Figure	  4:	  Pathways	  induced	  by	  Xmrk	  
Dimerization	   of	   the	   receptor	   tyrosine	   kinase	   Xmrk	   results	   in	   the	   induction	   of	   various	   pathways.	   STAT5	   is	  
phosphorylated	   upon	   binding	   to	   Xmrk,	   translocates	   to	   the	   nucleus	   and	   activates	   target	   genes	   that	   promote	  
proliferation	   as	   well	   as	   anti-­‐apoptotic	   signals.	   Anti-­‐apoptotic	   signals	   are	   also	   transmitted	   via	   the	   PI3K/Akt	  
pathway.	  The	  interaction	  of	  FAK	  and	  fyn	  with	  Xmrk	  leads	  to	  an	  increase	  in	  cell	  motility.	  In	  addition,	  binding	  of	  
GRB2	  initiates	  the	  activation	  of	  MAPK	  through	  Ras	  and	  Raf	  resulting	  in	  cell	  survival	  and	  proliferation.	  Besides,	  
MAPK-­‐dependent	  MMP13	  expression	  enhances	  proliferation	  and	  diminishes	  melanocyte	  pigmentation.	  
3.3 HERmrk	  
The	   receptor	   tyrosine	   kinase	   and	   EGFR	   orthologue	   Xmrk	   is	   constitutively	   active	   due	   to	   at	  
least	  two	  dimerizing	  mutations	   in	  the	  extracellular	  domain	  of	  the	  receptor.	  The	  first	  one	   is	  
the	   substitution	   of	   a	   conserved	   cysteine	   for	   a	   serine	   (C578S)	   involved	   in	   intramolecular	  
disulfide	  bonding.	  The	  second	  one	  is	  a	  glycine	  to	  arginine	  exchange	  (G359R)	  in	  subdomain	  III.	  
Either	   mutation	   leads	   to	   constitutive	   dimer	   formation,	   thereby	   activating	   the	   oncogenic	  
version	   of	   the	   Xmrk	   receptor	   67,69.	   Interestingly,	   these	   mutations	   not	   only	   result	   in	  
constitutive	  activity	  of	  the	  oncogene,	  but	  also	  slow	  down	  its	  processing	  in	  the	  endoplasmic	  
reticulum	  70.	  	  	  	  
The	   problem	   of	   continuous	   Xmrk	   acitivity	   can	   be	   circumvented	   by	   the	   use	   of	   an	   EGF-­‐
inducible	  chimeric	  receptor	  (‘HERmrk’	  or	  shortly	  ‘Hm’).	  Hm	  consists	  of	  the	  extracellular	  part	  
of	  the	  human	  EGFR	  (HER)	  and	  the	  cytoplasmic	  part	  of	  Xmrk	  (mrk).	  To	  analyze	  Xmrk	  signalling	  
specifically	  in	  the	  pigment	  cell	  lineage,	  the	  mouse	  melanocyte	  cell	  line	  melan	  a	  71	  was	  stably	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transfected	  with	  the	  chimeric	  HERmrk	  receptor	  72.	  This	  allows	  HERmrk	  signalling	  induction	  by	  
providing	   the	  cells	  with	  human	  EGF	   (Figure	  5),	  which	   is	   readily	  available	  as	  a	   recombinant	  
protein,	  while	  keeping	  the	  cytoplasmic	  kinase	  domain	  and	  docking	  sites	  of	  the	  fish	  receptor	  
intact.	  	  
	  
Figure	  5:	  HERmrk	  receptor	  
The	   chimeric	   receptor	  HERmrk	   (shortly	  Hm)	   consists	   of	   the	  extracellular	   part	   (HER)	  of	   the	  human	  epidermal	  
growth	  factor	  receptor	  (EGFR)	  and	  the	  intracellular	  part	  (mrk)	  of	  Xmrk.	  Supplementing	  the	  culture	  medium	  of	  
stably	   transfected	  melan	   a-­‐Hm	   cells	  with	   human	   epidermal	   growth	   factor	   (EGF)	   results	   in	   ligand-­‐dependent	  
signalling	  and	  target	  gene	  activation.	  
3.4 Senescence	  
Apoptosis	   and	   senescence	   are	   cellular	   failsafe	   programs.	   The	   term	   “senescence”	   derives	  
from	  the	  Latin	  word	  “senescere”	  which	  translates	  to	  “ageing”.	  Cellular	  senescence	  was	  first	  
described	  by	  Hayflick	  and	  Moorhead	  in	  1961	  73	  as	  a	  process	  that	  prevents	  human	  fibroblasts	  
from	  growing	   indefinitely	   in	   culture,	  as	   for	  all	  differentiated	  cell	   types	  proliferation	  ceases	  
after	  a	  cell	  type	  specific	  number	  of	  divisions	  74.	  	  
The	  phenotype	  of	  senescent	  cells	  is	  generally	  characterized	  by	  an	  irreversible	  growth	  arrest,	  
an	   increased	   cell	   size,	   a	   distinct	   flat,	   enlarged	  morphology,	   the	   accumulation	   of	   lipofuscin	  
granules	   and	   senescence	   associated-­‐β-­‐galactosidase	   activity.	   In	   addition,	   an	   increased	  
expression	  of	  genes,	  e.g.	   those	   involved	   in	  cell	  cycle	  regulation,	  as	  well	  as	  gain	  and	   loss	  of	  
various	   biological	   functions	   has	   been	   observed	   for	   senescent	   cells	  while	   they	   remain	   in	   a	  
metabolically	   active	   state	   75.	   Besides,	   senescent	   cells	   have	   been	   shown	   to	   secrete	   factors	  
associated	  with	  senescence	  induction,	  inflammation	  (e.g.	  the	  chemokines	  IL-­‐6	  and	  IL-­‐8)	  and	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tumour	   development.	   This	   so-­‐called	   senescence-­‐associated	   phenotype	   (SASP)	   not	   only	  
occurs	  in	  cultured	  cells,	  but	  also	  in	  vivo	  upon	  DNA-­‐damage,	  e.g.	  chemotherapy	  4.	  	  
Two	   major	   types	   of	   senescence	   have	   been	   described.	   Replicative	   senescence	   (RS)	   is	   a	  
complex	   and	   heterogeneous	   process	   and	   is	   thought	   to	   occur	   once	   the	   telomeres	   have	  
reached	   a	   critically	   short	   length	   76.	   Every	   other	   kind	   of	   senescence	   is	   referred	   to	   as	  
premature	   senescence	   (PS),	   occurring	  due	   to	   stress	   after	   fewer	   cell	   divisions	   compared	   to	  
RS.	   As	   one	   example,	   stress-­‐induced	   senescence	   is	   caused	   by	   extrinsic	   factors,	   like	   lack	   of	  
nutrients	   or	   oxidative	   stress.	   One	   particular	   source	   of	   stress	   derives	   from	   the	   aberrant	  
proliferative	   signals	   of	   oncogenes,	   such	   as	   the	   activated	   form	   of	   the	   small	   G-­‐protein	   Ras	  
which	   can	   eventually	   trigger	   senescence.	   This	   process	   is	   referred	   to	   as	   oncogene-­‐induced	  
senescence	   (OIS).	   OIS	   counteracts	   the	   excessive	   mitogenic	   signalling	   from	   activated	  
oncogenes	   by	   restricting	   their	   cell	   division	   rate,	   so	   that	   the	   tumour	   remains	   in	   a	   non-­‐
aggressive,	   premalignant	   state.	   Therefore,	   OIS	   is	   observed	   in	   the	   vast	   majority	   of	  
premalignant	   neoplastic	   lesions,	   both	   in	   mouse	   models	   and	   humans,	   but	   is	   scarce	   in	  
malignant	  tumours	  77.	  	  
3.5 Mediators	  of	  OIS	  
Mutant-­‐Ras-­‐induced	  OIS	  has	  been	  linked	  to	  two	  major	  cell-­‐signalling	  pathways	  that	  are	  often	  
disrupted	   in	   cancer	   cells:	   the	   p19ARF-­‐p53	   and	   the	   p16INK4A-­‐Rb	   pathway	   78.	   Interestingly,	  
human	  melanocytes	  have	  been	   implied	   to	   senesce	  primarily	  via	   the	  pRb	  pathway	  upon	  N-­‐
RasQ61K	  oncogene	  expression	  in	  vitro	  79.	  However,	  p53	  not	  only	  induced	  a	  cell-­‐cycle	  arrest	  in	  
primary	  human	  melanocytes,	  but	  also	  effectively	  prevented	  the	  progression	  of	  small	  benign	  
lesions	  to	  malignant	  and	  metastatic	  melanoma	  in	  a	  TP-­‐ras0/+	  :	  Mdm4+/-­‐	  mouse	  model.	  These	  
mice	  expressed	  activated	  HRASV12G	  under	  a	  mouse	  tyrosinase	  promoter	  and	  lack	  one	  allele	  
of	  Mdm4,	  a	  negative	  regulator	  of	  p53.	  The	  TP-­‐ras0/+	  mouse	  is	  a	  highly	  appreciated	  model	  of	  
melanoma	   progression	   because	   a	   topical	   treatment	   of	   DMBA	   induces	   all	   the	   stages	   of	  
melanomagenesis	  80.	  Thus,	  mutations	  in	  both,	  the	  p19ARF	  and	  the	  p16INK4A-­‐Rb	  pathway	  allow	  
the	  oncogene-­‐driven	  progression	  into	  malignant	  tumours.	  	  
Both	  potent	  tumour	  suppressors,	  p16INK4a	  (inhibitor	  of	  cyclin	  dependent	  kinase	  4)	  and	  p19ARF	  
(alternative	  reading	  frame),	  are	  found	  on	  the	  same	  mammalian	  gene	  locus	  CDKN2A	  (cyclin-­‐
dependent	   kinase	   inhibitor	   2A),	   also	   known	   as	  MTS1	   (multiple	   tumour	   suppressor	   1).	   It	   is	  
deleted,	   mutated	   or	   silenced	   in	   a	   wide	   variety	   of	   human	  malignancies	   81.	   A	   unique	   gene	  
structure	  generates	  two	  distinct	  open	  reading	  frames	  that	  initiate	  in	  different	  first	  exons	  and	  
continue	  in	  alternative	  reading	  frames	  in	  a	  common	  second	  exon.	  This	  unusual	  utilization	  of	  
overlapping	   exonic	   sequences	   in	   mammalian	   cells	   enables	   a	   single	   gene	   to	   encode	   two	  
structurally	  and	  biochemically	  completely	  unrelated	  protein	  products	  82.	  The	  p16INK4a	  protein	  
inhibits	   the	  association	  of	  D-­‐type	  cyclins	  and	  CDK4/6,	   thereby	  blocking	  phosphorylation	  of	  
Rb	   and	   exit	   from	   G1	   phase	   83	   (Figure	   6).	   The	   p19ARF	   protein	   blocks	   the	   MDM2	   (Murine	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Double	  Minute	  Clone	  2)	  inhibition	  of	  p53	  and	  induces	  G1	  and	  G2	  checkpoint	  arrests	  84.	  The	  
fact	  that	  the	  two	  structurally	  and	  biochemically	  dissimilar	  products	  of	  the	  CDKN2A	  locus	  can	  
modulate	   different	   tumour	   suppressor	   pathways,	   makes	   it	   uniquely	   effective,	   yet,	   at	   the	  
same	  time,	  exquisitely	  vulnerable	  as	  a	  tumour	  suppressor	  85.	  
Figure	  6:	  Role	  of	  CDKN2A	  in	  cell	  cycle	  regulation	  
The	  mammalian	  gene	   locus	  CDKN2A	   encodes	   two	  potent	   tumour	   suppressors	   that	  differentially	   regulate	  cell	  
cycle	  progression.	  P19ARF	  protein	  blocks	  MDM2-­‐mediated	  inhibition	  of	  p53,	  leading	  to	  a	  G1	  and	  G2	  check-­‐point	  
arrest	  via	  upregulation	  of	  p21.	  P16INK4a	  inhibits	  the	  association	  of	  D-­‐type	  cyclins	  and	  CDK4/6,	  thereby	  inducing	  a	  
pRb-­‐depending	  G1	  arrest.	  
Since	  senescent	  cells	  are	  abundant	  in	  premalignant	  lesions	  like	  nevi,	  but	  scarce	  in	  malignant	  
tumours,	   it	   is	   vital	   to	   investigate	   the	   mechanisms	   underlying	   OIS.	   Besides,	   a	   detailed	  
understanding	  of	  senescence	  might	  identify	  crucial	  aspects	  for	  the	  switch	  from	  the	  benign	  to	  
the	  malignant	  state	  of	  melanoma.	  	  
3.6 INK4	  proteins	  
P16INK4a	  is	  one	  of	  four	  INK4	  isoforms	  sharing	  a	  structural	  motif,	  the	  ankyrin	  repeats,	  that	  are	  
involved	  in	  cyclin	  dependent	  kinase	  4/6	  (CDK4/6)	  binding	  86.	  INK4	  proteins	  are	  differentially	  








Interestingly,	  p16INK4a	  expression	   increases	  with	  age	  89.	  The	  expression	  of	  p16INK4a	   is	   tightly	  
regulated	  on	  the	  transcriptional	  level	  by	  a	  number	  of	  proteins.	  Inhibitor	  of	  differentiation	  1	  
(Id1)	   usually	   represses	   the	  p16INK4a	   promoter	   and	   keeps	   p16INK4a	   expression	   in	   check.	   This	  
effect	  is	  potentiated	  by	  mitogen-­‐activated/extracellular	  signal-­‐regulated	  kinase	  kinase	  (Mek)	  
expression.	   The	   polycomb	   protein	   and	   transcriptional	   repressor	   B	   lymphoma	   Mo-­‐MLV	  
insertion	   region	   1	   (Bmi-­‐1)	   is	   another	   negative	   regulator	   of	   p16INK4a.	   Id1	   as	   well	   as	   Bmi-­‐1-­‐
deficient	   mice	   undergo	   premature	   senescence	   75.	   Members	   of	   the	   erythroblast	  
transformation	  specific	  domain	  (Ets)	  transcription	  factors	  have	  been	  described	  as	  activators	  
of	  p16INK4a,	  whereas	   the	  Twist	   and	  E2F3	  proteins	   act	   as	   repressors	  of	  p19ARF	   transcription.	  
Proteins	  like	  T-­‐box	  2	  transcription	  factor	  (Tbx2),	  T-­‐box-­‐3	  transcription	  factor	  (Tbx3),	  Jun-­‐like	  
transcription	   factor	   B	   (JunB)	   and	   others	   have	   also	   been	   implicated	   in	   the	   regulation	   of	  
CDKN2A.	   The	   T-­‐box	   factors	   repress	   p19ARF	   transcription,	   whereas	   JunB	   activates	   p16INK4a	  
expression	   90,91.	   Interestingly,	  p16INK4a-­‐/-­‐	   p19ARF-­‐/-­‐	  mice	   develop	   normally	  with	   spontaneous	  
tumours	   occurring	   with	   rather	   short	   latency	   and	   these	   mice	   are	   highly	   sensitive	   to	  
carcinogenic	   insults.	   Mice	   exclusively	   lacking	   p19ARF	   show	   the	   same	   phenotype	   92,	   yet	  
p16INK4a-­‐/-­‐	  mice	  suffer	  from	  a	  variety	  of	  tumours	  with	  rather	  long	  latency	  and	  from	  thymocyte	  
hypercellularity	  93.	  Surprisingly,	  mice	  solely	  lacking	  exon	  1α	  of	  p16INK4a	  develop	  tumours	  at	  a	  
higher	   rate.	   This	   suggests	   an	   indirect	   effect	   of	   the	   exclusive	   lack	   of	   exon	   1α	   on	   p19ARF	  
expression	  in	  this	  mutant	  mouse	  strain	  93.	  The	  ablation	  of	  each	  of	  the	  other	  INK4	  loci	  does	  
not	  result	  in	  significant	  developmental	  abnormalities	  94–96.	  	  
The	  cyclin	  dependent	  kinase	  inhibitor	  p15INK4b	  shows	  significant	  similarities	  to	  p16INK4a	  85	  and	  
is	  one	  of	  the	  best-­‐established	  OIS	  markers.	  CDKN2B	  encodes	  for	  p15INK4b,	  which	  inhibits	  Cdk4	  
and	  Cdk6,	  thereby	  arresting	  the	  cells	  in	  G1	  88	  	  and	  acting	  as	  a	  tumour	  suppressor	  97.	  P15INK4b	  
shows	  increased	  expression	  levels	  specifically	  in	  premalignant	  neoplastic	  lesions	  of	  the	  skin,	  
lung	  and	  pancreas	  but	  not	  in	  corresponding	  malignant	  tumours	  77.	  The	  frequent	  alteration	  of	  
p15INK4b	   in	  human	  and	  murine	  hematopoietic	  malignancies	  suggests	   that	   its	  absence	  might	  
predispose	  hematopoietic	  cells	  to	  malignant	  transformation	  89.	  In	  addition,	  p15INK4b	  has	  been	  
described	   to	   be	   involved	   in	   growth	   arrest	   that	   is	   imposed	   during	   mutant-­‐Ras-­‐induced	  
senescence	  and	  was	  shown	  to	  oppose	  transformation	  by	  Ras	  in	  cultured	  cells	  77.	  
In	  contrast	  to	  CDKN2A,	  mutations	  in	  the	  neighbouring	  CDKN2B	  gene	  encoding	  p15INK4b	  occur	  
less	  frequently	  in	  human	  malignancies.	  Even	  though	  p15INK4b-­‐/-­‐	  mice	  have	  been	  described	  as	  
less	   cancer-­‐prone	   than	   p16INK4a-­‐/-­‐	   animals	   85,	   some	   mice	   do	   develop	   tumours	   with	  
hemangiosarcoma	  being	  the	  most	  frequent	  type	  98.	  
Genetic	   alterations	   of	   p18INK4c	   gene	   are	   rare	   events	   in	   human	   tumours.	   However,	   several	  
studies	   reported	   that	  p18INK4c	   is	   a	  haploinsufficient	   tumour	   suppressor	   in	  mice,	   suggesting	  
the	   possibility	   that	   a	   quantitative	   decrease	   of	   this	   INK4	   may	   be	   involved	   in	   human	  
tumourigenesis	   99.	   Besides,	   p18INK4c	   is	   down-­‐regulated	   in	   human	   pituitary	   adenoma	   100.	  
Additionally,	  p18INK4c	  gene	  silencing	  by	  promoter	  methylation	  has	  been	  observed	  in	  Hodgkin	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lymphoma	  101	  and	  medulloblastoma	  102.	  Furthermore,	  deletions	  of	  CDKN2C,	  which	  encodes	  
for	   p18INK4c,	   are	   frequently	   found	   in	   multiple	   myeloma	   103.	   Taken	   together,	   these	   data	  
suggest	  a	  possible	  role	  for	  p18INK4c	  as	  a	  tumour	  suppressor.	  
In	   contrast,	   p19INK4d	   null	   mice	   do	   not	   develop	   tumours	   or	   other	   types	   of	   proliferative	  
disorders.	  Furthermore,	  they	  are	  not	  more	  susceptible	  to	  tumour	  formation	  than	  wild-­‐type	  
mice	   in	   response	   to	   carcinogenic	   treatment	   98.	   The	  only	   phenotype	  observed	   for	   p19INK4d-­‐
deficient	   mice	   is	   testicular	   atrophy	   even	   though	   the	  mice	   remain	   fertile	   96.	   These	   results	  
render	  it	  unlikely	  that	  p19INK4d	  alone	  acts	  as	  a	  tumour	  suppressor.	  
Even	  though	  neither	  p18INK4c	  nor	  p19INK4d	  have	  been	  reported	  to	  play	  a	  role	   in	  senescence,	  
both	  p15INK4b	  and	  p16INK4a	  are	  important	  for	  this	  tumour-­‐protecting	  mechanism.	  Hence,	  it	  is	  
important	   to	   further	   investigate	  the	  detailed	  mechanisms	  underlying	  senescence	   induction	  
in	  melanocytes	  to	  better	  understand	  melanoma	  formation.	  Since	  CDKN2A	  is	  most	  frequently	  
lost	   in	   tumours	   and	   seems	   to	   be	   the	   vital	   player	   in	   senescence	   induction,	   I	   will	   focus	   on	  
p16INK4a.	  
3.7 The	  p16INK4a-­‐Rb	  pathway	  
The	  p16INK4a/Rb	  pathway	  plays	  a	  key	   role	   in	   controlling	  cell	   growth	  by	   integrating	  multiple	  
mitogenic	  and	  antimitogenic	  stimuli.	   In	  addition,	   this	  pathway	   is	  deregulated	   in	  more	  than	  
80%	  of	  human	  tumours	  either	  by	  genetic	  or	  epigenetic	  alterations	  that	  target	  at	  least	  some	  
of	  its	  key	  members	  like	  Cyclin	  D1,	  cyclin	  dependent	  kinase	  4	  (CDK4),	  INK4a	  or	  retinoblastoma	  
protein	   (pRb)	   98.	   P16INK4a	   expression	   is	   low	   in	   young	   and	   high	   in	   senescent	   cells,	  whereby	  
demethylation	  or	  overexpression	  often	  goes	  along	  with	  a	  senescent	  phenotype.	  In	  addition,	  
p16INK4a	   is	  highly	  expressed	   in	  human	  nevi,	   the	  benign	  precursors	  of	  malignant	  melanoma,	  
and	   frequently	   deleted	   in	   melanoma	   cells	   78.	   Linkage-­‐analysis	   studies	   have	   shown	   a	   high	  
incidence	   of	   CDKN2A	   and	   CDK4	   mutations	   in	   familial	   melanomas,	   which	   represent	  
approximately	  10%	  of	  all	  melanoma	  cases	  90.	  	  
P16INK4a	   protein	   sequesters	   Cdk4	   and	   6	   and	   prevents	   them	   from	   phosphorylating	   and	  
inactivating	  Rb.	  The	  Rb	  family	  of	  proteins,	  pRb,	  p107	  and	  p130	  ultimately	  regulate	  the	  critical	  
transition	   from	   mitogen	   dependence	   to	   mitogen	   independence,	   the	   so-­‐called	   restriction	  
point	  (R)	  or	  point	  of	  no	  return.	  Having	  passed	  through	  R	  that	  divides	  early	  and	  late	  G1,	  cells	  
become	  committed	  to	  a	  new	  round	  of	  replication.	  Early	  in	  G1	  the	  synthesis	  of	  D-­‐type	  cyclins	  
which	  heterodimerize	  with	  CDK4	  and	  6	  to	  phosphorylate	  pRb,	  leads	  to	  the	  release	  of	  the	  E2F	  
transcription	  factor	  and	  progression	  of	  the	  cell	  cycle	  104–106	  (Figure	  6	  and	  7).	  	  
The	   histone-­‐lysine	  N-­‐methyltransferase	   suppressor	   of	   variegation	   3-­‐9	   homolog	   1	   (Suv39h)	  
functions	  in	  concert	  with	  Rb	  by	  methylating	  histone	  proteins	  78.	  This	  global	  heterochromatin	  
formation	   initiated	   by	   Rb	   results	   in	   the	   permanent	   and	   stable	   repression	   of	   genes	   with	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crucial	   roles	   in	   proliferation,	   such	   as	   those	   regulated	   by	   the	   E2F	   family	   of	   transcription	  
factors107.	  	  
Most	   cells	   carrying	   a	   null	   mutation	   in	   the	   Rb	   gene	   senesce	   normally,	   yet	   inactivation	   of	  
additional	  Rb	  family	  members,	  p107	  and	  p130,	  is	  sufficient	  to	  prevent	  senescence	  108.	  	  
3.8 p53,	  the	  p19ARF-­‐p53	  pathway	  and	  the	  p53-­‐Mdm2	  loop	  
The	   gene	   locus	   TP53	   encodes	   p53	  which	   is	   also	   known	   as	   the	   “guardian	   of	   the	   genome”	  
109,110	   as	   it	   is	   involved	   in	   checkpoint	   control,	   cell-­‐cycle	   arrest,	   chromosomal	   stability,	  
apoptosis	   and	   senescence	   111	   by	   acting	   as	   a	   transcription	   factor	   for	  more	   than	   60	   known	  
target	  genes.	  P53	   is	   regulated	  by	  at	   least	   ten	   feedback	   loops,	   seven	  of	  which	  are	  negative	  
and	   three	   are	   positive.	   As	   all	   of	   them	   are	   autoregulatory,	   they	   are	   either	   induced	   or	  
repressed	   by	   p53	   transcriptional	   activity	   or	   p53-­‐induced	   proteins	   112.	   Hence,	   it	   is	   not	  
surprising	   that	   a	  malfunction	   or	  mutation	   of	   p53	   is	   observed	   in	   far	  more	   than	   half	   of	   all	  
human	  cancers.	  P53	  mutations	  are	  mainly	  missense	  mutations	  (80%	  of	  tumours)	  resulting	  in	  
aberrant	   proteins	   with	   an	   increased	   half-­‐life,	   which	   in	   turn	   leads	   to	   the	   appearance	   of	  
dominant	  negative	  and/or	  gain	  of	  function	  phenotypes	  associated	  with	  tumour	  progression	  
and	  metastasis	  113.	  However,	  as	  p53	  is	  generally	  functional	  in	  melanoma,	  other	  events	  must	  
contribute	  to	  p53	  inactivation.	  	  
P53	   is	   highly	   conserved	   among	   mammalian	   species	   (74-­‐90%)	   and	   even	   though	   sequence	  
identity	   is	   divergent	   among	   lower	   vertebrates	   (38-­‐53%),	   DNA	   binding	   domains	   as	   well	   as	  
crucial	   residues	   involved	   in	   oligomerization	   and	   MDM2	   binding	   are	   highly	   conserved	   110.	  
Intrinsic	   or	   extrinsic	   stress	   results	   in	   posttranslational	  modification	   of	   the	   p53	   protein	   112.	  
One	  of	  the	  major	  players	  in	  the	  p53-­‐mediated	  G1	  arrest	  induced	  by	  p19ARF	  overexpression	  is	  
the	  p21	  gene	  product	  that	  inhibits	  the	  cyclin	  E-­‐dependent	  cyclin	  dependent	  kinase	  2	  (CDK2)	  
(Figure	  7).	  	  




Figure	  7:	  Cell	  cycle	  control	  
Combinatorial	   interactions	  of	  CDKs	  and	  cyclins	  promote	  the	  transition	  through	  the	  cell	  cycle.	  Cyclin	  D/CDK4,5	  
and	   Cyclin	   E/CDK2	   complexes	   promote	   pRb	   phosphorylation	   and	   transition	   from	   G1	   (cell	   prepares	   for	   DNA	  
synthesis)	  to	  S	  (DNA	  synthesis	  occurs)	  phase.	  Cyclin	  A/CDK2	  interaction	  supports	  DNA	  synthesis	  and	  the	  onset	  
of	  G2	  (cells	  prepare	  to	  complete	  the	  cell	  cycle	  by	  undergoing	  mitosis).	  Cyclin	  B/CDK1	  complexes	  then	  promote	  
transition	   through	   G2	   and	   M	   (mitosis)	   before	   pRb	   is	   finally	   dephosphorylated	   again.	   Two	   families	   of	   CDK	  
inhibitors,	  INK4	  and	  CIP1/KIP1	  proteins	  (p21CIP1/WAF1,	  p27KIP1,	  p57KIP2),	  provide	  the	  major	  negative	  regulation	  of	  
CDKs.	  	  
As	  CDK2	  usually	  promotes	  the	  progress	  from	  G1	  to	  S	  phase	  of	  the	  cell	  cycle	  the	  expression	  of	  
p21	   induces	  G1	   arrest	   of	   the	   cells	   112.	   It	   does	   not	   seem	   surprising	   that	   p21-­‐/-­‐	   cells	   bypass	  
senescence	   75,	   supporting	   the	   proposed	   linear	   model	   linking	   p53	   and	   Rb	   via	   p21	   114.	   In	  
contrast	   to	   that,	   MEFs	   carrying	   a	   null	   mutation	   in	   p21	   undergo	   senescence	   normally	   115,	  
indicating	   that	   other	   proteins	   compensate	   for	   the	   function	   of	   p21.	   Supporting	   this	  
suggestion,	   Li-­‐Fraumeni	   patients,	   who	   suffer	   from	   a	   rare	   autosomal	   dominant	   syndrome	  
characterized	  by	  multiple	   cases	  of	  early-­‐onset	  primary	   tumours,	   are	  defective	   for	  p53	  and	  
therefore	   do	   not	   express	   any	   p21.	   Yet,	   their	   cells	   can	   still	   undergo	   senescence,	   indicating	  
that	  p53	  and	  p21	  must	  be	  dispensable	  for	  RS	  75.	  	  
Similar	   to	   the	   situation	   in	   Li-­‐Fraumeni	   patients,	   the	   absence	   of	   p53	   leads	   to	   induction	   of	  
cancer	  at	   low	  age	  112	   in	  other	  mammals	  and	  in	  Xenopus	  75.	   In	  mouse	  embryonic	  fibroblasts	  
(MEFs),	  inactivation	  of	  p53	  is	  sufficient	  to	  prevent	  senescence,	  allowing	  these	  cells	  to	  divide	  
indefinitely	  116.	  Surprisingly,	  p53+/-­‐	  patients	  show	  a	  decrease	  in	  tumour	  incidence,	  but	  also	  a	  

























development	  after	  eight	  months	  in	  approximately	  30%	  of	  all	  fish	  117.	  Nevertheless,	  no	  effect	  
of	  UV	   irradiation	  and	  chemicals	  on	  p53	  expression	   in	  medaka	  and	  other	  fish	  cells	  could	  be	  
observed,	  even	  though	  a	  three	  to	  ten-­‐fold	  increase	  in	  p53	  expression	  is	  detected	  in	  human	  
cell	  lines	  110,118	  upon	  such	  treatment.	  This	  difference	  might	  be	  due	  to	  the	  different	  p53	  gene	  
regulation	  because	  of	  different	  intron	  sizes	  as	  the	  medaka	  gene	  of	  8.7	  kb	  is	  smaller	  than	  that	  
of	  mouse	   (12	   kb)	   and	  human	   (20	   kb).	   These	   structural	   differences	  might	  point	   to	   species-­‐
dependent,	  functional	  differences	  in	  transcriptional	  control	  118.	  	  
The	  tumour	  suppressor	  p19ARF	  (Alternative	  Reading	  Frame)	  is	  a	  positive	  regulator	  upstream	  
of	   p53	   that	   is	   induced	   in	   situations	   of	   stress	   and	   senescence	   and	   activated	   by	   ectopic	  
expression	  of	  oncoproteins	  such	  as	  Myc,	  Ras,	  E2F1	  and	  E1A	  90.	  The	  disruption	  of	  the	  p19ARF-­‐
p53	   pathway,	   the	   primary	   failsafe	   cascade	   engaged	   by	   Myc,	   is	   shown	   to	   facilitate	   Ras-­‐
initiated	  transformation	  111.	  P19ARF	  protein	  binds	  to	  Mdm2	  protein,	  one	  of	  the	  key	  players	  in	  
p53	  regulation	  119	  mediating	  the	  downmodulation	  of	   its	  p53-­‐ubiquitin	   ligase	  activity,	  which	  
in	  turn	  leads	  to	  a	  higher	  p53	  protein	  level	  within	  the	  cell.	  	  
The	  transcription	  of	  the	  tumour	  suppressor	  p19ARF	  is	  positively	  regulated	  by	  E2F-­‐1	  and	  beta-­‐
catenin	  and	  negatively	  regulated	  by	  p53.	  High	  levels	  of	  E2F-­‐1	  not	  bound	  to	  pRb	  switches	  the	  
p53	   response	   from	  G1	  arrest	   to	  apoptosis	   112.	  Besides,	  p53	  binds	   specifically	   to	   the	  mdm2	  
gene	   and	   stimulates	   its	   transcription	   120,121.	   Hence,	   p53	   itself	   induces	   one	   of	   its	   negative	  
feedback	   regulators	   in	   order	   to	   diminish	   p53	   levels.	   Mdm2/p53	   binding	   is	   mediated	   by	  
phosphorylation	  of	  p53	  at	  the	  Mdm2-­‐N-­‐terminal	  binding	  site.	  	  
Overexpression	  of	  Mdm2	   leads	   to	   tumour	   formation	   in	  mammals	   and	  Xenopus	   but	   not	   in	  
zebrafish,	  indicating	  a	  MDM2-­‐independent	  p53	  regulation	  110	  which	  fits	  to	  the	  fact	  that	  fish	  
lack	  p19ARF.	  	  
In	   mice,	   inactivation	   of	   the	   mdm2	   gene	   results	   in	   early	   embryonic	   lethality,	   which	   is	  
completely	   prevented	   by	   simultaneous	   inactivation	   of	   p53	   122,123.	   This	   shows	   that	   a	   tight	  
regulation	  of	  p53	  is	  important	  for	  development	  and	  growth	  control.	  
Since	   p53	   is	   a	   potent	   tumour	   suppressor	   with	   a	   vital	   role	   in	   senescence	   induction,	   it	   is	  
important	   to	   elucidate	   the	   possible	   role	   of	   p53	   in	  melanocyte	   senescence	   and	  melanoma	  
development. 
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3.9 Myc	  and	  its	  role	  in	  cancer	  
3.9.1 Growth-­‐promoting	  functions	  of	  Myc	  
Almost	   30	   years	   ago,	   MYC,	   the	   human	   homologue	   of	   the	   retrovirus	   v-­‐gag-­‐myc,	   was	  
discovered.	   To	   date,	   more	   than	   22.000	   scientific	   articles	   on	   MYC	   have	   been	   published	  
indicating	   its	   pivotal	   role	   in	   development	   and	   disease.	   MYC	   transcription	   factors	   are	  
commonly	  deregulated	  in	  tumourigenesis.	  All	  three	  known	  MYC	  protein	  family	  members	  (c-­‐
Myc,	   N-­‐Myc	   and	   L-­‐Myc)	   promote	   proliferation,	   growth	   and	   apoptosis;	   inhibit	   terminal	  
differentiation;	   and	  are	   involved	   in	   the	  genesis	  of	   an	  extremely	  wide	   range	  of	   cancers	   124.	  
Moreover,	  MYC	  can	  also	  drive	  vasculogenesis	   125,	   reduce	  cell	   adhesion	   126,127	  and	  promote	  
metastasis	   128	   as	   well	   as	   genomic	   instability	   129.	   The	   basic-­‐helix-­‐loop-­‐helix-­‐zipper	   (bHLHZ)	  
domain	   of	   MYC	   heterodimerizes	   with	   the	   bHLHZ	   Max	   to	   form	   a	   sequence-­‐specific	   DNA	  
binding	   complex,	   which	   recognizes	   the	   E-­‐box	   sequence	   CACGTG	   (as	   well	   as	   related	   non-­‐
canonical	   sites)	   and	   activates	   transcription	   (Figure	   8)	   130–132.	   Intriguingly,	   MYC	   can	   also	  
function	  as	  a	  negative	  regulator	  of	   transcription	  133,134.	  Most,	  but	  not	  all,	   functions	  of	  MYC	  
depend	  on	  interaction	  with	  MAX,	  but	  there	  are	  exceptions.	  For	  example,	  in	  Drosophila	  MYC	  
forms	   a	   complex	   with	   TfIIIb	   to	   stimulate	   transcription	   of	   RNA	   polymerase	   III	   genes	  
independently	  of	  MAX	  135.	  	  
The	  c-­‐MYC	  proto-­‐oncogene	  is	  one	  of	  the	  most	  frequently	  activated	  oncogenes,	  regulating	  as	  
many	  as	  15	  -­‐	  20%	  of	  all	  genes	  136,137.	  Hence	  it	  is	  not	  surprising	  that	  both,	  targeted	  c-­‐Myc	  and	  
N-­‐Myc	  deletions,	   lead	  to	  early	  embryonic	   lethality	   in	  mice	  138,139.	  However,	  to	  date,	   little	   is	  
known	  about	  which	  target	  genes	  are	  actually	  crucial	  for	  MYC	  function.	  Nevertheless,	  p21CIP1	  
suppression	  by	  MYC	  expression	   is	  postulated	   to	  be	  responsible	   for	   the	  G1	  arrest	   failure	  of	  
MYC-­‐transformed	   cells	   upon	   DNA	   damage	   140,141.	   Furthermore,	   observations	   indicate	   that	  
cyclin-­‐D–CDK4	   functions	   downstream	   of	   MYC	   in	   transformation.	   Accordingly,	   fibroblasts	  
lacking	  all	  three	  D-­‐type	  cyclins	  fail	  to	  be	  transformed	  by	  MYC	  and	  Ras	  oncogenes,	  while	  the	  
defects	   in	   cell	   proliferation	   are	  moderate	   142.	   Similarly,	   the	   loss	   of	   CDK4	   inhibits	   C-­‐MYC’s	  
tumourigenic	   activities	   in	   epithelial	   tissues	   143.	   Even	   though	   further,	   crucial	   MYC	   targets	  
remain	  to	  be	  elucidated,	  c-­‐MYC	  is	  estimated	  to	  be	  involved	  in	  20%	  of	  all	  human	  cancers	  144,	  
especially	  in	  hematopoietic	  lesions	  by	  causing	  inappropriate	  gene	  expression,	  which	  in	  turn	  
results	  in	  autonomous	  cellular	  proliferation	  and	  blocks	  cellular	  differentiation	  145.	  In	  all	  cases,	  
the	   relative	   amounts	   of	   MYC	   protein	   are	   increased	   in	   the	   tumour	   tissue	   relative	   to	   the	  
surrounding	  normal	  tissues,	  which	  indicates	  that	  the	  elevated	  expression	  of	  MYC	  contributes	  
to	  tumourigenesis.	  Several	  studies	  using	  transgenic	  animals,	  which	  express	  MYC	  proteins	  in	  a	  
deregulated	   manner,	   support	   this	   view	   146.	   High	   C-­‐MYC	   expression	   was	   also	   reported	   to	  
enhance	  melanoma	  growth	  in	  SCID	  mice	  147	  while	  being	  associated	  with	  IFN-­‐α	  resistance	  in	  
human	  melanoma	  treatment	   148.	  Besides,	  C-­‐MYC	   amplifications	  are	  observed	   in	  about	  one	  
third	   of	   uveal	  melanoma	   149.	   	   In	   accordance,	  C-­‐MYC	   downregulation	   sensitizes	  melanoma	  
cells	  for	  chemo-­‐	  and	  radiotherapy	  150,151.	  Interestingly,	  both	  N-­‐RAS	  and	  BRAF	  but	  not	  K-­‐RAS	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can	   induce	   C-­‐MYC	   expression	   152,153.	   Conversely,	   lymphomas	   undergo	   proliferative	   arrest,	  
differentiation	  and	  apoptosis	  associated	  with	  sustained	  regression	  upon	  C-­‐MYC	  inactivation	  
in	   transgenic	   mice.	   Similarly,	   C-­‐MYC	   inactivation	   in	   osteosarcoma	   results	   in	   the	  
differentiation	  into	  mature	  osteocytes	  and	  the	  formation	  of	  bone,	  whereas	  in	  hepatocellular	  
carcinoma,	   C-­‐MYC	   inactivation	   differentiates	   tumour	   cells	   into	   normal	   hepatocytes	   and	  
biliary	   cells,	   while	   a	   subpopulation	   of	   the	   cells	   retains	   its	   neoplastic	   properties.	   Taken	  
together,	  C-­‐MYC	   inactivation	   can	   reverse	   the	  process	  of	   transformation	   -­‐	   even	   in	   tumours	  
with	   genomic	   complexity	   154,155.	   In	   accordance,	   C-­‐MYC	   downregulation	   by	   expression	   of	  
constitutively	   active	   STAT5	   in	   human	   fibroblasts	   induced	   p53	   and	   pRb-­‐dependent	  
senescence,	  which	  could	  be	  circumvented	  when	  C-­‐MYC	  was	  overexpressed	  156.	  Furthermore,	  
C-­‐MYC	   inactivation	   by	   RNA	   interference	   has	   been	   shown	   to	   trigger	   cellular	   senescence	   in	  
diverse	   cancer	   cell	   lines	   including	  melanoma	   cells	   157–159.	   However,	   C-­‐MYC	   overexpression	  
alone	  is	  not	  sufficient	  to	  transform	  cells.	  Only	  in	  cooperation	  with	  other	  oncogenes,	  e.g.	  Ras,	  
is	   C-­‐MYC	   capable	   of	   inducing	   cellular	   transformation	   and	   tumourigenesis	   160,161.	   Whether	  
deregulated	  C-­‐MYC	  actually	   drives	   transformation	  or	   forces	   cells	   to	   enter	   apoptosis	  might	  
rely	  on	  its	  expression	  level	  162.	  	  
	  
Figure	  8:	  The	  Myc-­‐Max	  complex	  activates	  transcription	  
Once	   MYC	   has	   associated	   with	   MAX,	   the	   MYC-­‐MAX	   complex	   recognizes	   and	   binds	   to	   the	   E-­‐box	   sequence	  
CACGTG	   before	   activating	   transcription.	  MYC	   target	   gene	   expression	   results	   in	   proliferation,	   transformation	  
and	  apoptosis,	  while	  blocking	  senescence	  and	  differentiation.	  
3.9.2 Growth-­‐suppressive	  functions	  of	  Myc	  and	  the	  role	  of	  Miz-­‐1	  
Interestingly,	   oncogenically	   activated	   c-­‐Myc	   (from	   now	   referred	   to	   as	   Myc)	   is	   not	   only	   a	  
potent	   inducer	   of	   cell	   proliferation	   but	   also	   engages	   growth-­‐suppressive	   programs	   that	  
restrict	   Myc’s	   oncogenic	   potential.	   In	   a	   Myc	   transgenic	   mouse,	   where	   latent	   Myc	   is	  
expressed	  under	  the	  control	  of	   the	  ubiquitously	  active	  Rosa26	  promoter,	  apoptosis	  can	  be	  
detected	  exclusively	  in	  the	  tissue	  with	  the	  highest	  Myc	  levels,	  namely	  in	  colonial	  epithelium.	  
Since	   Myc	   also	   dimerizes	   with	   MAX	   when	   inducing	   programmed	   cell	   death,	   a	   threshold	  
model	  might	  explain	  the	  different	  Myc	  functions	  162.	  Like	  apoptosis,	   induction	  of	  p19ARF	  by	  
oncogenic	  Myc	  via	  inhibition	  of	  Mdm2	  and	  the	  subsequent	  activation	  of	  p53	  can	  either	  drive	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apoptosis	  163–165	  or	  suppress	  proliferation	  166.	  Besides,	  repression	  of	  Miz-­‐1	  (Myc-­‐interacting	  
zinc	   finger	   protein	   1)	   activity	   by	   Myc	   is	   important	   in	   Myc-­‐induced	   apoptosis	   as	   Miz-­‐1	  
activates	  the	  cell	  cycle	  inhibitor	  p21,	  leading	  to	  growth	  arrest	  instead	  of	  apoptosis	  140.	  
The	   transcription	   factor	   MYC-­‐interacting	   protein	   1	   (MIZ-­‐1)	   was	   identified	   by	   virtue	   of	   its	  
ability	   to	   bind	  MYC.	  MIZ-­‐1	   targets	   include	   the	   genes	   encoding	   the	   low-­‐density	   lipoprotein	  
receptor	  gene	  LDLR,	  p21CIP1,	  p15INK4B,	  and	  MAD4	  140,167–169.	  MIZ-­‐1	  directly	  binds	  to	  the	  core	  
promoters	  of	  these	  genes	  and	  activates	  their	  transcription.	  	  
Miz-­‐1	  upregulates	   the	  expression	  of	  p15INK4B	   leading	   to	   its	   accumulation,	  which	   is	   strongly	  
linked	   to	   cellular	   senescence	   168.	   Accordingly,	   Miz-­‐1	   overexpression	   induces	   replicative	  
senescence	   by	   arresting	   the	   cells	   in	   G1	   via	   upregulation	   of	   p15INK4B	   168,170.	   A	   number	   of	  
studies	   provided	   evidence	   to	   support	   a	   model	   in	   which	   C-­‐MYC	   serves	   to	   repress	   the	  
transcriptional	  activation	  function	  of	  MIZ-­‐1	  171,	  e.g.	  for	  the	  regulation	  of	  p15INK4B	  expression	  
168,170.	  C-­‐MYC	  does	  not	  directly	  bind	  to	  Miz-­‐1	  target	  genes,	  but	  is	  recruited	  to	  them	  via	  Miz-­‐1.	  
Transcriptional	   activation	   by	  Miz-­‐1	   is	   abolished	   upon	   c-­‐Myc	   recruitment	   and	   the	  Miz-­‐1/C-­‐
MYC/MAX	   complex	   functions	   to	   repress	   transcription	   (Figure	   9).	   However,	  MYC-­‐mediated	  
suppression	  of	  MIZ-­‐1	  transcriptional	  activation	  can	  be	  counteracted	  by	  transforming	  growth	  
factor	   β	   signalling,	   which	   results	   in	   decreasing	   levels	   of	   the	   inhibitory	   MYC	   protein	   170.	  
Furthermore,	  MIZ-­‐1	   transcriptional	   activity	   can	   also	   be	  modulated	   by	  UV	   exposure,	  which	  
induces	   a	   decrease	   in	   topoisomerase	   II-­‐binding	   protein	   (TopBP1).	   TopBP1,	   like	   MYC,	  
associates	  with	  MIZ-­‐1	  and	  inhibits	  its	  ability	  to	  activate	  transcription	  of	  certain	  target	  genes	  
such	   as	   the	   cyclin-­‐dependent	   kinase	   inhibitors,	   p21CIP1	   141.	   Moreover,	   the	   transcriptional	  
repressor	   Gfi-­‐1	   was	   reported	   to	   interact	   with	   Miz-­‐1	   to	   repress	   CDKN1A	   transcription	   by	  
forming	  a	  ternary	  complex	  in	  cooperation	  with	  C-­‐MYC	  172.	  
Thus,	  MIZ-­‐1	   is	   a	   tightly	   regulated	   transcription	   factor	  whose	  activity	   can	  be	  modulated	  by	  
association	  with	  various	  regulatory	  partners.	  
Apart	  from	  its	  interaction	  with	  binding	  partners,	  the	  subcellular	  localization	  of	  MIZ-­‐1	  is	  vital	  
for	   its	   regulation.	   Cytoplasmic	   localisation	   of	   MIZ-­‐1	   has	   been	   reported	   together	   with	   its	  
coactivator	  p300	  and	  MYC	  168,171.	  However,	  physiological	  signals	  that	  regulate	  the	  subcellular	  
localization	   of	   endogenous	   MIZ-­‐1	   have	   been	   difficult	   to	   pinpoint.	   Since	   MYC	   is	   mainly	  
localized	  to	  the	  nucleus	  at	  low	  cell	  densities,	  but	  accumulates	  in	  the	  cytoplasm	  upon	  growth	  
at	  high	  density	  or	  serum	  withdrawal	  173,	  this	  might	  also	  be	  relevant	  to	  the	  control	  of	  MIZ-­‐1	  
localization	  and	  activity.	  In	  addition	  to	  these	  diverse	  mechanisms	  of	  MIZ-­‐1	  regulation,	  MIZ-­‐1	  
activity	   can	   also	   be	   regulated	   by	   its	   association	   with	   microtubules.	   According	   to	   this	  
regulatory	  pathway,	  MIZ-­‐1	  is	  sequestered	  in	  the	  cytoplasm	  by	  association	  with	  microtubules.	  
Upon	  drug-­‐induced	  microtubule	  depolymerization,	  MIZ-­‐1	  is	  free	  to	  enter	  the	  nucleus,	  where	  
it	  binds	  to	  target	  sequences	  and	  activates	  transcription	  174.	  An	  essential	  co-­‐activator	  of	  Miz-­‐
1,	   nucleophosmin,	   is	   required	   for	   Miz-­‐1-­‐induced	   cell	   cycle	   arrest.	   By	   retaining	  
nucleophosmin	   in	   the	   nucleolus,	   the	   ribosomal	   protein	   L23,	  which	   is	   encoded	   by	   a	   direct	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target	   gene	   of	  Myc,	   acts	   as	   a	   negative	   regulator	   of	  Miz-­‐1-­‐dependent	   transactivation.	   This	  
regulatory	   circuit	  may	   provide	   a	   feedback	  mechanism	   that	   links	   translation	   of	  Myc	   target	  
genes	  and	  cell	  growth	  to	  Miz-­‐1-­‐dependent	  cell-­‐cycle	  arrest	  175.	  
	  
Figure	  9:	  The	  MIZ-­‐1-­‐MYC-­‐MAX	  complex	  represses	  transcription	  
Association	  of	  the	  MYC-­‐MAX	  complex	  to	  MIZ-­‐1	  results	  in	  a	  repressive	  MIZ-­‐1-­‐MYC-­‐MAX	  complex.	  The	  repression	  
of	  MIZ-­‐1	  target	  genes	  in	  turn	  leads	  to	  cell	  cycle	  arrest	  and	  differentiation.	  
Taken	   together,	   several	   intrinsic	   tumour	   suppressor	   mechanisms	   limit	   Myc’s	   oncogenic	  
potential.	   However,	   the	   factors	   that	   determine	   whether	   proliferation	   or	   cell	   death	   is	   the	  
predominant	  outcome	  of	  Myc	  activation	  remain	  unclear.	  With	  Myc´s	  potential	  role	  in	  up	  to	  
20%	   of	   human	   cancers	   and	   the	   fact	   that	   the	   down-­‐regulation	   of	   Myc	   protein	   activates	  
apoptosis	  in	  melanoma	  cells	  and	  increases	  the	  susceptibility	  of	  cells	  to	  various	  antitumoural	  
treatments	  151,176,177	  suggests	  a	  possible	  role	  for	  Myc	  in	  melanoma. 
3.10 Polyploidy	  and	  aneuploidy	  in	  cancer	  development	  
Polyploidy,	   a	   state	   in	   which	   cells	   possess	   more	   than	   the	   usual	   two	   sets	   of	   homologous	  
chromosomes,	   occurs	   frequently	   in	   nature.	   Cellular	   stress,	   ageing,	   and	   various	   diseases	  
trigger	  polyploidy,	  which	   are	  normally	   diploid	   178,179.	   Besides,	   polyploidy	   is	   also	   a	   frequent	  
event	   during	   evolution	   as	   genome	   sequencing	   reveals	   many	   contemporary	   genomes,	  
including	  those	  of	  higher	  vertebrates,	  to	  have	  evolved	  from	  ancient	  genome	  duplications	  180.	  
However,	  mounting	  evidence	  suggests	  that	  polyploid	  cells	  are	  genetically	  unstable	  and	  can	  
act	  as	  intermediates	  on	  the	  road	  to	  aneuploidy	  and,	  ultimately,	  cancer	  178,181.	  	  
Aneuploidy,	   the	   numeric	   aberrations	   of	   chromosomes,	   is	   frequently	   observed	   in	   human	  
cancer.	   It	  has	   long	  been	  known	  that	  malignant	  cells	  accumulate	  a	   large	  number	  of	  genetic	  
mutations	   that	   affect	   differentiation,	   proliferation	   and	   cell	   death.	   In	   addition,	   it	   is	   also	  
recognized	  that	  most	  cancers	  are	  clonal,	  although	  they	  display	  extensive	  heterogeneity	  with	  
respect	  to	  karyotypes	  and	  phenotypes	  of	  individual	  clonal	  populations.	  It	  has	  been	  proposed	  
that	   an	   underlying	   acquired	   genetic	   instability	   is	   responsible	   for	   the	   multiple	   mutations	  
detected	  in	  cancer	  cells	  that	  lead	  to	  tumour	  heterogeneity	  and	  progression	  182,183.	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Aneuploidy	   is	   suggested	   to	   have	   a	   causative	   role	   in	   tumourigenesis	   since	   chromosomal	  
instabilities	   and	   aberrations	   correlate	   with	   tumour	   grade	   and	   prognosis	   184,185.	   Further	  
supporting	   this	   argument,	   genes	   involved	   in	   maintaining	   chromosome	   stability	   are	  
frequently	  deregulated	  in	  human	  tumours	  186.	  	  
However,	  even	  though	  aneuploidy	   is	  one	  of	  the	  most	  obvious	  differences	  between	  normal	  
and	  cancer	  cells,	   there	   remains	  debate	  over	  how	  aneuploid	  cells	  arise	  and	  whether	  or	  not	  
they	   are	   a	   cause	   or	   consequence	   of	   tumourigenesis.	   Accumulating	   evidence	   suggests	  
unstable	  tetraploid	  intermediates	  to	  be	  the	  prerequisite	  for	  aneuploidy	  and	  cancer.	  Several	  
mechanisms	   promote	   the	   genesis	   of	   tetraploid	   cells,	   e.g.	   DNA	   replication	   without	  
subsequent	   cell	   division,	   a	   process	   termed	   endoreplication	   187;	   cytokinesis	   failure	   188;	  
defective	   chromosome	   segregation	   189,190;	   chromosome	   non-­‐disjunction	   191;	   defective	  
kinetochore-­‐microtubule	  attachment	  192;	  cell	  fusion	  193	  or	  mitotic	  slippage	  194,195.	  This	  theory	  
is	  in	  accordance	  with	  the	  observation	  of	  tetraploid	  cells	  in	  early-­‐stage	  cervix	  cancer	  196	  or	  the	  
premalignant	  condition	  Barrett´s	  oesophagus	  197,	  whereas	  more	  mature	  tumours	  have	  near-­‐
tetraploid	   karyotypes	   198.	   On	   top,	   inoculation	   of	   tetraploid,	   actin	   inhibitor	   DCB	  
(dihydrocytochalasin	  B)-­‐treated,	  p53-­‐/-­‐	  mouse	  mammary	  epithelial	  cells	  resulted	  in	  malignant	  
mammary	   epithelial	   tumours	   in	   nude	  mice.	   By	   contrast,	   diploid	   cells	   carried	   through	   the	  
same	   isolation	   procedure,	   did	   not.	   Interestingly,	   the	   tetraploid-­‐derived	   tumours	   displayed	  
massive	   chromosomal	   instability,	   including	   both	   numerical	   and	   structural	   chromosome	  
aberrations,	  the	  hallmarks	  of	  aneuploidy	  199.	  
Several	   cell	   cycle	   regulation-­‐relevant	   genes,	   which	   are	   involved	   in	   G2/M	   or	   cytokinesis	  
phases	  of	  the	  cell	  cycle	  have	  been	  described.	  One	  of	  these	  genes	  is	  B-­‐myb,	  which	  is	  induced	  
during	  G1/S	   transition	   of	   proliferating	   cells	   200,201.	   B-­‐myb	   not	   only	   activates	   anti-­‐apoptotic	  
genes	  such	  as	  Bcl-­‐2	  thereby	  promoting	  cell	  survival	  202,	  but	  also	  bears	  essential	  functions	  in	  
stem	  cell	  formation	  203,204.	  Accordingly,	  murine	  B-­‐myb	  knockouts	  are	  early	  embryonic	  lethal	  
204,	   while	   shRNA	   knockdown	   of	   B-­‐myb	   in	   mouse	   embryonic	   stem	   cells	   results	   in	   delayed	  
G2/M	   transit	   and	  polyploidy	   205.	  Aurora	   kinase	  B	   is	   also	   vital	   for	   chromosome	   segregation	  
and	   cytokinesis	   206.	   Inhibition	   of	   Aurora	   B	   function	   results	   in	   multinucleation	   and	  	  
polyploidy207.	   Interestingly,	  Aurora	  B	  is	  overexpressed	  in	  several	  tumour	  types	  and	  in	  some	  
melanoma	   cell	   lines	   208.	   Progression	   through	   the	   cell	   cycle	  mainly	   relies	   on	   two	   classes	   of	  
molecules,	   namely	   cyclin-­‐dependent	   kinases	   (Cdks)	   and	   cyclins	   209.	   In	   late	   G1	   Cdk2	   is	  
activated	  by	  binding	  Cyclin	  E,	  which	  completes	  the	  phosphorylation	  of	  Rb	  family	  members,	  
followed	  by	   further	   transcription	  of	   E2F-­‐responsive	   genes	  ultimately	   allowing	   cells	   to	  pass	  
the	  G1/S	  boundary	  210,211.	  Finally,	  Cdk1/cyclin	  B	  complexes	  actively	  participate	  in	  mitosis	  and	  
allow	  its	  completion	  212.	  Besides,	  degradation	  of	  cyclin	  B	  was	  shown	  to	  be	  the	  prerequisite	  to	  
drive	  human	  cells	  out	  of	  mitosis	  194	  and	  overexpression	  of	  cyclin	  E1	  is	  frequently	  observed	  in	  
tumours	   213.	   DNA	   damage	   induces	   p53-­‐dependent	   transcription	   of	   Krüppel-­‐like	   factor	   4	  
(KLF4)	  214	  in	  turn	  causing	  a	  G1/S	  or	  G2/M	  arrest	  of	  the	  damaged	  cells	  215,216.	  Moreover,	  KLF4	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was	   shown	   to	   exhibit	   anti-­‐apoptotic	   activity	   by	   arresting	   ɣ-­‐irradiated	   cancer	   cells	   and	  
fibroblasts	   in	   a	   p21-­‐dependent	  manner	   217.	   Last	   but	   not	   least,	   KLF4	   directly	   interacts	  with	  
Oct4	   and	   Sox2	   when	   ectopically	   expressed	   to	   reprogram	   somatic	   cells	   into	   induced	  
pluripotent	   stem	   cells	   218.	   Another	   factor	   implicated	   to	   be	   important	   for	   cell	   division	   and	  
apoptosis	   suppression	   is	   a	  16.5	  kDa	  protein,	   the	   smallest	   inhibitor	  of	  apoptosis	   (IAP)	  gene	  
family	   member	   survivin	   219,220.	   Therefore,	   it	   is	   not	   surprising	   that	   survivin	   is	   not	   only	  
overexpressed	  in	  67%	  of	  malignant	  melanoma	  but	  also	  associated	  with	  poor	  prognosis	  in	  a	  
variety	   of	   human	   cancers	   221.	   Besides,	   survivin	   expression	   peaks	   during	   G2/M	   as	   survivin	  
functions	   as	   a	   chromosome	   passenger	   protein	   to	   enable	   correct	   cytokinesis	   222,223.	  
Furthermore,	  survivin	  ablation	  was	  shown	  to	  activate	  a	  p53-­‐dependent	  mitotic	  checkpoint,	  
followed	  by	  upregulation	  of	  p21	  and	  polyploidy	  224.	  For	  megakaryocytes,	  even	  though	  both	  
survivin	  and	  Aurora	  B	  were	  thought	  to	  be	  vital	  for	  the	  chromosome	  passenger	  complex	  and	  
the	   course	   of	   endomitosis	   225,	   a	   megakaryocyte-­‐specific	   knockout	   of	   Survivin,	   did	   not	  
influence	  cell	  survival	  but	  instead	  enhanced	  polyploidy	  226. 
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 Aim	  of	  project	  4.
Cancers	   are	   prevented	   by	   the	   activation	   of	   intrinsic	   tumour	   suppressor	   programmes	   that	  
either	   fix	   the	  damage	   in	  cells	  or	  ensure	  that	   the	  damaged	  cells	  cannot	  propagate.	  Cancers	  
can	   only	   arise	   once	   these	   tumour	   suppressor	   pathways	   are	   abrogated.	   Importantly,	  
activation	  of	   such	   tumour	   suppressor	   pathways	  must	   be	   restricted	  only	   to	   oncogenic,	   not	  
normal,	  growth	  signals.	  Using	  the	  HERmrk	  system,	  my	  PhD	  project	  was	  to	  analyze	  whether	  
and	   if	   so	   how	   the	   highly	   potent	   oncogene	   Xmrk	   was	   capable	   of	   inducing	   senescence	   in	  







 Materials	  and	  Methods	  5.
5.1 Software	  
§ Microsoft	  Word	  2007,	  2010	  
§ Microsoft	  Excel	  2007,	  2010	  
§ Microsoft	  Powerpoint	  2007,	  2010	  
§ CorelDraw	  X5	  
§ Image	  J	  
§ SigmaPlot	  10.0	  
§ Leica	  DMI6000	  software	  
§ Mendeley	  Desktop	  
5.2 Kits	  
 
5.3 Special	  Technical	  Devices	  
§ Inverted,	  fluorescence	  microscope:	  DMI6000	  (Leica)	  and	  Zeiss	  Axiovert	  100	  (Zeiss)	  
§ Microscope	  cameras:	  DFC350	  FX	   (black	  and	  white;	   Leica),	  DFC	  320R2	   (color;	   Leica),	  
Nikon	  Coolpix	  990	  (Nikon)	  and	  Zeiss	  Axiocam	  HRc	  (Zeiss)	  
§ Quantitative	  Realtime	  PCR:	  iCycler	  (Bio-­‐Rad)	  
§ PCR	  cycler:	  T3000	  Thermocycler	  (Biometra)	  
§ DNA/RNA	  quantification:	  NanoDrop	  1000	  (Thermo	  Scientific)	  
§ DNA	  gel	  documentation:	  Decon	  Science	  Tec	  GmbH	  Imaging	  Systems	  
§ Incubators:	  Heraeus	  Typ	  B	  5061	  EK-­‐CO2	   (Heraeus),	  Galaxy	   S	   (RS	  Biotech/nunc)	   and	  
HERAcell	  150i	  (Thermo	  Scientific)	  





§ pSUPER	  (kindly	  provided	  by	  Prof.	  Martin	  Eilers,	  Univerity	  of	  Wuerzburg,	  Wuerzburg,	  
Germany)	  
§ pSUPER-­‐shMiz-­‐1	   (kindly	   provided	   by	   Prof.	   Martin	   Eilers,	   University	   of	   Wuerzburg,	  
Germany)	  




§ pBabe-­‐puro-­‐MYC-­‐wt	  (kindly	  provided	  by	  Prof.	  Martin	  Eilers,	  University	  of	  Wuerzburg,	  
Wuerzburg,	  Germany)	  
§ pBabe-­‐puro-­‐MYCV394D	   (kindly	   provided	   by	   Prof.	   Martin	   Eilers,	   University	   of	  
Wuerzburg,	  Wuerzburg,	  Germany)	  




§ pBabe-­‐MN[EF1a-­‐red	  membrane	  and	  green	  nucleus]-­‐2A-­‐puro	  (kindly	  provided	  by	  Dr.	  




§ PL-­‐SIN-­‐EOS-­‐S(4+)-­‐eGFP	  (a	  gift	  from	  James	  Ellis,	  University	  of	  Toronto,	  Canada,	  kindly	  
provided	  by	  Dr.	  Toni	  Wagner,	  University	  of	  Wuerzburg,	  Wuerzburg,	  Germany)	  
§ pH2B-­‐eGFP	   (kindly	   provided	   by	   Dr.	   Toni	   Wagner,	   University	   of	   Wuerzburg,	  
Wuerzburg,	  Germany)	  
§ pH2B-­‐eBFP2	   (kindly	   provided	   by	   Dr.	   Toni	   Wagner,	   University	   of	   Wuerzburg,	  
Wuerzburg,	  Germany)	  
§ pCDH-­‐CMV-­‐N-­‐RAS61K-­‐EF1-­‐copGFP	   (kindly	   provided	   by	   R.	   Houben,	   University	   of	  
Wuerzburg,	  Wuerzburg,	  Germany)	  
§ p-­‐mOrangeN1	   (kindly	   provided	   by	   Dr.	   Toni	   Wagner,	   University	   of	   Wuerzburg,	  
Wuerzburg,	  Germany)	  
§ p-­‐mCherry-­‐LYN	   (kindly	   provided	   by	   Dr.	   Toni	   Wagner,	   University	   of	   Wuerzburg,	  
Wuerzburg,	  Germany)	  




5.5.1 Primary	  Antibodies	  
 
	  
Antibody	  dilutions	  used	  for	  Western	  blotting	  (WB)	  are	  indicated.	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5.5.2 Secondary	  antibodies	  
 
	  
Antibody	  dilutions	  used	  for	  Western	  blotting	  (WB)	  are	  indicated.	  
5.6 Oligonucleotides	  
 
All	  oligonucleotides	  were	  purchased	  from	  Sigma-­‐Aldrich,	  Mannheim,	  Germany. 
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5.7 shRNA	  Oligonucleotides	  
 
	  





Polymerase	  chain	  reaction	  was	  used	  to	  screen	  bacterial	  clones	  and	  to	  amplify	  CTH	  DNA	  prior	  
to	  sequencing	  and	  subsequent	  cloning	  into	  the	  pBabe-­‐puro	  expression	  vector.	  
PCR	  reaction:	  
§ 19µl	  H2O	  
§ 2µl	  reaction	  buffer	  (10x)	  
§ 1µl	  forward	  primer	  (10pM)	  
§ 1µl	  reverse	  primer	  (10pM)	  
§ 0.7µl	  dNTP	  mix	  (10mM	  each)	  
§ 0.3µl	  Taq	  polymerase	  (5U/µl)	  
§ 1µl	  template	  
PCR	  programme:	  
step	   temperature	  [°C]	   duration	   repetition	  
1	   95	   pre-­‐heating	   	  
2	   95	   5	  min	   	  
3	   57	   30	  sec	   30	  times	  
4	   72	   2	  min	   	  
5	   72	   10	  min	   	  
6	   10	   until	  removed	  from	  the	  cycler	  
6.2 Sequencing	  
Sequencing	   was	   performed	   by	   GATC	   Biotech,	   Konstanz,	   Germany.	   DNA	   samples	   were	  
prepared	  as	  follows:	  First,	  DNA	  was	  diluted	  using	  ddH2O	  to	  a	  final	  concentration	  of	  60ng/µl.	  
30µl	   were	   pipetted	   into	   a	   1.5ml	   reaction	   tube,	   which	  was	   then	   labeled	  with	   a	   green	   bar	  
code,	   which	   had	   previously	   been	   purchased.	   Then	   35µl	   of	   each	   sequencing	   primer	  
(10pmol/µl)	   were	   put	   in	   two	   1.5ml	   reaction	   tubes	   labeled	   with	   according	   yellow	  
oligonucleotide	   bar	   codes.	   Upon	   online	   registration	   on	   the	  GATC	   homepage	   the	   barcodes	  
were	   registered	  and	   the	  primer	   sequences	  were	  deposited.	   Finally,	   a	   small	  box	   containing	  
the	   prepared	   reaction	   tubes	   were	   taken	   to	   the	   university´s	   pick	   up	   point.	   After	   e-­‐mail	  
notification,	  the	  obtained	  sequences	  can	  be	  downloaded.	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6.3 Realtime	  PCR	  
Cells	  were	  starved	  and	  EGF-­‐treated	  as	  described	  and	  RNA	  isolation	  was	  performed	  with	  TRIR	  
solution	   (ABGene,	  Hamburg,	  Germany).	  Whole	  RNA	   (4	  µg)	  was	   reversely	   transcribed	  using	  
the	   RevertAidTM	   First	   Strand	   cDNA	   Synthesis	   Kit	   (Fermentas,	   Leon-­‐Rot,	   Germany).	  
Fluorescence-­‐	   based	   quantitative	   real-­‐time	   polymerase	   chain	   reaction	   (qRT-­‐PCR)	   was	  
performed	   using	   the	   iCycler	   (Bio-­‐Rad,	   Munich,	   Germany).	   See	   materials	   section	   for	  
oligonucleotides	   used.	   Gene	   expression	   was	   normalized	   to	   hypoxanthineguanine	  
phosphoribosyltransferase.	   Relative	   expression	   levels	   were	   calculated	   applying	   REST	  
software	  227.	  
25µl	  qRT-­‐PCR	  reactions	  consisted	  of	  14.25µl	  sterile	  ddH2O,	  2.5µl	  10x	  PCR	  buffer,	  0.7µl	  dNTPs	  
(10	  mM),	   0.25µl	   FITC	   (0.5	   nM	   in	   DMSO),	   0.75µl	   SYBRGreen	   	   	   (2.5x10-­‐3units/µl	   in	   DMSO),	  
0.75µl	  of	  each	  primer	  (10pmol/µl),	  4µl	  template	  and	  0.3µl	  (1.5	  units)	  Taq	  polymerase.	  	  
A	  95°C	  denaturation	  step	  for	  3min	  was	  followed	  by	  an	  amplification	  parameter	  of	  40	  cycles	  
of	  denaturation	  at	  95°C	  for	  25sec,	  annealing	  at	  60°C-­‐	  63°C	  for	  25sec	  and	  primer	  extension	  at	  
72°C	   for	   45sec.	   In	   order	   to	   record	   the	   melting	   curves,	   a	   95°C	   incubation	   for	   1	   min	   was	  
performed	  before	  the	  starting	  temperature	  of	  55°C	  for	  1min	  was	  steadily	  increased	  by	  a	  final	  
incubation	  of	  80	  times	  10sec	  followed	  by	  a	  15°C	  hold.	  Products	  were	  electrophoresed	  on	  2%	  
agarose/	  1xTAE,	  stained	  with	  ethidium	  bromide	  (to	  0.5µg	  /	  ml)	  and	  visualized	  with	  a	  Herolab	  
E.A.S.Y.	  429K	  gel	  documentation	  system.	   
6.4 Microarray	  Analysis	  
NRAS61K	  cells	  were	  treated	  for	  6,	  14	  or	  28	  days	  with	  1µg/ml	  doxycycline	  (Sigma)	  and	  NRAS61K-­‐
AR	   cells	   underwent	   the	   same	   treatment	   for	   10	   days	   before	   being	   harvested.	   RNA	   was	  
isolated	   using	   the	   miRNeasy	   Kit	   (Qiagen).	   The	   following	   analysis	   was	   performed	   by	   Dr.	  
Susanne	   Kneitz	   [Microarray	   Core	  Unit,	   IZKF	   (Interdisciplinary	   Center	   for	   Clinical	   Research),	  
University	   of	   Wuerzburg,	   Wuerzburg,	   Germany],	   using	   the	   Affymetrix	   Gene	   Chip	   Mouse	  
Genome	  430	  2.0.	  All	  data	  were	  analyzed	  using	  different	  R	  packages	  from	  the	  Bioconductor	  
project	  (www.bioconductor.org).	  	  
6.5 Cloning	  
6.5.1 Survivin	  shRNA	  vectors	  
150pg	  (1.5µl	  of	  10pM	  dilution	  in	  H2O)	  of	  each	  shRNA	  oligonucleotide	  pair	  were	  mixed	  with	  
50µl	   annealing	   buffer	   (100mM	  NaCl,	   50mM	  Hepes	   pH	   7.4)	   in	   a	   1.5ml	   Epperdorf	   reaction	  
tube	  before	  being	  boiled	  for	  5	  minutes	  at	  95°C.	  Upon	  switching	  off	  the	  water	  bath	  the	  tube	  
was	  left	  floating	  in	  the	  slowly	  but	  steadily	  cooling	  water	  over	  night.	  The	  following	  day	  1µl	  of	  
a	  1:20	  dilution	  of	  the	  annealing	  reaction	  and	  50ng	  of	  purified	  (Wizard	  SV	  Gel	  &	  PCR	  Clean-­‐Up	  
System;	   Promega,	  Mannheim,	   Germany),	   previously	   digested	   (BglI	   and	   HindIII	   in	   Buffer	   R	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(red)	   (Fermentas/Thermo	   Scientific,	   St.	   Leon-­‐Rot,	   Germany)	   for	   1.5	   hours	   at	   37°C)	  
pRetroSUPER	  vector	  were	  used	  for	  ligation	  with	  T4	  Ligase	  (Fermentas/Thermo	  Scientific,	  St.	  
Leon-­‐Rot,	  Germany)	  in	  the	  corresponding	  buffer	  for	  1	  hour	  at	  room	  temperature. 
6.5.2 Transformation	  
The	  ligation	  reaction	  was	  then	  mixed	  with	  50µl	  of	  competent	  DH5α	  bacteria	  (freshly	  thawed	  
on	  ice	  upon	  removal	  from	  storage	  at	  -­‐80°C)	  and	  put	  at	  42°C	  for	  90	  seconds,	  followed	  by	  a	  45	  
minute	   incubation	   period	   on	   ice	   at	   4°C.	   Transformed	   bacteria	   were	   supplemented	   with	  
800µl	  LB	  and	  incubated	  on	  a	  shaker	  at	  37°C	  for	  about	  1	  hour	  followed	  by	  centrifugation	  at	  
3000rpm	  for	  5	  minutes.	  Supernatant	  was	  discarded	  and	  pellets	  were	  re-­‐suspended	  in	  100µl	  
LB	  before	  plated	  onto	  LB-­‐Amp-­‐agar	  dishes	  before	  being	  incubated	  upside-­‐down	  at	  37°C.	  
6.5.3 Colony	  Screen	  
Colonies	  were	  screened	  for	  successful	  insertion	  of	  annealed	  shRNA	  oligos	  performing	  colony	  
PCR	   with	   pRS_seq	   forward	   and	   reverse	   primers.	   The	   DNA	   of	   two	   positive	   clones	   was	  
amplified	   via	   Midipreps	   (Pure	   Yield	   Midiprep	   System;	   Promega,	   Mannheim,	   Germany)	  
according	  to	  manufacturer´s	  instructions.	  Prior	  to	  transfection	  into	  Hmhi	  cells,	  the	  insert	  was	  
sequenced.	  	  	  	  
6.5.4 CTH	  overexpression	  vector	  
Mouse	  CTH	  DNA	  was	  amplified	  via	  PCR	  using	  Cth-­‐overex	  oligonucleotides	  (CTH-­‐5-­‐BamHI	  and	  
CTH-­‐3flag	   Sal1)	   and	   25ng	   of	   Hmhi-­‐MYC-­‐TA-­‐14	   days	   EGF-­‐cDNA	   as	   template.	   Upon	   gel	  
electrophoresis	  to	  visualize	  PCR	  products	  followed	  by	  gel	  purification	  (Wizard	  SV	  Gel	  &	  PCR	  
Clean-­‐Up	  System,	  Promega)	  both	  CTH	  DNA	  and	  pBabe-­‐puro	  DNA	  was	  sequentially	  digested	  
using	   Sal1	   (Buffer	   O,	   orange;	   Fermentas/Thermo	   Scientific,	   St.	   Leon-­‐Rot,	   Germany)	   and	  
BamHI	  (BamHI	  Buffer;	  Fermentas/Thermo	  Scientific,	  St.	  Leon-­‐Rot,	  Germany)	  for	  1	  hour	  each	  
at	  37°C	  followed	  by	  a	  purification	  step	  upon	  each	  digestion	  step	  (Wizard	  SV	  Gel	  &	  PCR	  Clean-­‐
Up	   System;	   Promega,	   Mannheim,	   Germany).	   Ligation,	   transformation	   and	   screening	   for	  
positive	  clones	   followed	  by	  DNA	  amplification	  was	  performed	  as	  described	  above.	  Prior	   to	  
transfection	  into	  Hmhi	  cells,	  the	  insert	  was	  sequenced. 
6.6 Cell	  Culture	  
The	   EGF-­‐inducible	   version	   of	   the	   oncogenic	   EGFR	   orthologue	   Xmrk	   (“HERmrk”	   or	   shortly	  
“Hm”),	   consisting	  of	   the	  extracellular	  domain	  of	   the	  human	  EGF	   receptor	   (“HER”)	   and	   the	  
intracellular	   part	   of	   Xmrk	   (”mrk”’),	   was	   used	   to	   establish	   stable	   cell	   lines	   of	   the	   mouse	  
melanocyte	   cell	   line	  melan	   a	   71,228.	   Three	   cell	   clones	  with	   different	   expression	   levels	  were	  
chosen	  for	  further	  analyses.	  	  
In	  accordance	  with	  RTK	  expression	  levels,	  cell	  lines	  were	  termed	  Hmlo,	  Hmme	  and	  Hmhi.	  Cells	  
were	  then	  transfected	  with	  pWHE459	  vector,	   that	  allows	  the	  expression	  of	  the	  doxycyclin-­‐
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inducible	  reverse	  transactivator	  229,	  using	  Gene	  Juice	  transfection	  reagent	  (Novagen/Merck,	  
Schwalbach,	   Germany).	   Cells	   were	   selected	   applying	   2mg/ml	   puromycin	   for	   14	   days.	  
pTRE2hyg2-­‐NRAS61K	  was	  transfected	   into	  melan	  a–pWHE459	  cells	  using	  Gene	  Juice	  reagent	  
according	   to	   manufacturer´s	   instructions.	   After	   hygromycin	   selection	   (350mg/ml)	   for	   3	  
weeks,	  cells	  were	  used	  for	  further	  analyses.	  
To	   overexpress	  MYC-­‐TA	   in	  melan-­‐a-­‐N-­‐RAS*	   cells,	  melan	   a	   cells	  were	   first	   transfected	  with	  
the	   TetON	   (see	   TetON/OFF	   section	   for	   detailed	   description)	   plasmid.	   Upon	   neomycin	  
selection	   (800µg/mlfor	   14	   days),	  melan	   a-­‐pTetON	   cells	   underwent	   a	   subsequent	   round	   of	  
transfection	   with	   pTRE2hyg	   or	   pTRE2hyg-­‐N-­‐RAS61K	   followed	   by	   hygromycin	   selection	  
(350mg/ml	  for	  3	  weeks)	  and	  the	  final	  transfection	  with	  pBabe-­‐puro	  or	  pBabe-­‐puro-­‐MYCT58A	  
(kindly	   provided	   by	   Prof.	   Martin	   Eilers,	   University	   of	   Wuerzburg,	   Wuerzburg,	   Germany).	  
Melan	   a-­‐pTRE2hyg-­‐N-­‐RAS*-­‐pBabe-­‐MYC-­‐TA	   and	   the	   respective	   control	   line	   were	   selected	  
applying	  2	  mg/ml	  puromycin	  for	  14	  days	  and	  used	  for	  further	  analyses.	  
All	  melan	  a-­‐derived	  cell	  lines	  were	  grown	  at	  37°C	  and	  5%	  CO2	  in	  DMEM	  medium	  containing	  
10%	  fetal	  calf	  serum	  (FCS;	  PAN	  Biotech,	  Aidenbach,	  Germany)	  supplemented	  with	  antibiotics	  
[penicillin	  (100	  U/ml;	  Gibco/Invitrogen,	  Karlsruhe,	  Germany),	  and	  streptomycin	  (100	  µg/ml,	  
Gibco/Invitrogen,	   Karlsruhe,	   Germany)],	   12nM	   cholera	   toxin	   (Sigma-­‐Aldrich,	   Munich,	  
Germany)	   to	   support	   melanin	   synthesis	   and	   tetradecanoyl-­‐phorbol-­‐acetate	   (TPA;	   PMA)	  
(200nM;	   Sigma-­‐Aldrich,	   Munich,	   Germany)	   (complete	   medium).	   TPA	   supports	   the	   cells`	  
proliferation	  and	  acts	  as	  an	   inducer	  of	  protein	  kinase	  C	  (PKC)	  followed	  by	  activation	  of	  the	  
mitogen-­‐activated-­‐protein-­‐kinase	  (MAPK)	  pathway.	  
For	  senescence	  and	  proliferation	  assays,	  cells	  were	  cultured	  in	  starving	  medium	  [DMEM	  with	  
10%	   dialyzed	   FCS	   (Invitrogen,	   Karlsruhe,	   Germany)]	   for	   three	   days	   before	   the	   assay	   was	  
started.	   Where	   indicated,	   100ng/ml	   human	   epidermal	   growth	   factor	   (EGF)	   (Tebu-­‐bio,	  
Offenbach,	  Germany),	  1mg/ml	  doxycycline	  (Dox;	  Sigma-­‐Aldrich,	  Munich,	  Germany)	  or	  2mM	  
N-­‐acetylcysteine	   (NAC;	   Sigma-­‐Aldrich,	   Munich,	   Germany)	   was	   added.	   Medium	   was	  
supplemented	  with	  EGF,	  Dox	  and	  NAC	  every	  second	  day	  and	  renewed	  every	  four	  days.	  
Normal	   human	   embryonic	   melanocytes	   (NHEM)	   cells	   were	   purchased	   from	   PromoCell	  
(Heidelberg,	   Germany)	   and	   transfected	   with	   pCDH-­‐CMV-­‐NRAS61K-­‐EF1-­‐copGFP	   (kindly	  
provided	   by	   R.	   Houben,	   University	   of	   Wuerzburg,	   Germany)	   before	   being	   cultivated	   in	  
melanocyte	  growth	  medium	  (Promocell,	  Heidelberg,	  Germany)	  throughout	  the	  assay	  period.	  
B16-­‐F1	  murine	  melanoma	  cells	  were	  purchased	  from	  LGC	  Standards/ATCC	  (Wesel,	  Germany)	  
and	  cultured	   in	  DMEM	  (Invitrogen,	  Karlsruhe,	  Germany)	  supplemented	  with	  10%	  FCS	  (PAN	  
Biotech,	   Aidenbach,	   Germany)	   and	   antibiotics	   [penicillin	   (100	   U/ml;	   Gibco/Invitrogen,	  
Karlsruhe,	  Germany),	  and	  streptomycin	  (100	  µg/ml,	  Gibco/Invitrogen,	  Karlsruhe,	  Germany)].	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6.7 SA-­‐β-­‐Galactosidase	  Assay	  
For	   the	   first	  part	  of	  my	  thesis	   (as	  published	   in	   230),	  cells	  were	  plated	   in	  12-­‐well	  dishes	  at	  a	  
density	  of	  4x104	  cells	   /	  well.	  The	  cells	  were	   incubated	   in	  serum-­‐free	  DMEM	  supplemented	  
with	   10%	   dialysed	   FCS	   (Gibco/Invitrogen,	   Karlsruhe,	   Germany;	   starving	   medium)	   and	  
antibiotics	   for	   3	   days	   before	   EGF	   stimulation	   (100ng/ml;	   Tebu-­‐bio,	   Offenbach,	   Germany),	  
NAC	   (2mM)	   or	   doxycycline	   (1mg/ml)	   treatment	   (Sigma-­‐Aldrich,	   Munich,	   Germany)	   	   TPA	  
treatment	   (200	  nM)	  or	   culturing	   in	   complete	  medium.	  These	  media	  were	  also	  used	   for	  all	  
other	  senescence-­‐associated	  assays.	  Cells	  were	  washed	  with	  PBS	  (pH	  7.2)	  and	  fixed	  with	  ice	  
cold	  0.5%	  glutardialdehyde	  in	  PBS	  (pH	  7.2)	  for	  10	  min	  at	  room	  temperature.	  After	  washing	  
the	   cells	   with	   PBS	   (pH	   7.2,	   1mM	  MgCl2)	   they	   were	   stained	   (PBS	   pH	   6.0,	   1	   mg/ml	   X-­‐Gal,	  
0.12mM	  K3Fe(CN)6,	   0.12mM	  K4Fe(CN)6,	   1mM	  MgCl2)	   protected	   from	   light	   for	   3.5	   hours	   at	  
37°C	  and	  5%	  CO2.	  Cells	  were	  washed	  with	  PBS	  (pH	  7.2)	  and	  examined	  by	  light	  microscopy.	   
In	   the	   following,	   an	   enhanced	   SA-­‐β-­‐Gal	   staining	   protocol	  was	   used.	   Cells	  were	   cultured	   in	  
starving	  medium	   (Dulbecco’s	  Modified	  Eagle’s	  Medium	  with	  10%	  dialysed	   fetal	   calf	   serum	  
(Gibco/Invitrogen,	  Karlsruhe,	  Germany)	  for	  3	  days	  before	  the	  assay	  was	  started.	  Cells	  were	  
plated	  in	  six-­‐well	  dishes	  at	  a	  density	  of	  1x105	  cells	  /	  well.	  Where	  indicated,	  100ng/ml	  human	  
EGF	   (Tebu-­‐bio,	   Offenbach,	   Germany),	   2mM	   NAC	   or	   1	   mg/ml	   doxycycline	   (Sigma-­‐Aldrich,	  
Munich,	  Germany)	  was	  added.	  Medium	  was	   renewed	  every	  4	  days,	   and	  EGF	  or	  NAC	  were	  
freshly	  supplied	  every	  second	  day.	  After	  3,	  7	  and	  14	  days,	  cells	  were	  analysed	  as	  described	  
below.	  
At	   indicated	  staining	   time	  points	  cells	  were	  washed	  with	  PBS	   (pH	  7.2)	  and	   fixed	  with	  3.7%	  
formaldehyde	   in	  PBS	   (pH	  7.2)	   for	  5	  min	  at	   room	  temperature.	  After	   rinsing	   the	  cells	   twice	  
with	  PBS	  (pH	  7.2),	  they	  were	  stained	  in	  the	  dark	  for	  12	  h	  at	  37°C	  (using	  1	  mg/mL	  of	  X-­‐Gal,	  
40mM	   citric	   acid/sodium	   phosphate	   buffer	   (pH	   6.0),	   5mM	   potassium	   ferricyanide,	   5mM	  
potassium	  ferrocyanide,	  150mM	  NaCl,	  and	  2mM	  MgCl2).	  Cells	  were	  then	  washed	  with	  PBS	  
(pH	  7.2)	  and	  examined	  by	  light	  microscopy.	   
6.8 Crystal	  violet	  staining	  
Cells	  were	   cultured	   and	  prepared	   as	   described	   for	   the	   SA-­‐β-­‐Gal	   assay	   and	   fixed	   at	   day	  14	  
using	  methanol	   (-­‐20°C)	   before	   cells	   and	   colonies	   were	   stained	   with	   0.1%	   crystal	   violet	   in	  
distilled	   water.	   To	   ensure	   equal	   staining	   distribution,	   six-­‐well	   cell	   culture	   dishes	   were	  
incubated	  on	  a	  shaker.	  Upon	  staining,	  cells	  were	  washed	  10	  times	  for	  5	  minutes	  each	  using	  
distilled	   water.	   Intensive	   washing	   ensures	   removal	   of	   stain	   excess.	   Afterwards	   cells	   were	  
examined	  by	  light	  microscopy.	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6.9 Cell	  Quantification	  
Multinuclear	  as	  well	  as	  SA-­‐β-­‐Gal	  stained	  multinuclear	  cells	  were	  enumerated	  manually.	  Per	  
assay,	   four	   phase	   contrast	   images	   (altogether	   approximately	   12.6mm2	   per	  well)	   and	   their	  
brightfield	  counterparts,	  both	  taken	  at	  100-­‐fold	  magnification,	  were	  used	  to	  determine	  the	  
propotion	  of	  senescent	  and	  multinucleated	  cells	  on	  the	  total	  cell	  number	  manually.	  	  
6.10 Cell	  Proliferation	  Assay	  
5x104	  cells	  per	  well	  were	  seeded	  onto	  a	  six-­‐well	  plate	  and	  either	  left	  untreated	  or	  stimulated	  
with	  100ng/ml	  EGF	  or	  1µg/ml	  Dox.	  Cells	  were	  harvested	  by	  trypsinization	  at	  indicated	  time	  
points,	   pelleted,	   resolved	   in	   PBS	   and	   enumerated	   manually	   using	   a	   standard	   Neubauer	  
counting	  chamber. 
6.11 Soft	  Agar	  Growth	  Assay	  
One	   millilitre	   of	   1.2%	   agar	   in	   H2O,	   which	   had	   been	   boiled	   until	   completely	   dissolved,	  
autoclaved	  and	  then	  cooled	  down	  and	  kept	  at	  50°C	  for	  further	  usage,	  was	  mixed	  with	  1ml	  
2x-­‐Dulbecco’s	  Modified	  Eagle’s	  Medium	  (DMEM)	  prepared	  from	  DMEM	  powder	  purchased	  
from	  Gibco	  (#52100-­‐039	  containing	  4.5g/l	  glucose,	  lacking	  pyruvate	  and	  NaHCO3)	  and	  plated	  
onto	   six-­‐well	  plates	   (BD	  Falcon).	  Upon	  polymerization,	   the	   solid	  agar	  was	  overlain	  with	  an	  
equal	  amount	  of	  soft	  agar	  mix	   (0.6%	  agar)	  containing	  4x104cells	  per	  well.	  The	  polymerized	  
soft	  agar	  was	  supplied	  with	  100µl	  of	  starving	  media	  for	  the	  controls	  and	  the	  same	  amount	  of	  
starving	   media	   including	   EGF	   (final	   concentration	   per	   well:	   100ng/ml),	   doxycycline	   (final	  
concentration	   per	   well:	   1µg/ml),	   medium	   supplemented	   with	   FCS	   alone	   (D10,	   final	  
concentration	  per	  well:	  10%)	  or	  supplemented	  with	  TPA	  and	  cholera-­‐toxin	   (complete,	   final	  
concentration	   per	   well:	   200nM	   and	   12nM,	   respectively).	   This	   solution	   was	   added	   every	  
second	  day	  and	  six-­‐wells	  were	   left	  open	  until	   liquid	  had	  been	  completely	  absorbed	  by	   the	  
agar.	  After	  14	  days	  of	  growth	  under	  standard	  culture	  conditions	  (37°C,	  5%	  CO2),	  the	  number	  
of	  cell	  colonies	  was	  counted,	  with	  “colony”	  being	  defined	  as	  more	  than	  eight	  cells	  per	  spot.	  If	  
counting	  was	  impossible	  due	  to	  high	  colony	  numbers,	  phase	  contrast	  images	  were	  taken	  at	  
25-­‐fold	  magnification	  using	  the	  DMI-­‐6000	  inverted	  microscope.	   
6.12 Reactive	  Oxygen	  Species	  Detection	  Assay	  
Cells	   were	   starved	   and	   treated	   as	   described	   for	   the	   SA-­‐β-­‐Gal	   assay.	   At	   times	   indicated,	  
20mM	  2´,7´-­‐dichlorofluorescein	  diacetate	  was	  added	   to	   the	  medium,	   thoroughly	  mixed	  by	  
pipetting	  up	  and	  down	  twice	  and	  cells	  were	  stained	  for	  5min	  before	  being	  washed	  with	  PBS	  
and	   overlain	   with	   fresh	   starving	  medium.	   Cells	   were	   analysed	  microscopically	   at	   200-­‐fold	  
magnification	  for	  the	  presence	  of	  ROS-­‐induced	  dichlorofluorescein	  (excitation	  488	  nm)	  using	  
the	  DMI-­‐6000	  Leica	  inverted	  microscope. 
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6.13 Comet	  Assay	  	  
Cells	   were	   cultured	   in	   starving	   medium	   for	   three	   days	   before	   5x104	   cells	   per	   well	   were	  
seeded	   onto	   six-­‐well	   dishes.	   Cells	  were	   either	   left	   untreated	   or	   stimulated	  with	   100ng/ml	  
EGF	   for	   14	   days.	   Cells	   were	   then	   trypsinized	   and	   used	   for	   the	   assay	   as	   described	   in	  
http://www.cometassayindia.org/Dusinska-protocol.PDF.	  Shortly,	  2x104	  cells	  were	  mixed	  
with	  140µl	   low	  melting	  agarose	  (LMP)	   in	  PBS	  at	  37°C.	  The	  mixture	  was	  then	  transferred	  as	  
two	  equal	  drops	   to	  coated	  slides	   (1%	  standard	  agarose	   in	  H2O,	  homemade:	  dip,	  clean	  one	  
side,	   leave	  the	  other	  at	  room	  temperature	  until	  solidified,	  store	  at	  room	  temperature	  until	  
needed).	   Upon	   polymerization,	   the	   slides	   were	   put	   into	   lysis	   solution	   (2.5M	   NaCl,	   0.1M	  
EDTA,	  10mM	  Tris,	  1%	  Triton	  X-­‐100)	  for	  1	  hour	  at	  4°C.	  After	  washing	  the	  slides	  three	  times	  in	  
enzyme	  reaction	  buffer	  (40mM	  HEPES,	  0.1M	  KCl,	  0.5mM	  EDTA,	  0.2mg/ml	  BSA,	  pH	  8.0)	  they	  
were	  treated	  with	  enzyme	  solution	  (0.5mg/ml	  proteinase	  K	  in	  enzyme	  reaction	  buffer)	  and	  
left	   in	   a	   moist	   box	   for	   1	   hour	   at	   37°C	   followed	   by	   alkaline	   treatment	   in	   electrophoresis	  
solution	   (0.3M	  NaOH,	  1mM	  EDTA)	   for	  40	  minutes	   at	   4°C.	   Subsequent	  electrophoresis	  was	  
performed	   at	   room	   temperature	   and	   25V	   for	   30	   minutes.	   Slides	   were	   then	   washed	   in	  
neutralising	  solution	  (0.4M	  Tris,	  pH	  7.5)	  before	  DNA	  was	  stained	  with	  5µg/ml	  Hoechst	  33258	  
in	  ddH2O.	  	  	  	   
6.14 Time	  Lapse	  Analysis	  
Melan	   a-­‐N-­‐RAS61K	   cells	   were	   transiently	   transfected	  with	   pBabe-­‐MN	   [EF1a-­‐red	  membrane	  
and	   blue	   nucleus]-­‐2APuro	   (kindly	   provided	   by	   Dr.	   Toni	  Wagner,	   University	   of	  Wuerzburg,	  
Wuerzburg,	  Germany)	  before	  being	  plated	  onto	  glass	  cover-­‐slips	  or	  Ibidi	  chambers.	  Upon	  16	  
to	  28	  days	  of	  doxycycline	  treatment,	  cells	  were	  monitored	  for	  up	  to	  30	  hours	  at	  a	  100-­‐fold	  
magnification	  with	  pictures	  being	  taken	  every	  15	  to	  20	  minutes. 
6.15 Confocal	  Imaging	  
Confocal	   scans	   were	   taken	   by	   Dr.	   Toni	   Wagner	   with	   a	   Nikon	   C1	   confocal	   laser	   scanning	  
microscope	  using	  a	  60x	  oil	   immersion	  objective.	  Dr.	  Wagner	   stained	   the	  cells’	  membranes	  
with	  cell	  mask	  deep	  red	  and	  DNA	  with	  Hoechst	  33342.	  Imaging	  areas	  were	  randomly	  chosen.	  
Z-­‐stacks	   covered	   the	   full	   depths	   of	   all	   imaged	   cells	   and	   overlapped	   3-­‐fold	   to	   allow	   for	  
maximum	  accuracy	  during	  reconstruction.	  3-­‐dimensional	  reconstruction	  and	  rendering	  were	  
performed	  using	  Volocity	   4.0	   Software	   from	  PerkinElmer.	   The	   same	   software	  was	  used	   to	  
calculate	  cytoplasmic	  and	  nuclear	  volumes.	  Cellmask	  staining	  allowed	  to	  deterimine	  total	  3D	  
cell	   volume	   modelling,	   while	   nuclear	   volumes	   were	   reconstructed	   using	   the	   saturated	  
Hoechst	  signal.	  By	  3-­‐dimensional	  subtraction	  of	  the	  resulting	  virtual	  objects	  the	  cytoplasmic	  
volume	  was	  calculated	  before	  the	  ratio	  between	  nuclear	  and	  cytoplasmic	  volumes	  could	  be	  
determined.	  No	  cells	  in	  metaphase	  were	  used;	  otherwise	  selection	  was	  purely	  random. 
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6.16 In	  Vivo	  Growth	  
Before	  injection	  into	  nude	  mice,	  melan-­‐a	  control	  cells	  (stably	  transfected	  with	  pTRE2hyg	  as	  
empty	  vector	  control)	  and	  N-­‐RAS61R	  cells	  were	  cultured	  in	  DMEM	  containing	  10%	  foetal	  calf	  
serum	  supplemented	  with	  antibiotics,	  12nM	  cholera	  toxin	  to	  support	  melanin	  synthesis	  and	  
200nM	   tetradecanoyl-­‐12,13-­‐phorbolacetate	   (TPA)	   to	   allow	   proliferation.	   In	   contrast,	   N-­‐
RAS61R-­‐AR	  cells	  were	  cultured	  in	  the	  absence	  of	  both	  cholera	  toxin	  and	  TPA.	   	  The	  following	  
experiments	   were	   done	   by	   Dr.	   Christoph	   Otto	   and	   coworkers	   [Experimental	   Surgery,	  
Experimental	  Transplantation	  Immunology,	  Clinic	  of	  General,	  Visceral,	  Vascular	  and	  Pediatric	  
Surgery	   (Surgical	   Clinic	   I),	   University	   of	  Wuerzburg	   Hospital,	  Wuerzburg,	   Germany]:	   Nude	  
mice	  (NMRI,	  Harlan	  strain)	  were	  subcutaneously	  injected	  with	  2.5x106	  melan-­‐a,	  N-­‐RAS61R	  or	  
N-­‐RAS61R-­‐AR	  cells	  per	  flank.	  Where	  indicated,	  2mg/ml	  doxycycline	  (Sigma)	  dissolved	  in	  10%	  
saccharose	  solution	  was	  supplied	  ad	   libitum	  by	  administration	   to	   the	  drinking	  water.	  After	  
four	  weeks,	  N-­‐RAS61R-­‐AR	  mice	  were	  sacrificed	  due	  to	  considerable	  tumour	  load.	  In	  all	  other	  
mice,	  growth	  of	  injected	  cells	  was	  monitored	  for	  10	  weeks	  after	  injection	  before	  sacrificing	  
the	  mice.	   
6.17 Statistical	  Analysis	  
Generally,	   all	   graphs	   depict	   the	   mean	   values	   of	   at	   least	   three	   independent	   experiments	  
unless	   stated	   otherwise,	   standard	   deviations	   are	   indicated.	   Student`s	   t	   test	   (two-­‐tailed,	  
paired)	  revealed	  statistical	  significance	  highlighted	  by	  asterisks	   (*:	  p<0.05;	  **:	  p<0.01,	  ***:	  
p<0.001).	  
6.18 Protein	  Methods	  
6.18.1 Cell	  Lysis	  and	  Immunoblot	  Analysis	  
All	  stimulation	  experiments	  were	  performed	  in	  serum-­‐free	  DMEM	  containing	  antibiotics	  and	  
2.5%	   (characterization	   of	   HERmrk	   clones)	   or	   10%	   dialysed	   FCS	   (senescence	   assays).	  	  
Stimulating	  reagents	  were	  added	  every	  second	  day	  and	  culturing	  medium	  was	  changed	  after	  
four	  days.	  Cells	  were	  harvested,	  transferred	  into	  a	  1.5ml	  tube,	  pelleted	  at	  10.000	  rpm	  for	  2	  
min	  	  and	  washed	  twice	  in	  PBS	  before	  being	  lysed	  in	  lysis	  buffer	  (20mM	  4-­‐(2-­‐hydroxyethyl)-­‐1-­‐
piperazineethanesulphonic	   acid	   (pH	   7.8),	   500mM	   NaCl,	   5mM	   MgCl2,	   5mM	   KCl,	   0.1%	  
deoxycholate,	   0.5%	  Nonidet-­‐P40,	   10mg/ml	   aprotinin,	   10mg/ml	   leupeptin,	   200mM	  Na3VO4,	  
1mM	  phenylmethanesulphonylfluoride	  and	  100mM	  NaF)	  for	  1-­‐3	  hours	  at	  4°C	  and	  pelleted	  at	  
13.000rpm	  for	  15min.	  Cell	  extracts	  were	  standardized	  for	  protein	  content	  using	  the	  Bradford	  
protein	  assay.	  25	  to	  100µg	  were	  used	  for	  Western	  blot	  analysis.	  Proteins	  were	  resolved	  by	  
SDS/PAGE	  using	  SDS	  running	  buffer	  (50mM	  Tris,	  150mM	  glycine,	  0.1%	  SDS)	  and	  transferred	  
to	   nitrocellulose	   according	   to	   standard	   Western	   blotting	   protocols.	   Membranes	   were	  
blocked	  for	  1h	  with	  TBS/0.1	  %	  Tween/1.5	  or	  5	  %	  BSA	  and	  incubated	  with	  the	  first	  antibody	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over	   night	   at	   4°C.	   Blots	   were	   then	   washed	  with	   TBS/0.1	   %	   Tween	   3-­‐5	   times	   for	   5-­‐10min	  
before	  being	  incubated	  with	  the	  secondary	  antibody	  diluted	  in	  TBS/0.1	  %	  Tween/1.5%	  or	  5%	  
BSA	  for	  1h	  at	  room	  temperature.	  After	  a	  final	  round	  of	  washing	  in	  TBS/0.1	  %	  Tween,	  protein	  
levels	   were	   detected.	   Chemiluminescent	   detection	   relied	   on	   horseradish	   peroxidase–
conjugated	   secondary	   antibodies	   (SuperSignal	   West	   Pico	   Chemiluminescent	   Substrate,	  
Pierce/Thermo	   Scientific).	   To	   reprobe	   Western	   blots,	   membranes	   were	   stripped	   with	  
62.5mM	  Tris/HCl	  pH	  6.7,	  2%	  SDS,	  100	  mM	  2-­‐mercapto-­‐ethanol	  for	  20	  min	  at	  50°C	  and	  then	  
washed	  in	  PBS	  and	  TBS/0.1%	  Tween. 
6.18.2 Immunolocalization	  
Melan	  a-­‐HERmrk	  cells	  were	  plated	  onto	  glass	  coverslips	  at	  a	  density	  of	  1x105	  cells	  /	  well	  in	  6-­‐
well-­‐dishes.	  The	  cells	  were	  incubated	  in	  serum-­‐free	  DMEM	  supplemented	  with	  10%	  dialysed	  
FCS	  and	  antibiotics	  for	  3	  days	  before	  EGF	  stimulation	  (100ng/ml),	  TPA	  (200nM)	  and/or	  NAC	  
treatment	   (2mM).	  Cells	  were	  washed	  with	  PBS,	   fixed	  with	  methanol	   (-­‐20°C	   for	  5	  min)	  and	  
permeabilized	  with	  aceton	  (-­‐20°C	  for	  2min).	  Coverslips	  were	  blocked	  with	  PBS/	  1%	  BSA	  for	  
40min	   before	   incubation	   with	   the	   primary	   antibody	   [anti-­‐ɣH2AX	   (1:100;	   Cell	   Signalling,	  
Danvers,	   USA)	   or	   survivin	   (1:100;	   Novus	   Biologicals,	   Littleton,	   USA)]	   and	   CY3-­‐conjugated	  
goat-­‐anti-­‐rabbit	   secondary	   antibody	   (1:100;	   Jackson	   ImmunoResearch	   Laboratories,	  
Newmarket,	  Suffolk,	  UK)	  for	  1h	  each.	  DNA	  was	  DAPI	  stained	  by	  mounting	  the	  coverslips	   in	  






7.1 HERmrk	  expression	  levels	  determine	  cellular	  fate	  in	  melanocytes	  
Three	   different	  mouse	  melan	   a-­‐HERmrk	   (termed	   `HERmrk`,	   abbreviation	   `Hm`)	   cell	   clones	  
expressing	   different	   levels	   of	   the	   EGF-­‐inducible	   variant	   of	   the	   oncogenic	   EGFR	   orthologue	  
Xmrk	   were	   used	   to	   exemplarily	   study	   the	   transformation	   capacity	   of	   receptor	   tyrosine	  
kinases.	   According	   to	   their	   relative	   HERmrk	   expression,	   these	   clones	   were	   termed	   Hmlo,	  
Hmme	  and	  Hmhi,	   indicating	   low,	  medium	  and	  high	   receptor	   levels.	  Western	  blot	  analysis	  of	  
serum-­‐deprived	   and	   EGF-­‐stimulated	   cells	   revealed,	   that	   apart	   from	   Hm	   levels,	   the	  
downstream	  signalling	  molecules	  were	  likewise	  affected	  (Figure	  10).	  Interestingly,	  the	  basal	  
protein	   level	   of	   phosphorylated	  mitogen-­‐activated	   protein	   kinase	   ERK1/2	   (Thr202/Tyr204)	  
was	  higher	  in	  unstimulated	  Hmme	  and	  Hmlo	  cells	  compared	  to	  Hmhi	  cells.	  This	  increased	  basal	  
expression	  level	  is	  likely	  to	  account	  for	  the	  stronger	  P-­‐MAPK	  signal	  of	  Hmme	  and	  Hmlo	  upon	  
EGF	  stimulation	  compared	  to	  the	  Hmhi	  response.	  
 
Figure	  10:	  Western	  blot	  analysis	  determining	  Hm	  receptor	  levels	  and	  downstream	  ERK1/2	  signalling	  
Western	  blot	  analysis	  of	  whole-­‐cell	   lysates	  of	  melan	  a	  and	   the	  melan	  a	  Hm	  cell	   clones	  Hmhi,	  Hmme	  and	  Hmlo	  
probed	  against	  the	  C-­‐terminal	  part	  of	  Xmrk,	  P-­‐ERK1/2	  [(the	  antibody	  detects	  endogenous	  levels	  of	  p44	  and	  p42	  
mitogen-­‐activated	  protein	  kinase	  (ERK1	  and	  ERK2)	  when	  dually	  phosphorylated	  at	  Thr202	  and	  Tyr204	  of	  ERK1	  
or	  Thr185	  and	  Tyr187	  of	  ERK2,	  and	  singly	  phosphorylated	  at	  Thr202	  thus	  generating	  a	  double	  band]	  and	  ERK2	  
(loading	  control).	  Protein	  weights	  are	  indicated	  in	  kDa.	  
To	   see	   whether	   the	   difference	   in	   receptor	   abundance	   and	   downstream	   signalling	   has	   an	  
impact	  on	  proliferation	  and	  transformation	  capacity,	  I	  performed	  proliferation	  and	  soft	  agar	  
assays.	   Long-­‐term	  EGF	   stimulation	  did	  not	   affect	   the	  proliferation	  of	   the	  parental	   cell	   line	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melan	  a,	  but	  it	  stimulated	  proliferation	  of	  all	  three	  Hm	  clones.	  Hmhi	  cells	  showed	  a	  modest	  
proliferation	   increase	  upon	   EGF	   treatment,	  whereas	   both	  Hmme	   and	  Hmhi	   showed	   a	  more	  
than	  threefold	  higher	  proliferation	  capacity	  (Figure	  11).	  
 
	  
Figure	  11:	  Hm	  receptor	  level	  determines	  proliferation	  extent	  of	  melanocytes	  
Graphs	  depict	  the	  total	  cell	  number	  (mean	  values	  of	  three	  independent	  experiments)	  of	  melan	  a	  and	  the	  melan	  
a-­‐Hm	  cell	  clones	  Hmhi,	  Hmme	  and	  Hmlo	  over	  time	  in	  the	  absence	  (ctrl.)	  or	  presence	  of	  EGF	  (EGF).	  Student´s	  t-­‐test	  
revealed	  statistical	  significances	  indicated	  by	  asterisks	  (*p<0.05,	  **p<0.01,	  ***p<0.001).	  
These	  findings	  were	  in	  accordance	  with	  the	  soft	  agar	  colony	  numbers	  observed	  upon	  14	  days	  
of	  treatment.	  Neither	  melan	  a,	  nor	  any	  of	  the	  Hm	  clones	  formed	  colonies	  in	  starving	  media-­‐
supplemented	  agar.	  However,	  EGF	  treatment	  led	  to	  colony	  formation	  in	  the	  Hm	  clones	  with	  
the	   number	   of	   colonies	   observed	   being	   inversely	   related	   to	   the	   receptor	   levels.	   Notably,	  
melan	  a	  cells	  did	  not	  form	  colonies	  upon	  EGF	  stimulation	  (Figure	  12).	  Taken	  together,	  I	  found	  





Figure	  12:	  Hm	  receptor	  level	  determines	  transformation	  capacity	  of	  melanocytes	  
The	  graph	  depicts	  the	  total	  number	  of	  soft	  agar	  colonies	  (mean	  values	  of	  three	  independent	  experiments)	  per	  
6-­‐well	  upon	  14	  days	  of	  EGF	  treatment	  of	  indicated	  cell	  clones.	  
To	   check	  whether	   the	   limited	   proliferation	   capacity	   of	  Hmhi	  might	   be	   the	   consequence	   of	  
senescence	   induction,	   I	   performed	   senescence-­‐associated	   β-­‐galactosidase	   (SA-­‐β-­‐Gal)	  
stainings	  (Figure	  13).	  Even	  though	   long-­‐term	  cultivation	  of	  melan	  a	  as	  well	  as	  all	   three	  Hm	  
clones	   in	  starving	  medium	  increased	  the	  number	  of	  SA-­‐β-­‐Gal	  positive	  cells	  over	  time,	  their	  
proportion	  never	  exceeded	  1.1%.	  Besides,	  melan	  a	  cells	  were	  indifferent	  to	  EGF	  stimulation,	  
but	   Hmlo	   and	   Hmme	   melanocytes	   responded	   with	   a	   modest	   increase	   in	   the	   number	   and	  
proportion	  of	   SA-­‐β-­‐Gal	  positive	   cells	  over	   time.	  However,	  Hmhi	   cells	   showed	  a	   strong	   shift	  
towards	  senescence,	  resulting	  in	  about	  one	  third	  being	  multinucleated	  and	  15%	  being	  SA-­‐β-­‐
Gal	  positive	  upon	  14	  days	  of	   EGF	   stimulation	   (Figure	  14).	  Hence,	  high	  expression	   levels	  of	  





Figure	  13:	  Hm	  receptor	  level	  determines	  senescence	  extent	  of	  EGF-­‐treated	  melanocytes	  
SA-­‐β-­‐Gal	  pictures	   (100-­‐fold	  magnification)	   illustrating	   the	  parental	   cell	   line	  melan	  a	  and	   the	   three	  Hm	  clones	  
upon	  14	  days	  of	  cultivation	   in	  starving	  medium	  alone	  (ctrl.)	  or	  supplemented	  with	  EGF	  (EGF).	  The	  upper	  two	  
panels	  show	  phase	  contrast	  and	  the	  lower	  one	  brightfield	  (BF)	  images.	  	  




Figure	  14:	  Hm	  receptor	  level	  determines	  senescence	  extent	  of	  EGF-­‐treated	  melanocytes	  
The	  graphs	  depict	  the	  proportion	  of	  SA-­‐β-­‐Gal	  positive	  cells	  on	  the	  total	  cell	  number	  observed	  over	  time	  for	  the	  
parental	   cell	   line	   melan	   a	   and	   the	   three	   Hm	   clones	   when	   cultivated	   in	   starving	   medium	   alone	   (ctrl.)	   or	  
supplemented	  with	  EGF	  (EGF).	  At	  indicated	  time	  points	  SA-­‐β-­‐Gal	  stainings	  were	  performed.	  Graphs	  display	  the	  
mean	   values	   of	   three	   independent	   experiments,	   standard	   deviations	   are	   shown.	   Statistical	   significance	   was	  
assessed	  by	  student´s	  t-­‐test	  (2-­‐sided,	  paired)	  comparing	  ctrl.	  to	  EGF	  samples	  at	  each	  time	  point	  and	  highlighted	  
by	  an	  asterisk	  (*p<0.05).	  Please	  note	  the	  different	  scales	  of	  the	  y-­‐axes.	  
7.2 Multinuclear	  melanocytes	  are	  senescent	  and	  generated	  by	  endomitosis	  
and	  fusion	  	  
One	  of	   the	  most	  notable	   features	  of	   the	  Hmhi	   line	  was	   the	  occurrence	  of	   enlarged,	  highly	  
multinucleated	  cells	  upon	  long-­‐term	  EGF	  stimulation,	  which	  preceded	  the	  positive	  SA-­‐β-­‐Gal	  
response.	  Moreover,	  the	  vast	  majority	  of	  blue	  cells	  had	  multiple	  nuclei,	  suggesting	  that	  the	  
multinucleated	   phenotype	   is	   the	   prerequisite	   for	   senescence	   induction	   in	   our	  melanocyte	  
system.	   To	   gain	   insight	   into	   the	   mechanistic	   processes,	   which	   allow	   the	   cells	   to	   become	  
multinucleated,	   I	   stimulated	   a	  mixture	  of	   50%	  Hmhi	   cells	   stably	   transfected	  with	  mOrange	  
(cytosolic),	   25%	   Hmhi	   cells	   transiently	   transfected	   with	   H2BeGFP	   (nuclear),	   and	   25%	  
untransfected	  Hmhi	   cells	  with	   EGF.	  Upon	  14	  days	   of	   EGF	   treatment	   I	   analysed	   16	  pictures	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taken	  at	  randomly	  chosen	  positions	  and	  found	  the	  vast	  majority	  of	  multinucleated	  cells	  had	  
been	  generated	  by	  endomitosis	  and	  only	  few	  had	  undergone	  fusion	  events.	  
 
 
Figure	  15:	  Multinucleated	  cells	  are	  mainly	  generated	  by	  endomitosis	  
(a)	  Image	  of	  Hmhi	  mix	  (50%	  stably	  transfected	  with	  mOrange,	  25%	  transiently	  transfected	  with	  H2BeGFP,	  25%	  
untransfected)	  upon	  14	  days	  of	  EGF	  treatment	  at	  100-­‐fold	  magnification.	  Encircled	  cells	  are	  those	  with	  green	  
and	  unstained	  nuclei	  (highlighted	  by	  yellow	  arrows),	  which	  have	  undergone	  one	  or	  several	  fusion	  events	  upon	  
14	  days	  of	  EGF	  stimulation.	  (b)	  The	  graph	  depicts	  the	  proportion	  of	  cells	  which	  have	  undergone	  either	  fusion	  
(differently	  coloured	  nuclei	  or	  red	  cytoplasm	  and	  stained	  nucleus/nuclei)	  or	  endomitosis	  (two	  or	  more	  nuclei	  of	  
the	  same	  colour	   in	  a	  single	  cell)	  or	  both	  on	  the	  total	  cell	  number.	  Bars	  represent	  mean	  values	  of	  the	  cellular	  
events	  observed	  in	  16	  pictures	  taken	  at	  randomly	  chosen	  positions	  within	  the	  6-­‐wells.	  Cells	  were	  enumerated	  
manually.	  	  	  
To	   ensure	   that	   multinucleated	   cells,	   which	   contain	   many	   equally	   coloured	   nuclei,	   were	  
indeed	  the	  result	  of	  nuclear	  divisions	  without	  successive	  cytokinesis	  rather	  than	  the	  effect	  of	  
numerous	   fusion	   events,	   we	   performed	   time	   lapse	   analyses	   of	   EGF-­‐stimulated	   Hmhi	   cells	  
(Figure	  16).	  With	  the	  help	  of	  Professor	  J.	  Hoppe´s	  heatable	  incubation	  chamber	  attached	  to	  a	  
microscope	   (see	   acknowledgement	   section	   in230),	   I	   could	   observe	   endomitoses	   as	   well	   as	  
rare	  fusion	  events.	  Interestingly,	  even	  in	  cases	  of	  fusion,	  endomitosis	  frequently	  occurred	  in	  





Figure	  16:	  Endomitosis	  and	  fusion	  generate	  multinucleated	  melanocytes	  
Hmhi	  cells	  were	  monitored	  for	  17	  hours	  upon	  7	  days	  of	  EGF	  treatment.	  Pictures	  were	  taken	  every	  20	  minutes	  at	  
100-­‐fold	   magnification.	   Equally	   cropped	   images	   are	   shown.	   Time	   points	   are	   indicated.	   (a)	   Endomitosis.	   (b)	  
Fusion.	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7.3 pRB	  and	  p53	  are	  induced	  by	  HERmrk	  	  
The	  two	  major	  senescence-­‐inducing	  pathways	  are	  p53	  and	  pRb	  231.	  To	  identify	  crucial	  players	  
in	  our	  melanocyte	  senescence	  model,	  I	  examined	  the	  transcript	  as	  well	  as	  the	  protein	  levels	  
of	   these	   senescence	   inducers	   and	   their	   upstream	   activators	   p19ARF	   (Arf),	   the	   cyclin-­‐
dependent	  kinase	  inhibitors	  p16INK4A	  (Ink4a),	  p15INK4B	  (Ink4b),	  p21WAF	  (p21)	  and	  p27KIP1	  (p27)	  
(Figure	   17).	   Arf	   transcription	   and	   protein	   levels	   were	   elevated	   upon	   long-­‐term	   EGF	  
stimulation	   in	   Hmlo	   and	   Hmhi	   cells,	   whereas	   the	   induction	   in	   Hmme	  melanocytes	  was	   only	  
modest.	  Interestingly,	  ARF´s	  downstream	  target	  p53	  was	  found	  to	  increase	  concurrently	  with	  
the	  p53	  protein	  level	  being	  highest	  in	  the	  senescent	  Hmhi	  cells.	  However,	  data	  obtained	  for	  
the	   cyclin-­‐dependent	   kinase	   inhibitor	   genes	  were	   inconclusive.	  While	   Ink4a	   transcript	  was	  
slightly	   induced	   in	   the	  non-­‐senescing	  Hmlo	   and	  Hmme	   as	  well	   as	   the	   senescing	  Hmhi	   clone,	  
increased	   protein	   levels	   could	   only	   be	   detected	   in	   Hmhi	   cells.	   Besides,	   Ink4b	  mRNA	   levels	  
were	  exclusively	  elevated	  in	  Hmlo	  cells,	  whereas	  INK4B	  protein	  was	  detected	  in	  Hmhi	  cells	  at	  
day	  14.	  Moreover,	  even	  though	  p21	  transcripts	  were	  found	  to	  be	  highly	  up-­‐regulated	  in	  the	  
senescent	  cell	  line	  Hmhi,	  only	  a	  faint	  increase	  of	  p21	  protein	  was	  observed,	  while	  p27	  protein	  
remained	   undetectable.	   Finally,	   investigaton	   of	   the	   protein	   levels	   of	   the	   downstream	  
effector	  pRB	  revealed	  the	  hyperphosphorylated,	   inactive	   form	  was	  no	   longer	  detectable	   in	  
Hmhi	  cells	  at	  late	  time	  points,	  while	  hypophosphorylated,	  active	  pRB	  accumulated	  similarly	  in	  




Figure	  17:	  Inconclusive	  mRNA	  expression	  levels	  of	  known	  senescence-­‐associated	  genes	  
qRT-­‐PCR	  analyses	  of	  known	  senescence-­‐associated	  p53	  and	  pRb	  pathway	  components	  for	  the	  parental	  cell	  line	  
melan	   a	   and	   the	   Hm	   clones	   Hmlo,	   Hmme	   and	   Hmhi.	   The	   graphs	   depict	   the	  mean	   values	   of	   3-­‐5	   independent	  
experiments;	  each	  bar	  represents	  the	  mRNA	  fold	   induction	  upon	  EGF	  treatment	   in	  reference	  to	  starved	  cells.	  
Expression	  levels	  were	  normalized	  to	  HPRT.	  




Figure	  18:	  Analysis	  of	  protein	  levels	  of	  senescence	  markers	  
Western	   blot	   analyses	   of	   known	   senescence-­‐associated	   p53	   and	   pRb	   pathway	   components	   for	  melan	   a	   Hm	  
clones	   Hmlo	   (a),	   Hmme	   (b)	   and	   Hmhi	   (c).	   β-­‐actin	   served	   as	   loading	   control.	   The	   respective	   protein	   weight	   is	  
indicated	  in	  kDa.	  
Taken	   together,	   the	  molecular	   events	   accompanying	   HERmrk-­‐induced	   senescence	   did	   not	  
point	   to	   a	   single	   senescence	   mediator.	   Besides,	   the	   changes	   we	   observed	   in	   cyclin-­‐
dependent	   kinase	   inhibitor	   expression	   were	   only	   humble	   compared	   to	   those	   observed	   in	  
other	  premature	  senescence	  systems	  10,88,232,233.	  However,	  the	  combination	  of	  high	  ARF	  and	  
p53	  protein	  together	  with	  the	  slightly	  enriched	  INK4A	  and	  INK4B	  levels	  accompanied	  by	  the	  
lack	   of	   hyperphosphorylated	   pRb	   exclusively	   observed	   for	   Hmhi	   cells	   might	   account	   for	  
senescence	  induction.	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7.4 DNA	  damage	  response	  is	  activated	  in	  cells	  bearing	  high	  levels	  of	  active	  
HERmrk	  	  
Since	  the	  p53	  pathway	  was	  found	  to	  be	  strongly	  activated	  in	  Hmhi	  cells,	   I	  was	  interested	  in	  
p53	   regulation	   in	   this	   melanocyte	   clone.	   Besides,	   DNA	   damage	   response	   pathways	   are	  
known	   to	   play	   a	   crucial	   role	   for	   p53	   function	   and	   senescence	   induction	   234–236.	   The	   DNA	  
damage	   response	   is	   activated	  when	   DNA-­‐damaging	   events,	   e.g.	   oxidative	   stress,	   threaten	  
the	   cell.	   Then,	   ataxia	   telangiectasia	   mutated	   (ATM)	   is	   one	   of	   the	   first	   components	   to	   be	  
activated	  and	  recruited	  to	  the	  DNA	  damage	  site.	  In	  turn,	  the	  ATM	  target	  checkpoint	  kinase	  2	  
(CHK2)	  is	  activated	  and	  blocks	  cell	  cycle	  progression.	  Interestingly,	  CHK2	  activation	  has	  been	  
described	   to	   be	   both	   necessary	   and	   sufficient	   for	   senescence	   induction	   in	   various	   non-­‐
melanocyte	   cell	   culture	   systems	   237–239.	   The	  DNA	   damage	   response	   components	   ATM	   and	  
ataxia	   telangiectasia	   and	   Rad3	   related	   (ATR)	   share	   a	   common	   target,	   namely	   p53,	   and	  
phosphorylate	  the	  protein	  at	  Ser15	  (human)	  or	  Ser18	  (mouse).	  This	  activating	  modification	  
allows	  p53	  to	   interact	  with	  vital	  transcriptional	  co-­‐activators	  240,241.	  To	  scrutinize	  a	  possible	  
role	   for	   DNA	   damage	   response	   in	   our	   melanocyte	   senescence	   model,	   I	   monitored	   the	  
protein	  levels	  of	  P-­‐CHK2	  Thr77	  (=	  human	  Thr68)	  and	  P-­‐p53	  Ser18	  (Figure	  19).	  Western	  blot	  
analyses	   revealed	  EGF	  treatment	  of	  Hmhi	  cells	   to	  augment	  both	  P-­‐CHK2	  and	  P-­‐p53	  protein	  
levels	   (Figure	   19c).	   This	   strong	   increase	   was	   neither	   observed	   for	   EGF-­‐stimulated,	   non-­‐
senescing	   Hmlo	   nor	   for	   Hmme	   cells	   (Figure	   19a	   and	   b).	   Hence,	   the	   DNA	   damage	   response	  
seems	  to	  contribute	  to	  senescence	  in	  our	  melanocyte	  model.	  
Figure	  19:	  DNA	  damage	  response	  is	  activated	  in	  senescent	  Hmhi	  cells	  
Western	  blot	  analyses	  of	  the	  DNA	  damage	  markers	  P-­‐p53	  (Ser18)	  and	  P-­‐CHK2	  (Thr	  77)	  for	  melan	  a	  Hm	  clones	  
Hmlo	  (a),	  Hmme	  (b)	  and	  Hmhi	  (c).	  β-­‐actin	  served	  as	  loading	  control.	  The	  respective	  protein	  weight	  is	  indicated	  in	  
kDa.	  
To	   investigate	   the	  DNA	  damage	   level	  more	  closely,	  we	  performed	  an	   immunofluorescence	  
staining	  using	  an	  antibody	  recognizing	  phospho-­‐histone	  2A.X	  (Ser139)	   (ɣ-H2AX).	  At	  sites	  of	  
double-­‐strand	   breaks,	  ɣ-H2AX	   accumulates	   in	   a	   distinctive,	   spotty	   pattern.	   Even	   though	   a	  
basal	  level	  of	  DNA	  damage	  was	  detectable	  for	  all	  Hm	  clones	  upon	  long-­‐term	  starvation,	  EGF	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treatment	   exclusively	   augmented	   ɣ-H2AX	   in	   senescent	   Hmhi	   cells	   (Figure	   20).	   Fittingly,	  
highest	  ɣ-H2AX	  levels	  could	  be	  detected	  in	  multinucleated	  Hmhi	  cells.     
Figure	  20:	  DNA	  double	  strand	  breaks	  in	  senescent	  Hmhi	  cells	  
ɣ-H2AX	  immunofluorescence	  images	  (400x	  magnification)	  illustrating	  the	  level	  of	  DNA	  double	  strand	  breaks	  for	  
melan	  a	  Hm	  clones	  Hmlo	  (a),	  Hmme	  (b)	  and	  Hmhi	  (c)	  after	  14	  days	  in	  starving	  medium	  alone	  (-­‐)	  or	  supplemented	  
with	  EGF	  (EGF).	  DAPI	  was	  used	  to	  counterstain	  DNA.	  
7.5 Reactive	  oxygen	  species	  mediate	  the	  senescence	  response	  	  
DNA	  damage	  can	  be	  caused	  by	  reactive	  oxygen	  species	  (ROS).	  Aberrant	  RAS	  signalling	  often	  
goes	   along	   with	   ROS	   242,243,	   which	   cause	   senescence	   in	   fibroblasts	   74,244.	   Therefore,	   we	  
performed	   senescence	   assays	   to	   analyse	   ROS	   production	   in	   Hmhi	   cells	   applying	   2`,7`-­‐
dichlorodihydrofluorescein	   diacetate	   (DCF-­‐DA).	   This	   non-­‐fluorescent	   dye	   is	   converted	   to	  
fluorescent	  DCF	  only	   in	  presence	  of	  ROS.	   In	  accordance	  with	  the	  data	  obtained	  in	  the	  DNA	  
damage	  assays,	  ROS	  were	  exclusively	  present	   in	   EGF-­‐stimulated	  Hmhi	   cells	   at	   stages	  when	  
cells	   had	   become	   senescent.	   Then,	   I	   co-­‐treated	   EGF-­‐stimulated	   Hmhi	   cells	   with	   the	   ROS	  
scavenger	  N-­‐acetylcysteine	  (NAC).	  NAC	  treatment	  both	   lowered	  the	  senescence	  degree	  (to	  
~33%)	   and	   induced	   proliferation	   of	   Hmhi	   cells	   upon	   EGF	   stimulation	   (Figure	   21)	   further	  
supporting	  the	  role	  of	  ROS	  for	  senescence	  induction	  in	  our	  melanocyte	  model.	  	  




Figure	  21:	  NAC	  treatment	  counteracts	  HERmrk-­‐induced	  senescence	  
DCF	   staining	   images	   (200-­‐fold	   magnification;	   DCF)	   of	   melan	   a	   cell	   clones	   melan	   a,	   Hmlo,	   Hmme	   and	   Hmhi	   in	  
absence	   or	   presence	   of	   the	   reactive	   oxygen	   species	   scavenger	   NAC	   upon	   14	   days	   of	   EGF	   treatment.	  
Corresponding	  phase	  contrast	  images	  (PH)	  are	  shown.	  
These	  data	  allow	   for	   the	  conclusion	   that	  ROS	  mediate	   the	  HERmrk-­‐induced	  appearance	  of	  
multinucleated	  and	  senescent	  cells.	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7.6 Oncogenic	   N-­‐RAS	   expression	   also	   drives	   melanocytes	   into	   a	  
multinucleated,	  senescent	  state	  
To	  check	  if	  oncogenes	  other	  than	  Xmrk	  were	  also	  capable	  of	  inducing	  senescence	  in	  mouse	  
melanocytes,	   I	   performed	   senescence	   assays	   with	   melan	   a	   cells	   bearing	   a	   doxycycline-­‐
inducible	  version	  of	  the	  human	  melanoma	  oncogene	  N-­‐RAS61K	  (‘N-­‐RAS*’).	  SA-­‐β-­‐Gal	  stainings,	  
DCF-­‐DA	   assays	   as	   well	   as	   DNA	   damage	   assays	   of	   empty	   vector	   control	   cells	   (ctrl.)	   were	  
compared	   to	   N-­‐RAS*-­‐expressing	   melanocytes	   (N-­‐RAS*,	   Figure	   22).	   Interestingly,	   N-­‐RAS*	  
expression	   mimicked	   the	   phenotype	   observed	   upon	   Hmhi	   stimulation	   in	   our	   melanocyte	  
model.	  Not	  only	  did	  N-­‐RAS*	  force	  melanocytes	  into	  a	  SA-­‐β-­‐Gal-­‐positive,	  multinucleated	  state	  
(Figure	   22a)	   but	   also	   induced	   the	   DNA	   damage	   marker	   P-­‐p53	   and	   allowed	   for	   ɣ-­‐H2AX	  
presence	  (Figure	  22c),	  as	  well	  as	  ROS	  detection	  (Figure	  22d).	  However,	  ROS	  levels	  in	  N-­‐RAS*	  
cells	  were	  lower	  than	  those	  observed	  upon	  EGF	  treatment	  of	  Hmhi	  cells.	  Hence,	  oncogenic	  N-­‐
RAS	   alone	   also	   lead	   to	   increased	   ROS	   levels,	   DNA	   damage	   and	   a	   multinucleated	   and	  
senescent	  phenotype	  that	  resembled	  the	  situation	  observed	  upon	  activation	  of	  HERmrk,	  an	  
upstream	  activator	  of	  the	  RAS/RAF/MAPK	  pathway.	  
Figure	  22:	  Oncogenic	  N-­‐RAS	  results	  in	  ROS	  generation,	  DNA	  damage	  and	  senescence	  
(a)	  Brightfield	   images	  (100-­‐fold	  magnification)	  of	  melan	  a	  cells	  bearing	  the	  empty	  vector	  control	   (ctrl.)	  or	  the	  
doxycycline-­‐inducible	   oncogenic	   N-­‐RAS	   (N-­‐RAS*)	   upon	   14	   days	   of	   doxycycline	   treatment.	   (b)	   P-­‐p53	   (Ser18)	  
Western	   blot	   analyses	   of	  melan	   a-­‐control	   (ctrl.)	   and	  N-­‐RAS*	   cells	   upon	   long-­‐term	   doxycycline	   treatment.	   β-­‐
actin	  served	  as	  loading	  control	  and	  protein	  weights	  are	  stated	  in	  kDa.	  (c)	  ɣ-H2AX	  (Ser139)	  immunofluorescence	  
images	   (400-­‐fold	   magnification)	   of	   melan	   a-­‐control	   (ctrl.)	   and	   N-­‐RAS*	   cells	   upon	   14	   days	   of	   doxycycline	  
treatment.	  DNA	  was	   counterstained	  with	  DAPI.	   (d)	   Phase	   contrast	   (PH)	   and	   corresponding	  DCF	   fluorescence	  
images	  upon	  14	  days	  of	  doxycyclin	  treatment	  (400-­‐fold	  magnification).	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Taken	  together,	  the	  data	  obtained	  from	  Hmhi-­‐	  and	  N-­‐RAS*-­‐expressing	  melanocytes,	  provide	  
evidence	   for	   a	   ROS-­‐dependent	   activation	   of	   the	   DNA	   damage	   response,	   which	   ultimately	  
drives	   melanocytes	   into	   multinucleation	   and	   senescence.	   This	   in	   vitro	   phenomenon	   is	  
oncogene	   level	  dependent	  and	   likely	  resembles	  the	  multinucleated	  phenotype	  observed	   in	  
human	   nevi.	   These	   data	   are	   summarized	   in	   a	   published	  	  
manuscript	  230.	  
7.7 Expression	  analyses	  of	  cytokinesis-­‐associated	  genes	  	  
Since	   multinucleation	   seemed	   to	   be	   the	   prerequisite	   for	   senescence	   induction	   in	   our	  
melanocyte	  model,	   I	   analysed	   the	  expression	  of	   cell	   cycle	   regulation-­‐relevant	  genes	  which	  
are	  involved	  in	  G2/M	  or	  cytokinesis	  phases	  of	  the	  cell	  cycle	  (Figure	  23).	  
I	  therefore	  chose	  to	  look	  at	  the	  mRNA	  regulation	  of	  a	  number	  of	  cell-­‐cycle	  relevant	  genes:	  B-­‐
myb,	   a	   cell-­‐cylce	   regulator	   usually	   induced	   during	   G1/S	   transition	   200,201,	  Aurora	   Kinase	   B,	  
which	  is	  vital	  for	  chromosome	  segregation	  and	  cytokinesis	  206,	  KLF4	  (Krüppel-­‐like	  factor	  4)	   ,	  
which	  is	  DNA	  damage-­‐induced	  214,	  Cyclin	  E1	  that	  influences	  Rb	  phosphorylation	  210,211,	  while	  
Cyclin	  B1	   is	   involved	   in	   the	   regulation	  of	  mitosis	  exit	   212	   and	  Survivin	  which	  plays	  a	   critical	  
role	  in	  ploidy-­‐control	  224.	  	  
Quantitative	   realtime	  PCR	  experiments	  were	  performed	   to	   compare	   the	  mRNA	  expression	  
levels	   of	   cell	   cycle-­‐related	   genes	   in	   the	   three	   Hm	   lines.	   Fold	   induction	   of	   B-­‐myb,	   Aurora	  
kinase	  B	   (Aurk	  B),	  Cyclin	  B1	  and	  E1,	  as	  well	  as	  KLF4	  and	  the	   inhibitor	  of	  apoptosis	  Survivin	  
proved	  to	  be	  high	  in	  EGF-­‐treated,	  senescing	  Hmhi	  cells,	  whereas	  the	  mRNA	  expression	  levels	  
in	  the	  parental	  cell	  line	  melan	  a	  as	  well	  as	  the	  non-­‐senescing	  clones	  Hmlo	  and	  Hmme	  remained	  




Figure	  23:	  Cell	  cycle-­‐associated	  genes	  whose	  expression	  pattern	  parallels	  Hm	  levels	  
qRT-­‐PCR	  analyses	  of	  cell	  cycle-­‐associated	  genes	  for	  the	  parental	  cell	  line	  melan	  a	  and	  the	  Hm	  clones	  Hmlo,	  Hmme	  
and	   Hmhi.	   The	   graphs	   depict	   the	  mean	   values	   of	   3-­‐5	   independent	   experiments	   (exception:	  Aurk	   B	   14	   days,	  
where	  only	  1	  experiment	  was	  performed);	  each	  bar	  represents	  the	  mRNA	  fold	  induction	  upon	  EGF	  treatment	  in	  
reference	  to	  starved	  cells.	  Expression	  levels	  were	  normalized	  to	  HPRT.	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7.8 Survivin	  expression	  in	  HERmrk-­‐mediated	  senescence	  
Interestingly,	   Survivin	   is	   suggested	   to	   be	   a	   promising	   tumour	   marker	   as	   it	   usually	   lacks	  
expression	   in	  terminally	  differentiated	  tissue,	  but	   is	  up-­‐regulated	   in	  most	  cancers	  220,245,246.	  
Additionally,	   Survivin	   is	   a	   vital	   player	   in	   chromosome	   segregation	   and	   associated	   with	  
cytokinesis	  defects	  224.	  As	  described	  earlier,	  Hmhi	  cells	  do	  become	  multinucleated	  –	  probably	  
due	  to	  endomitosis	  based	  on	  a	  failure	  of	  cytokinesis.	  Matching	  these	  facts,	  I	  found	  Survivin	  
mRNA	  levels	  to	  be	  exclusively	  increased	  in	  senescing	  Hmhi	  cells.	  Concluding	  that	  Survivin	  was	  
a	   logically	   linked	   target	   between	   DNA-­‐damage	   and	   multinucleation	   in	   our	   system,	   I	  
investigated	   Survivin	  mRNA	   levels	   upon	   addition	   of	   the	   ROS	   scavenger	  NAC.	   As	   expected,	  
NAC	   treatment	   not	   only	   reduced	   the	   number	   of	   EGF-­‐induced,	   multinucleated,	   senescent	  
Hmhi	  cells,	  but	  also	   lowered	  Survivin	  expression	  (Figure	  24),	  pointing	  to	  a	   link	  between	  the	  
observed	   phenomena	   and	   Survivin	   expression.	   In	   case	   of	   starved	   Hmhi	   cells	   (ctrl.),	   NAC	  
treatment	  slightly	  enhanced	  Survivin	  mRNA	  levels	  (Figure	  24).	  	  
 
Figure	  24:	  ROS	  scavenger	  NAC	  limits	  Survivin	  induction	  upon	  EGF	  treatment	  of	  Hmhi	  cells	  	  
Survivin	   qRT-­‐PCR	   analyses	   for	   senescing	   Hmhi	   melanocytes.	  Where	   indicated,	   Hmhi	   cells	   were	   starved	   (ctrl.),	  
stimulated	   with	   EGF	   and/or	   treated	   with	   the	   ROS	   scavenger	   N-­‐acetylcysteine	   (NAC).	   The	   graph	   depicts	   the	  




To	   check	   if	   Survivin	  mRNA	   induction	   goes	   along	  with	   an	   increase	   in	   protein	   abundance,	   I	  
performed	  immunofluorescence	  assays	  comparing	  starved	  (-­‐)	  or	  EGF-­‐treated	  (EGF)	  Hmhi	  cells	  
(Figure	  25).	  Even	  though	  low	  levels	  of	  survivin	  protein	  could	  be	  detected	  in	  nuclei	  of	  starved	  
Hmhi	  cells	  at	  any	  time	  point,	  survivin	  protein	   levels	  were	  much	  higher	  upon	  EGF	  treatment	  
(Figure	  25).	  Interestingly,	  survivin	  protein	  could	  not	  only	  be	  detected	  in	  nuclei	  but	  also	  in	  the	  
cytoplasm	  of	  multinucleated,	  senescent	  Hmhi	  cells.	  	   
 
Figure	  25:	  Survivin	  protein	  levels	  increase	  upon	  EGF	  treatment	  of	  Hmhi	  cells	  
Representative	   survivin	   immunofluorescence	   images	   (400-­‐fold	  magnification)	   of	   starved	   (-­‐)	   and	   EGF-­‐treated	  
(EGF)	  Hmhi	  cells	  upon	  3,	  7	  and	  14	  days	  of	  treatment.	  DNA	  was	  counterstained	  with	  DAPI.	  
To	   investigate	   the	   effect	   of	   lowered	   Survivin	   mRNA	   levels	   on	   the	   senescing	   Hmhi	  
melanocytes,	   I	   transduced	   them	   with	   either	   an	   empty	   pRetroSUPER	   vector	   (ctrl.)	   or	   one	  
expressing	   one	   of	   three	   different	   short	   hairpin	   RNAs	   directed	   against	   Survivin	   before	  
selecting	   with	   antibiotics	   for	   cells,	   which	   had	   stably	   integrated	   the	   vector.	   Quantitative	  
realtime	  PCR	  and	  Western	  blot	  analyses	  of	  cells	  cultured	  in	  complete	  medium	  revealed	  only	  
a	   slight	   knockdown	   on	   mRNA	   level	   (Figure	   26a)	   and	   apparently	   an	   increase	   in	   survivin	  
protein	   (Figure	   26b).	   However,	   phase	   contrast	   images	   proved	   the	   presence	   of	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multinucleated	  cells	  under	  standard	  culture	  conditions	  in	  complete	  medium	  with	  the	  effect	  
being	  strongest	   for	  shRNA	  #3	  (Figure	  26c).	  Notably,	   the	  survivin	  protein	   level	   in	  any	  of	  the	  
three	   knockdown	   clones	  was	  much	   lower	   than	   than	   that	   in	   both	  melan	   a	   and	  Hmhi	   cells.	  
While	  the	  knockdown	  assay	  should	  be	  repeated	  due	  to	  the	  low	  survivin	  protein	  level	  in	  the	  
ctrl.	   clone,	  my	  observations	   strongly	   point	   towards	   a	   functional	   link	  between	   survivin	   and	  
Hmhi	   multinucleation.	   Unfortunately,	   I	   was	   not	   allowed	   to	   perform	   long-­‐term	   senescence	  
assays	  with	   these	   cells,	   so	   I	   can	   neither	   comment	   on	   the	   cellular	   features	   under	   starving	  
conditions,	  nor	  upon	  EGF	  stimulation.	  
Taken	  together,	  we	  could	  demonstrate	  that	  melan	  a	  cells	  undergo	  oncogene-­‐induced,	  ROS-­‐
mediated	  senescence	  upon	  HERmrk	  activation	  or	  N-­‐RAS*	  expression.	  This	  effect	  is	  oncogene	  
level-­‐dependent.	  However,	   even	   though	   some	  well-­‐known	   senescence	   inducers	   as	  well	   as	  
the	  mRNA	   expression	   levels	   of	   several	   cell	   cycle-­‐related	   genes	  were	   found	   to	   parallel	   Hm	  






Figure	  26:	  Effects	  of	  Survivin	  shRNA	  knockdown	  in	  Hmhi	  cells	  
(a)	  Survivin	  qRT-­‐PCR	  analysis	  of	  Hmhi	  melanocytes	  bearing	  an	  empty	  vector	  control	   (ctrl.)	  or	  stably	  expressing	  
one	  of	  three	  different	  shRNAs	  directed	  against	  Survivin.	  The	  graph	  depicts	  the	  Survivin	  mRNA	  expression	  level	  
normalized	  to	  the	  empty	  vector	  control	  (ctrl.);	  prior	  to	  that,	  Survivin	  mRNA	  fold	  induction	  had	  been	  normalized	  
to	  HPRT.	   (b)	  Survivin	  Western	  blot	  analysis	  of	  melan	  a	   	  and	  Hmhi	  cells	  as	  well	  as	  Hmhi	  cells	  bearing	  an	  empty	  
vector	   (ctrl.)	  or	  one	  with	  one	  of	   three	  shRNAs	  directed	  against	  Survivin.	  Cells	  had	  been	  cultured	   in	  complete	  
medium	  prior	   to	  harvesting.	  β-­‐actin	   served	  as	   loading	   control.	   (c)	   Phase	   contrast	   images	  of	  Hmhi	   cells	   stably	  
expressing	  the	  empty	  pRS	  vector	  (ctrl.)	  or	  one	  bearing	  a	  shRNA	  directed	  against	  Survivin	  (shRNA	  #1,	  #2	  and	  #3)	  
upon	  puromycin	  selection	  (100-­‐fold	  magnification).	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7.9 HERmrk	  receptor	  expression	  status	  in	  long-­‐term	  stimulation	  assay	  
Since	   we	   experienced	   some	   difficulties	   concerning	   our	   long-­‐term	   experiments	   after	   using	  
different	  kinds	  of	  serum	  as	  well	  as	  dialyzed	  serum,	  I	  was	  wondering	  what	  happened	  to	  the	  
Hm	  receptor	  status	  within	  the	  two	  weeks	  of	  the	  experiment.	  Prior	  to	  these	  Western	  blots,	  
Hm	   receptor	   status	   had	   only	   been	   determined	   upon	   short-­‐term	   receptor	   stimulation	   (10	  
minutes	  up	  to	  2	  hours	  of	  EGF	  treatment).	  
HERmrk	  Western	  blot	  analyses	  (Figure	  27)	  confirmed	  the	  difference	  in	  receptor	  protein	  level	  
for	   the	  Hm	  clones	   in	  starving	  medium:	  Hmlo	  showed	  the	   lowest	  HERmrk	   level,	   followed	  by	  
Hmme	  and	  Hmhi,	  which	  proved	  to	  express	  receptors	  at	  a	  very	  high	  level.	  Interestingly,	  these	  
levels	  changed	  upon	  EGF	  stimulation	  as	  protein	  levels	  diminished	  after	  EGF	  treatment.	  The	  
only	  exception	  seemed	  to	  be	  Hmme	  upon	  3	  days	  of	  treatment:	  The	  detected	  HERmrk	  levels	  
were	  found	  to	  be	  rather	  constant	  even	  though	  the	  detected	  band	  in	  case	  of	  EGF	  stimulation	  
appears	  to	  have	  a	  lower	  protein	  weight	  compared	  to	  its	  untreated	  counterpart.	  Additionally,	  
treatment	  with	  the	  ROS	  scavenger	  N-­‐acetylcysteine	  (NAC)	  apparently	  stabilized	  or	  enhanced	  
the	  HERmrk	  receptor	   level	   in	  Hmhi	  cells	  at	  day	  3,	  despite	  a	   lower	  HERmrk	  status	  upon	  EGF	  
stimulation.	   Nevertheless,	   after	   7	   and	   14	   days	   in	   culture,	   NAC-­‐treated	   Hmhi	   cells	   showed	  
lower	   HERmrk	   levels	   compared	   to	   Hmhi	   cells	   cultured	   in	   absence	   of	   the	   ROS	   scavenger.	  
Interestingly,	   even	   within	   each	   cell	   line	   and	   treatment,	   receptor	   levels	   varied	   over	   time.	  
However,	  one	  should	  keep	  in	  mind	  that	  we	  are	  looking	  at	  three	  independent	  blots,	  although	  





Figure	  27:	  Hm	  receptor	  status	  of	  Hm	  clones	  during	  long-­‐term	  assay	  
HERmrk	  Western	  blot	  analyses	  of	  Hmlo,	  Hmme	  and	  Hmhi	  cells	  after	  3,	  7	  and	  14	  days	   in	  starving	  medium	  (-­‐)	  or	  
EGF	  treatment	  (EGF)	  in	  absence	  or	  presence	  of	  the	  ROS	  scavenger	  N-­‐acetylcysteine	  (NAC).	  35µg	  of	  whole	  cell	  
lysates	  were	  separated	  using	  10%	  SDS	  gels.	  β-­‐actin	  served	  as	  loading	  control.	  Protein	  weights	  are	  indicated	  in	  
kDa.	  
Taken	  together,	  these	  Western	  blots	  suggest	  the	  Xmrk	  receptor	  to	  be	  internalized	  upon	  EGF	  
stimulation.	  However,	   these	  analyses	  only	  give	  us	  a	   first	  hint	  at	  what	   is	   likely	   to	  be	   taking	  
place.	  Hence,	  fluorescent	  labelling	  followed	  by	  realtime	  imaging	  of	  the	  receptor	  might	  be	  a	  
useful	  tool	  to	  further	  investigate	  the	  intracellular	  scenarios.	  	  
While	   this	   result	   can	   only	   be	   considered	   to	   be	   a	   primer	   for	   further	   investigation,	   it	  
demonstrates	   that	   there	   is	   an	   important	   additional	   level	   of	   complexity.	   Furthermore,	   it	  
shows	   that	   one	  would	   be	   ill-­‐advised	   to	   base	   conclusions	   on	   the	   assumption	   that	   HERmrk	  
receptor,	  and	  consequently	  signalling	  levels	  are	  constant	  and	  can	  always	  be	  categorized	  by	  
the	   average	   level	   assigned	   to	   the	   Hmlo,	   Hmme	   and	   Hmhi	   lines.	   This	   statement	   is	   further	  
supported	  by	  the	  varying	  P-­‐ERK1/2	  (Thr202/Tyr204)	  protein	  levels	  in	  the	  different	  Hm	  lines	  
upon	  EGF	  stimulation	  (Figure	  10).	  	  	  
Hence,	   this	   observation	   leads	   to	   a	   series	   of	   fascinating	   questions,	   such	   as:	   do	   HERmrk	  
receptors	  continue	  to	  signal	  after	  internalization	  247–249?	  Are	  they	  recycled	  to	  the	  membrane	  
or	  destroyed	   in	   lysosomes	   247,250?	   Is	   the	  HERmrk	   receptor	  surface-­‐density	   regulated	  by	  ER-­‐
retention	   251?	   Is	  EGF	  degraded	  after	   internalization,	  or	  maybe	   transported	  and	   re-­‐released	  
from	   the	   cell	   252?	   Is	   the	  multimerisation	  mode	   changed	   due	   to	   changes	   in	   ER-­‐	   or	   surface	  
density	  of	  the	  receptor	  253? 
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7.10 The	   impact	   of	   MYC	   overexpression	   on	   HERmrk-­‐induced	   melanocyte	  
senescence	  	  
Since	   C-­‐MYC	   is	   a	   well-­‐known	   hEGFR	   target	   gene	   254,255,	   which	   has	   been	   reported	   to	   be	  
involved	   in	   senescence	   prevention	   in	  melanoma	   159,	   we	   investigated	   the	   effect	   of	   C-­‐MYC	  
overexpression	   on	   Hmhi-­‐driven	   senescence.	   	   Hmhi	   cells	   were	   transfected	   with	   expression	  
plasmids	   containing	   either	   wildtype	   human	   MYC	   (MYC-­‐wt),	   MYCV394D	   (MYC-­‐VD)	   or	   the	  
mutant	  MYCT58A	   (MYC-­‐TA)	   (Figure	   28a).	   Notably,	  MYC-­‐VD	   is	   deficient	   in	   binding	  Miz-­‐1	   256,	  
while	  the	  MYC-­‐TA	  mutant	  cannot	  be	  phosphorylated	  by	  the	  ubiquitin	  ligase	  Fbw7	  at	  Thr58,	  
leaving	   us	   with	   a	   much	   more	   stable	   C-­‐MYC	   protein	   compared	   to	   its	   wildtype	   equivalent	  
257,258.	   First,	   I	   performed	   proliferation	   assays	   (Figure	   28b).	   Hmhi	   cells	   transfected	  with	   the	  
empty	   control	   vector	   did	   not	   grow	  when	   cultured	   in	   starving	  medium	   alone	   and	   became	  
multinucleated	  upon	  EGF	  stimulation.	  Hmhi-­‐MYC-­‐TA,	  Hmhi-­‐MYC-­‐VD	  and	  Hmhi–MYC-­‐wt	  cells,	  
however,	   only	   showed	   a	   limited	   proliferation	   potential	   in	   starving	   medium	   alone,	   but	  
strongly	  proliferated	  upon	  EGF	  treatment.	  	  




Figure	  28:	  MYC	  overexpression	  enhances	  proliferation	  potential	  in	  Hmhi	  cells	  
(a)	   C-­‐MYC	   Western	   blot	   analysis	   of	   Hmhi	   cells	   stably	   transfected	   with	   an	   empty	   control	   vector	   (ctrl.)	   or	  
overexpressing	  one	  of	   three	  human	  C-­‐MYC	  versions,	  namely	  MYC-­‐wt,	  MYC-­‐VD	  and	  MYC-­‐TA.	  100µg	  of	  whole	  
cell	   lysates	   were	   separated	   using	   a	   10%	   SDS	   gel.	   Cells	   had	   been	   cultured	   in	   complete	   medium	   prior	   to	  
harvesting.	  β-­‐actin	  served	  as	  loading	  control.	  Protein	  weights	  are	  indicated	  in	  kDa.	  (b)	  Graphs	  depict	  the	  total	  
cell	  number	  (mean	  values	  of	  three	  independent	  experiments)	  of	  Hmhi-­‐ctrl.	  (ctrl.),	  Hmhi-­‐MYC-­‐wt	  (MYC-­‐wt),	  Hmhi-­‐
MYC-­‐VD	   (MYC-­‐VD)	   and	   Hmhi-­‐MYC-­‐TA	   (MYC-­‐TA)	   cells	   over	   time	   in	   the	   absence	   (-­‐)	   or	   presence	   of	   EGF	   (EGF).	  
Student´s	  t-­‐test	  (paired,	  2-­‐tailed)	  revealed	  statistical	  significance	  comparing	  starved	  (-­‐)	  and	  EGF-­‐stimulated	  cells	  
at	  each	  time	  point	  indicated	  by	  asterisks	  (*p<0.05,	  **p<0.01,	  ***p<0.001).	  
To	   investigate	   the	   effect	   of	  MYC	  overexpression	  on	   the	   senescence	   extent	   of	  Hmhi	   cells,	   I	  
performed	  senescence	  assays.	  In	  accordance	  with	  the	  positive	  impact	  of	  MYC	  on	  melanocyte	  
proliferation	   upon	   EGF	   treatment,	   I	   found	  MYC	   overexpression	   to	   diminish	   Xmrk-­‐induced	  
senescence	   in	  our	  cell	   culture	  model	   (Figure	  29)	  with	   the	  effect	  being	  most	  prominent	   for	  
MYC-­‐TA	   cells	   (Figure	   29a).	   Enumeration	   revealed	   the	   proportion	   of	  multinucleated,	   SA-­‐β-­‐
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Gal-­‐positive	  cells	  on	  the	  total	  cell	  number	  not	  to	  exceed	  0.5%	  under	  starving	  conditions	  (-­‐)	  
regardless	  of	  MYC	  expression	  status	   (Figure	  29b).	  EGF	  stimulation	   induced	  multinucleation	  
and	  senescence	  in	  Hmhi	  cells	  expressing	  the	  empty	  vector	  control	  (ctrl.)	  mounting	  to	  about	  
15%	   after	   14	   days	   in	   culture.	   Concomitant	   overexpression	   of	   MYC,	   however,	   diminished	  
HERmrk-­‐induced	   senescence	   to	   an	   average	   of	   2.7%	   for	   MYC-­‐wt,	   0.75%	   for	   MYC-­‐VD,	   and	  
dropping	  to	  as	  low	  as	  0.43%	  for	  MYC-­‐TA	  cells	  upon	  EGF	  treatment	  (Figure	  29b).	  	  
 
Figure	  29:	  MYC	  overexpression	  diminishes	  HERmrk-­‐induced	  senescence	  in	  Hmhi	  cells	  
(a)	  Brightfield	  images	  (100-­‐fold	  magnification)	  of	  SA-­‐β-­‐Gal-­‐stained	  Hmhi	  cells	  stably	  transfected	  with	  an	  empty	  
control	  vector	  (ctrl.)	  oroverexpressing	  MYC-­‐TA	  upon	  14	  days	  of	  treatment.	  Where	  indicated,	  cells	  were	  cultured	  
in	  starving	  medium	  alone	  (-­‐)	  or	  stimulated	  with	  EGF	  (EGF).	  (b)	  Graphs	  depict	  the	  proportion	  of	  senescent	  cells	  
on	  the	  total	  cell	  number	  over	  time.	  Cells	  were	  either	  cultured	  in	  starving	  medium	  alone	  (-­‐)	  or	  stimulated	  with	  
EGF.	  Bars	  represent	  the	  mean	  values	  of	  three	  independent	  assays	  and	  standard	  deviations	  are	  indicated.	  
To	  test	  whether	  the	  enhanced	  proliferation	  potential	  of	  the	  Hmhi-­‐MYC	  clones	  correlated	  with	  
an	   increase	   in	   tumourigenic	  capacity,	   soft-­‐agar	  growth	  assays	  were	  performed	   (Figure	  30).	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While	  Hmhi	  cells	  did	  not	  form	  colonies	  under	  starving	  conditions	  when	  HERmrk	  was	  inactive	  
regardless	  of	  MYC	  expression	  status,	  MYC	  proved	  to	  dramatically	  enhance	  HERmrk-­‐mediated	  
colony	   forming	   capacity	  of	  melanocytes	  upon	  EGF	   stimulation.	  Notably,	   EGF-­‐treated	  Hmhi-­‐
MYC-­‐TA	  cells	  formed	  extremely	  large	  colonies	  which	  were	  visible	  to	  the	  naked	  eye.	  	  
 
Figure	  30:	  MYC	  overexpression	  enhances	  HERmrk-­‐mediated	  tumourigenic	  potential	  
Phase	   contrast	   images	   (25-­‐fold	  magnification)	   of	   Hmhi	   cells	   stably	   transfected	  with	   an	   empty	   control	   vector	  
(ctrl.),	   or	  overexpressing	  MYC-­‐wt,	  MYC-­‐VD	  or	  MYC-­‐TA	  upon	  14	  days	   in	   soft	   agar.	  Where	   indicated,	   agar	  was	  
overlain	  with	  starving	  medium	  alone	  (-­‐)	  or	  supplemented	  with	  EGF	  (EGF).	  	  
To	  analyse	  the	  ROS	  extent	  in	  MYC-­‐overexpressing	  Hmhi	  cells,	  DCF-­‐DA	  assays	  were	  performed	  
(Figure	  31).	  As	  expected,	  no	  fluorescent	  DCF	  and	  hence	  no	  ROS	  could	  be	  detected	  in	  starved	  
Hmhi	   cells	  upon	  11	  days	   in	   culture,	   regardless	  of	  MYC	  expression	  status.	  However,	   I	   found	  
DCF-­‐DA	  to	  convert	  to	  fluorescent	  DCF	  in	  multinucleated	  melanocytes	  upon	  EGF	  stimulation.	  
The	  ROS	  level	  in	  EGF-­‐treated	  Hmhi	  cells	  expressing	  the	  empty	  control	  vector	  (ctrl.,	  Figure	  31)	  
was	  equivalent	   to	   the	  one	  observed	   for	  Hmhi	   cells	   (Figure	  21).	  Since	  DCF	  was	   restricted	   to	  
multinucleated	  cells,	  the	  fluorescence	  signal	  decreased	  from	  MYC-­‐wt	  over	  MYC-­‐VD	  and	  was	  
lowest	   in	  MYC-­‐TA-­‐expressing	   Hmhi	   cells	   (Figure	   31).	   Notably,	   due	   to	   the	   high	   cell	   density	  
observed	   for	  MYC-­‐TA	   cells	   upon	   11	   days	   of	   EGF	   treatment,	   some	   cells	   had	   detached	   and	  
died.	  Thus,	  the	  very	  bright,	  compact	  and	  round	  signals	  are	  very	  likely	  dead	  cells	  still	  attached	  
to	  the	  dense	  cell-­‐layer	  occupying	  to	  the	  dish.	  In	  clear	  contrast	  are	  the	  multinucleated	  large	  





Figure	  31:	  MYC	  overexpression	  counteracts	  Xmrk-­‐induced	  ROS	  
DCF	  staining	  images	  (200-­‐fold	  magnification;	  DCF)	  of	  Hmhi	  cells	  stably	  transfected	  with	  an	  empty	  control	  vector	  
(ctrl.),	   overexpressing	   MYC-­‐wt,	   MYC-­‐VD	   or	   MYC-­‐TA	   upon	   11	   days	   in	   culture.	   Where	   indicated,	   cells	   were	  
cultured	  in	  starving	  medium	  alone	  (-­‐)	  or	  stimulated	  with	  EGF	  (EGF).	  Corresponding	  phase	  contrast	  images	  (PH)	  
are	  shown.	  
To	  test	  whether	  the	  ROS	  levels	  correlated	  with	  the	  DNA	  damage	  extent,	  I	  performed	  comet	  
assays	  under	  alkaline	  conditions	  (Figure	  32).	  Even	  though	  a	  background	  level	  of	  DNA	  damage	  
was	  observed	   regardless	  of	  MYC	  expression	  status	  upon	  14	  days	   in	   starving	  medium	  (-­‐),	   it	  
became	  obvious	   that	  MYC	  expression	   limits	   the	  DNA	  damage	  effect	  upon	  EGF	   stimulation	  
and	  subsequent	  HERmrk	  activation.	  The	  number	  and	  extent	  of	  the	  detected	  comets	  already	  
decreased	  when	  MYC-­‐wt	  was	  co-­‐expressed,	  but	  DNA	  damage	  was	  even	  lower	  in	  the	  MYC-­‐VD	  
clone	  and	  only	  rarely	  evident	  in	  MYC-­‐TA	  cells.	  	  




Figure	  32:	  MYC	  overexpression	  counteracts	  HERmrk-­‐induced	  DNA	  damage	  
Comet	   assay	   images	   (100-­‐fold	   magnification)	   of	   Hmhi	   cells	   stably	   transfected	   with	   an	   empty	   control	   vector	  
(ctrl.)	   or	   overexpressing	   MYC-­‐TA	   upon	   14	   days	   in	   culture.	   Where	   indicated,	   cells	   were	   cultured	   in	   starving	  
medium	  alone	  (-­‐)	  or	  stimulated	  with	  EGF.	  DNA	  was	  visualized	  using	  Hoechst	  33342.	  	  
Taken	   together,	   MYC	   overexpression	   was	   not	   only	   found	   to	   diminish	   HERmrk-­‐induced	  
senescence,	  but	  also	  significantly	  enhanced	  the	  proliferation	  potential	  as	  well	  as	  the	  in	  vitro	  
tumourigenic	   capacity	   of	   Hmhi	   melanocytes.	   In	   accordance	   with	   these	   findings,	   MYC	  
overexpression	   also	   limited	   the	   ROS	   and	   DNA	   damage	   extent	   upon	   HERmrk	   activation.	  
Intriguingly,	  all	  these	  phenomena	  were	  most	  prominent	  for	  the	  stable	  MYC-­‐TA	  mutant.	  
7.11 The	  impact	  of	  Miz-­‐1	  knockdown	  on	  melanocyte	  senescence	  	  
Since	  MYC	  negatively	  regulates	  Miz-­‐1	  259,	  we	  were	  wondering	  about	  the	  role	  of	  MIZ-­‐1	  in	  our	  
senescence	   model.	   I	   first	   checked	   whether	   Miz-­‐1	   was	   expressed	   in	   our	   Hm	   clones.	  
Quantitative	   realtime	   PCR	   analyses	   of	   HERmrk	   cells	   revealed	  Miz-­‐1	   mRNA	   to	   be	   induced	  
after	   14	   days	   of	   treatment	   (Figure	   33a).	   Interestingly,	   I	   found	   the	   ROS	   scavenger	   NAC	   to	  
suppress	   Miz-­‐1	   induction	   in	   EGF-­‐stimulated	   Hmhi	   cells	   to	   some	   extent	   (Figure	   33b).	  
Moreover,	   Western	   blot	   analysis	   of	   Hmhi	   whole	   cell	   lysates	   proved	   MIZ-­‐1	   protein	   to	  
accumulate	  over	   time	  upon	  EGF	   treatment,	  while	   in	   serum-­‐starved	  Hmhi	   cells	  only	  a	  weak	  





Figure	  33:	  Activated	  HERmrk	  induces	  Miz-­‐1	  on	  mRNA	  and	  protein	  level	  
(a)	  Miz-­‐1	  qRT-­‐PCR	  analyses	  for	  the	  parental	  cell	  line	  melan	  a,	  the	  non-­‐senescing	  Hm-­‐clones	  Hmlo	  and	  Hmme	  as	  
well	  as	  the	  senescing	  Hmhi	  melanocytes	  upon	  long-­‐term	  EGF	  stimulation.	  Expression	  levels	  were	  normalized	  to	  
HPRT	  and	  shown	  in	  reference	  to	  the	  serum-­‐starved	  equivalent	  of	  each	  cell	  line.	  Bars	  depict	  the	  mean	  values	  of	  
four	   independent	   experiments.	   Standard	   deviations	   are	   shown.	   (b)	   Miz-­‐1	   qRT-­‐PCR	   analyses	   for	   the	   the	  
senescing	  Hmhi	  clone	  upon	  long-­‐term	  serum	  starvation	  (ctrl.)	  or	  EGF	  stimulation	  (EGF)	  in	  absence	  or	  presence	  of	  
the	  ROS	  scavenger	  N-­‐acetylcysteine	  (NAC).	  Expression	   levels	  were	  normalized	  to	  HPRT.	  Bars	  depict	  the	  mean	  
values	   of	   four	   independent	   experiments.	   Standard	   deviations	   are	   shown.	   (c)	  MIZ-­‐1	  Western	   blot	   analysis	   of	  
Hmhi	  whole	  cell	  lysates	  upon	  3,	  7	  and	  14	  days	  in	  culture	  in	  absence	  (-­‐)	  or	  presence	  of	  EGF	  (EGF).	  β-­‐actin	  served	  
as	  loading	  control.	  Protein	  weights	  are	  indicated	  in	  kDa.	  
To	   elucidate	   the	   role	   of	   MIZ-­‐1	   in	   HERmrk-­‐induced	   melanocyte	   senescence,	   I	   used	   Hmhi	  
clones	  stably	  expressing	  either	  an	  empty	  control	  vector	  (Hmhi-­‐pS,	  simply	  termed	  pS	  later	  on)	  
or	   a	   shRNA	   directed	   against	   Miz-­‐1	   (Hmhi-­‐pS-­‐Miz-­‐1,	   simply	   termed	   pS-­‐Miz-­‐1	   later	   on).	  
Notably,	   both	   clones	   had	   been	   generated	   prior	   to	   my	   studies.	   Quantitative	   realtime	   PCR	  
analyses	   proved	  Miz-­‐1	   mRNA	   levels	   to	   be	   significantly	   down-­‐regulated	   in	   pS-­‐Miz-­‐1	   cells	  
compared	  to	  pS	  cells	  (Figure	  34).	  




         
Figure	  34:	  pS-­‐Miz-­‐1	  significantly	  down-­‐regulates	  Miz-­‐1	  mRNA	  levels	  in	  Hmhi	  cells	  	  
Miz-­‐1	  qRT-­‐PCR	  analyses	  for	  Hmhi	  cells	  stably	  expressing	  pS-­‐Miz-­‐1or	  the	  empty	  control	  vector	  (pS)	  after	  3	  days	  in	  
culture.	  Where	   indicated,	   cells	  were	   cultured	   in	   starving	  medium	  alone	   (-­‐)	   or	   supplemented	  with	  EGF	   (EGF).	  
Expression	  levels	  were	  normalized	  to	  HPRT	  and	  shown	  in	  reference	  to	  pS.	  Bars	  depict	  the	  mean	  values	  of	  three	  
independent	  experiments.	  Standard	  deviations	  are	  shown.	  Student´s	  t-­‐test	  (paired,	  2-­‐tailed)	  revealed	  statistical	  
significance	  indicated	  by	  asterisks	  (*p<0.05,	  **p<0.01,	  ***p<0.001).	  
Long-­‐term	  stimulation	  assays	   revealed	  a	   senescence-­‐protective	  effect	  of	  Miz-­‐1	   knockdown	  
on	  Hmhi	   cells.	  Unlike	  Hmhi-­‐pS	   cells,	  which	   started	   to	   become	  enlarged	   and	  multinucleated	  
after	  3	  days	  of	  EGF	  treatment,	  Hmhi-­‐pS-­‐Miz-­‐1	  melanocytes	  did	  not	  become	  multinucleated	  
regardless	  of	  EGF	  treatment	  duration	  (Figure	  35).	  
	   	  




Figure	  35:	  Long-­‐term	  senescence	  assay	  comparing	  Hmhi-­‐pS	  and	  Hmhi-­‐pS-­‐Miz-­‐1	  cells	  	  	  
Phase	  contrast	  images	  (100-­‐fold	  magnification)	  comparing	  the	  cellular	  features	  of	  Hmhi	  cells	  stably	  expressing	  
pS	  or	  pS-­‐Miz-­‐1	  in	  a	  long-­‐term	  senescence	  assay.	  Where	  indicated,	  cells	  were	  cultured	  in	  starving	  medium	  alone	  
(-­‐)	  or	  supplemented	  with	  EGF	  (EGF).	  
To	  check	  and	  quantify	   the	   senescence	  extent	   in	  Hmhi-­‐pS	  and	  Hmhi-­‐pS-­‐Miz-­‐1	  cells,	   SA-­‐β-­‐Gal	  
stainings	   were	   performed.	   I	   found	   Miz-­‐1	   knockdown	   to	   diminish	   HERmrk-­‐induced	  
senescence	  (Figure	  36).	  	  	  




Figure	  36:	  Miz-­‐1	  knockdown	  diminishes	  HERmrk-­‐induced	  senescence	  in	  Hmhi	  cells	  
(a)	   Brightfield	   images	   (100-­‐fold	  magnification)	   of	   SA-­‐β-­‐Gal-­‐stained	   Hmhi-­‐pS	   and	   Hmhi-­‐pS-­‐Miz-­‐1	   cells	   upon	   14	  
days	  of	   treatment.	  Where	   indicated,	   cells	  were	   cultured	   in	   starving	  medium	  alone	   (-­‐)	   or	   supplemented	  with	  
EGF	   (EGF).	   (b)	   The	   graph	   depicts	   the	   proportion	   of	  multinucleated,	   SA-­‐β-­‐Gal-­‐positive	   cells	   over	   time	   (mean	  
values	   of	   three	   independent	   experiments;	   standard	   deviations	   are	   shown).	   Miz-­‐1	   knockdown	   proved	   to	  
diminish	  HERmrk-­‐induced	  senescence	  in	  EGF-­‐treated	  Hmhi	  cells.	  	  
Not	   only	   did	   the	   stable	   Miz-­‐1	   knockdown	   prevent	   HERmrk-­‐induced	   senescence,	   it	   also	  
significantly	  enhanced	   the	  proliferation	  potential	  of	  Hmhi	   cells	   (Figure	  37).	  Even	   though	  pS	  
cells	  proliferated	  better	   in	  presence	  of	  EGF	   than	  when	  cultured	   in	   starving	  medium	  alone,	  
the	  EGF-­‐mediated	  proliferation	  boost	  observed	  for	  pS-­‐Miz-­‐1	  cells	  was	  much	  stronger	  (Figure	  
37a).	  	  	  
Using	   a	   different	   visualisation	   of	   the	   same	   data	   an	   additional,	   interesting	   effect	   becomes	  
clear:	  both	  pS	  and	  pS-­‐Miz-­‐1	  cells	  reach	  a	  growth	  plateau	  when	  cultured	  in	  starving	  medium	  
	  
77	  
alone	   (-­‐)	   for	   about	   8	   days,	  whereas	   unlike	   pS	   cells,	   pS-­‐Miz-­‐1	   do	   not	   stop	   to	   proliferate	   in	  
presence	  of	  the	  growth	  stimulus	  EGF	  (Figure	  37b).	  	  
	  
 
Figure	  37:	  Miz-­‐1	  knockdown	  enhances	  proliferation	  potential	  of	  Hmhi	  cells	  
(a)	  Graphs	  depict	  the	  total	  cell	  number	  (mean	  values	  of	  three	   independent	  experiments)	  of	  Hmhi-­‐pS	  (pS)	  and	  
Hmhi-­‐pS-­‐Miz-­‐1	  (pS-­‐Miz-­‐1)	  cells	  over	  time	  in	  the	  absence	  (-­‐)	  or	  presence	  of	  EGF	  (EGF).	  Student´s	  t-­‐test	  (paired,	  2-­‐
tailed)	  revealed	  statistical	  significance	  comparing	  starved	  (-­‐)	  and	  EGF-­‐stimulated	  (EGF)	  cells	  at	  each	  time	  point	  
indicated	  by	  asterisks	  (*p<0.05,	  **p<0.01,	  ***p<0.001).	  (b)	  As	  in	  (a),	  but	  statistics	  compare	  starved	  (-­‐)	  and	  EGF-­‐
stimulated	  (EGF)	  Hmhi-­‐pS	  cells	  with	  their	  Hmhi-­‐pS-­‐Miz-­‐1	  counterparts	  at	  each	  time	  point.	  
To	  test	  whether	  the	  enhanced	  proliferation	  potential	  of	  Hmhi-­‐pS-­‐Miz-­‐1	  cells	  correlated	  with	  
an	   increase	   in	   tumourigenic	  capacity,	   soft-­‐agar	  growth	  assays	  were	  performed	   (Figure	  38).	  
Miz-­‐1	  knockdown	  enhanced	  the	   in	  vivo	  transformation	  potential	  by	  about	  3-­‐fold	  compared	  
to	   Hmhi-­‐pS	   control	   cells	   upon	   EGF	   treatment.	   Notably,	   the	   colonies	   observed	   were	  much	  
smaller	  than	  those	  formed	  in	  MYC-­‐overexpressing	  Hmhi	  cells.	  




Figure	  38:	  Miz-­‐1	  knockdown	  enhances	  HERmrk-­‐mediated	  tumourigenic	  potential	  
(a)	  Phase	  contrast	  images	  (25-­‐fold	  magnification)	  of	  Hmhi	  cells	  stably	  transfected	  with	  an	  empty	  control	  vector	  
(pS)	   or	   a	  Miz-­‐1	   knockdown	  plasmid	   (pS-­‐Miz-­‐1)	   upon	  14	  days	   in	   soft	   agar	   supplemented	  with	   EGF.	   (b)	  Graph	  
depicts	   the	   transformation	   capacity	  of	  EGF-­‐stimulated	  Hmhi-­‐pS-­‐Miz-­‐1	   cells	   in	   reference	   to	  Hmhi-­‐pS	   cells.	  Bars	  
represent	  the	  mean	  values	  of	  three	  independent	  experiments.	  Standard	  deviation	  is	  shown.	  
To	   investigate	   the	   influence	   of	   MIZ-­‐1	   on	   intracellular	   ROS	   levels,	   DCF-­‐DA	   stainings	   were	  
performed	  (Figure	  39).	  While	  a	  strong	  DCF	  signal	  could	  be	  detected	  for	  Hmhi-­‐pS	  cells	  upon	  10	  
days	  of	  EGF	  stimulation,	  only	  a	  minor	  fluorescence	  signal	  became	  evident	  in	  case	  of	  Hmhi-­‐pS-­‐
Miz-­‐1.	   Besides,	   neither	  was	   a	   DCF	   signal	   detectable	   in	   serum-­‐starved	  Hmhi-­‐pS	   cells	   nor	   in	  
Miz-­‐1	  knockdown	  melanocytes	  (pS-­‐Miz-­‐1).	  




Figure	  39:	  Miz-­‐1	  knockdown	  counteracts	  HERmrk-­‐induced	  ROS	  
DCF	  staining	  images	  (200-­‐fold	  magnification;	  DCF)	  of	  Hmhi	  cells	  stably	  transfected	  with	  an	  empty	  control	  vector	  
(pS)	  or	  the	  Miz-­‐1	  knockdown	  plasmid	  (pS-­‐Miz-­‐1)	  upon	  10	  days	  in	  culture.	  Where	  indicated,	  cells	  were	  cultured	  
in	  starving	  medium	  alone	  (-­‐)	  or	  stimulated	  with	  EGF.	  Corresponding	  phase	  contrast	  images	  (PH)	  are	  shown.	  
To	  test	  whether	  the	  ROS	  levels	  correlated	  with	  the	  DNA	  damage	  extent,	  I	  performed	  comet	  
assays	   in	   alkaline	   conditions	   (Figure	   40).	   Even	   though	   a	   background	   level	   of	   DNA	  damage	  
was	  observed	  regardless	  of	  Miz-­‐1	  expression	  status	  upon	  14	  days	  in	  starving	  medium	  (-­‐),	   it	  
became	  obvious	  that	  Miz-­‐1	  knockdown	  limited	  the	  DNA	  damage	  effect	  upon	  EGF	  stimulation	  
and	  subsequent	  HERmrk	  activation.	  




Figure	  40:	  Miz-­‐1	  knockdown	  counteracts	  HERmrk-­‐induced	  DNA	  damage	  
Comet	  assay	  images	  (100-­‐fold	  magnification)	  of	  Hmhi	  cells	  stably	  transfected	  with	  an	  empty	  control	  vector	  (pS)	  
or	   the	  Miz-­‐1	  knockdown	  plasmid	   (pS-­‐Miz-­‐1)	  upon	  14	  days	   in	  culture.	  Where	   indicated,	  cells	  were	  cultured	   in	  
starving	  medium	  alone	  (-­‐)	  or	  stimulated	  with	  EGF.	  DNA	  was	  visualized	  using	  Hoechst	  33342.	  	  
To	   identify	   the	   molecular	   mediators	   of	   senescence	   prevention	   upon	   Miz-­‐1	   knockdown,	   I	  
performed	   Western	   blot	   analyses	   of	   the	   well-­‐established	   MIZ-­‐1	   targets	   and	   senescence	  
inducers	  p15Ink4b,	  p16Ink4a,	  p19Arf	  and	  p21Cip1/Waf1	  as	  well	  as	  the	  DNA	  damage	  markers	  P-­‐p53,	  
P-­‐Chk1	  and	  P-­‐Chk2	  and	  overall	  p53	  as	  well	  as	  pRb	  protein	  (Figure	  41).	  Surprisingly,	   I	   found	  
equal	  or	  even	  higher	  protein	  levels	  of	  senescence	  inducers	  and	  their	  regulators	  upon	  Miz-­‐1	  
knockdown	   (pS-­‐Miz-­‐1)	   in	  Hmhi	   cells	   compared	   to	   the	   control	   (pS)	  within	   the	   first	  week	   of	  
treatment.	  The	  only	  exception	  was	  hypophosphorylated,	  active	  pRb,	  whose	  level	  was	  lower	  
in	  Miz-­‐1	   knockdown	   cells.	   Moreover,	   upon	   14	   days	   of	   treatment,	   no	  more	   p21	   could	   be	  
detected	   regardless	   of	   Miz-­‐1	   expression	   status.	   Besides,	   the	   protein	   levels	   of	   the	   DNA	  
damage	  markers	   P-­‐p53	   and	   P-­‐Chk2	   as	  well	   as	   pRb	   levels	  were	   lower	   in	  Miz-­‐1	   knockdown	  
melanocytes.	  	  




Figure	  41:	  Miz-­‐1	  knockdown	  does	  not	  diminish	  the	  protein	  levels	  of	  senescence	  inducers	  
Western	   blot	   analyses	   of	   Hmhi	   cells	   stably	   transfected	   with	   an	   empty	   control	   vector	   (pS)	   or	   the	   Miz-­‐1	  
knockdown	   plasmid	   (pS-­‐Miz-­‐1)	   upon	   3,	   7	   and	   14	   days	   in	   culture.	   Where	   indicated,	   cells	   were	   cultured	   in	  
starving	  medium	   alone	   (-­‐)	   or	   stimulated	  with	   EGF	   (EGF).	   Cells	   were	   harvested	   at	   indicated	   time	   points	   and	  
whole	  cell	   lysates	  were	  separated	  using	  10%	  SDS	  gels.	  Protein	  weights	  are	  indicated	  in	  kDa.	  β-­‐actin	  served	  as	  
loading	  control.	  
Taken	   together,	   Miz-­‐1	   knockdown	   was	   not	   only	   found	   to	   diminish	   HERmrk-­‐induced	  
senescence,	  but	  also	  significantly	  enhanced	  the	  proliferation	  potential	  as	  well	  as	  the	  in	  vitro	  
tumourigenic	   capacity	   of	   Hmhi	   melanocytes.	   In	   accordance	   with	   these	   findings,	   Miz-­‐1	  
knockdown	  also	   limited	  ROS	   levels	   and	  DNA	  damage	  extent	  upon	  HERmrk	  activation.	   This	  
was	  mirrored	  by	  the	  decreased	  amount	  of	  DNA	  damage	  markers	  P-­‐p53	  and	  P-­‐Chk2	  after	  14	  
days	   of	   EGF	   stimulation.	   However,	   none	   of	   the	   classic	   MIZ-­‐1	   targets	   such	   as	   p15Ink4b	   or	  
p21Cip1/Waf1	  went	   along	  with	   the	   senescence-­‐protective	   effect	   of	  Miz-­‐1	   knockdown	   in	  Hmhi	  
cells.	   Instead,	   protein	   expression	   levels	   of	   the	  monitored	  MIZ-­‐1	   targets	  were	   even	   higher	  
upon	  Miz-­‐1	  knockdown	  in	  Hmhi	  melanocytes.	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7.12 The	   impact	   of	  MYC	   overexpression	   and	  Miz-­‐1	   knockdown	  on	  N-­‐RAS*-­‐
induced	  melanocyte	  senescence	  	  
Since	   Xmrk	   was	   not	   the	   only	   oncogene	   we	   had	   shown	   to	   induce	   senescence	   in	   our	  
melanocyte	  model,	   I	   was	  wondering	  whether	   N-­‐RAS*-­‐mediated	   senescence	   could	   also	   be	  
influenced	  by	  MYC	  overexpression	  or	  Miz-­‐1	  knockdown.	  Unfortunately,	   I	  could	  not	  use	  the	  
melan	   a-­‐N-­‐RAS*	   cells	   we	   had	   analysed	   previously	   due	   to	   antibiotics	   resistance	   overlaps.	  
Hence,	  I	  first	  transfected	  melan	  a	  cells	  with	  a	  doxycycline-­‐inducible	  pTetON	  vector	  followed	  
by	  a	  transfection	  with	  either	  the	  empty	  pTRE2hyg	  (ø)	  vector	  or	  pTRE2hyg-­‐N-­‐RAS61K-­‐flag	  (N-­‐
RAS*).	  Upon	  antibiotic	  selection,	  these	  cell	  lines	  were	  either	  transfected	  with	  pBabe	  (ctrl.)	  or	  
pBabe-­‐MYC-­‐TA	  (MYC-­‐TA)	  to	   investigate	  the	   influence	  of	  MYC	  overexpression	  (Figure	  42)	  or	  
with	  pRS	  (ctrl.)	  or	  pRS-­‐shMiz-­‐1	  (shMiz-­‐1)	  to	  check	  for	  a	  possible	  role	  of	  Miz-­‐1	  knockdown	  on	  
N-­‐RAS*-­‐induced	  melanocyte	  senescence	  (Figure	  43).	  	  
A	   long-­‐term	   senescence	   assay	   revealed	   MYC-­‐TA	   overexpression	   to	   strongly	   enhance	  
melanocyte	  proliferation	  as	  well	  as	  pigmentation,	  the	  latter	  of	  which	  was	  abolished	  upon	  N-­‐
RAS*	   expression.	   Unfortunately,	   N-­‐RAS*	   expression	   was	   not	   restricted	   to	   but	   could	   be	  
increased	  by	  doxycycline	  (Dox)	  treatment	  as	  in	  presence	  of	  Dox	  cell	  density	  of	  N-­‐RAS*-­‐MYC-­‐
TA	   melanocytes	   was	   higher	   than	   in	   their	   starved	   (-­‐)	   counterparts.	   Furthermore,	   N-­‐RAS*	  
melanocytes	  became	  multinucleated	  and	  SA-­‐β-­‐Gal-­‐positive	  and	  cell	  density	  was	  much	  lower	  
than	   in	   ø-­‐cells.	   Nevertheless,	   some	   multinucleated	   cells	   remained	   when	   MYC-­‐TA	   was	  
overexpressed.	  




Figure	  42:	  MYC	  overexpression	  counteracts	  N-­‐RAS*-­‐induced	  melanocyte	  senescence	  
Brightfield	   images	   (100-­‐fold	   magnification)	   of	   SA-­‐β-­‐Gal-­‐stained	   melan	   a-­‐pTetON-­‐pTRE2hyg	   and	   melan	   a-­‐
pTetON-­‐pTRE2hyg-­‐N-­‐RAS*	   cells	   stably	   transfected	   with	   an	   empty	   control	   vector	   (ctrl.)	   or	   the	   MYC-­‐TA	  
overexpression	   plasmid	   (MYC-­‐TA)	   upon	   14	   days	   in	   culture.	  Where	   indicated,	   cells	   were	   cultured	   in	   starving	  
medium	  alone	  (-­‐)	  or	  stimulated	  with	  doxycycline	  (Dox).	  
Hence,	   MYC	   overexpression	   counteracts	   N-­‐RAS*-­‐induced	   melanocyte	   senescence,	   while	  
strongly	  enhancing	  the	  proliferation	  potential.	  	  
Similar	   to	   MYC-­‐TA	   overexpression,	   did	   I	   find	   Miz-­‐1	   knockdown	   to	   enhance	   melanocyte	  
proliferation,	  but	  only	  when	  N-­‐RAS*	  was	  expressed.	  Unfortunately,	  N-­‐RAS*	  expression	  was	  
once	   again	   not	   restricted	   to,	   but	   could	   be	   increased	  by	   doxycycline	   (Dox)	   treatment	   as	   in	  
presence	  of	  Dox	   the	  number	  of	  multinucleated,	  SA-­‐β-­‐Gal-­‐positive	  N-­‐RAS*-­‐ctrl	  melanocytes	  
was	   higher	   than	   in	   their	   starved	   (-­‐)	   counterparts.	   This	   N-­‐RAS*-­‐induced,	   multinucleated	  
phenotype	  was	  diminished	  upon	  Miz-­‐1	  knockdown.	  




Figure	  43:	  Miz-­‐1	  knockdown	  counteracts	  N-­‐RAS*-­‐induced	  melanocyte	  senescence	  
Brightfield	   images	   (100-­‐fold	   magnification)	   of	   SA-­‐β-­‐Gal-­‐stained	   melan	   a-­‐pTetON-­‐pTRE2hyg	   and	   melan	   a-­‐
pTetON-­‐pTRE2hyg-­‐N-­‐RAS*	  cells	  stably	  transfected	  with	  an	  empty	  control	  vector	  (ctrl.)	  or	  the	  Miz-­‐1	  knockdown	  
plasmid	  (shMiz-­‐1)	  upon	  14	  days	  in	  culture.	  Where	  indicated,	  cells	  were	  cultured	  in	  starving	  medium	  alone	  (-­‐)	  or	  
stimulated	  with	  doxycycline	  (Dox).	  
Hence,	   Miz-­‐1	   knockdown	   counteracts	   N-­‐RAS*-­‐induced	   melanocyte	   senescence,	   while	  
enhancing	   the	   proliferation	   potential.	   Taken	   together,	   similar	   to	   our	   findings	   for	   Xmrk-­‐
induced	  senescence	   in	  Hmhi	  cells,	  both	  MYC	  overexpression	  and	  Miz-­‐1	  knockdown	   limit	  N-­‐
RAS*-­‐induced	  senescence	  in	  melan	  a	  cells.	  However,	  the	  senescence	  extent	  in	  the	  melan-­‐a-­‐
N-­‐RAS*	  clones	  used	  for	  these	  experiments	  was	  much	  lower	  than	  in	  EGF-­‐stimulated	  Hmhi	  cells	  
and	  quantification	  data	  is	  lacking.	  	  
	   	  
	  
85	  
7.13 CTH	   as	   a	   possible	   mediator	   of	   senescence-­‐protective	   effect	   of	   MYC	  
overexpression	  and	  Miz-­‐1	  knockdown	  in	  Hmhi	  melanocytes	  	  
Having	  determined	  that	  MYC	  and	  MIZ-­‐1	  are	  regulators	  of	  senescence,	  we	  wanted	  to	  identify	  
the	   molecular	   players	   underlying	   this	   phenomenon.	   To	   expand	   further	   analyses	   to	   a	  
genome-­‐wide	   level,	   an	   mRNA	   expression	   microarray	   was	   performed	   by	   Susanne	   Kneitz	  
[Microarray	   Core	   Unit,	   IZKF	   (Interdisciplinary	   Center	   for	   Clinical	   Research),	   University	   of	  
Wuerzburg,	   Wuerzburg,	   Germany],	   who	   	   compared	   unstimulated	   Hmhi	   cells,	   Hmhi	   cells	   +	  
EGF,	  Hmhi-­‐MYC-­‐TA	  cells	  +	  EGF,	  and	  Hmhi-­‐pS-­‐Miz1	  cells	  +	  EGF.	  The	  mRNA	  samples	  used	  were	  
prepared	  after	  14	  days	  of	  treatment,	  when	  EGF	  stimulation	  had	  already	  initiated	  senescence	  
in	   Hmhi	   cells.	   Six	   genes,	   represented	   by	   7	   Affymetrix	   Ids,	   were	   commonly	   upregulated	   by	  
Miz1	   knockdown	   or	   MYC-­‐TA	   overexpression	   in	   comparison	   to	   the	   senescent	   controls.	   In	  
literature,	  most	  of	  them	  are	  described	  to	  be	  associated	  with	  cancer	  progression	  (Table	  1).	  	  
	  
Table	  1:	  Genes	  co-­‐regulated	  by	  MIZ-­‐1	  and	  MYC	  in	  EGF-­‐stimulated	  Hmhi	  cells	  
Gene	  product	   Features	  
S100A6	  
Ca2+	  binding	  protein;	  high	  affinity	  to	  proteins	  of	  the	  
p53	   family;	   previously	   associated	   with	   senescence	  
261,262	  
MAL	  
(myelin	  and	  lymphocyte	  protein)	  
Proteolipid	   involved	   in	   membrane	   microdomains´	  
stabilization,	   transport	   machinery	   and	   signal	  
transduction;	   aberrant	  expression	   in	   various	   cancer	  
types	   (e.g.	   lymphomas,	   head	   and	   neck	   squamous	  
cell	  carcinoma,	  breast,	  ovary)	  263,264	  
MSLN	  
(mesothelin)	  
Cell	   surface	  antigen	  expressed	  on	  mesothelial	   cells;	  
Aberrant	   expression	   in	   various	   cancer	   types	   (e.g.	  
mesotheliomas,	  pancreas,	  ovary)	  263,265	  
TC1	  
(thyroid	  cancer	  1)	  
highly	   expressed	   in	   thyroid	   cancer	   266;	   induced	   by	  
heat	  shock,	  oxidative	  and	  other	  stresses	  267	  
GLIPR1	  
(glioma	  pathogenesis-­‐related	  1)	  
Secreted	   protein;	   matrix-­‐interacting;	   tumour	  
suppressive	  in	  prostate	  cancer	  268	  
CTH	  
(cystationase)	  
Enzyme;	   synthesis	   of	   cysteine	   from	   methionine	  
(transsulfuration	  pathway)	  269	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To	   elucidate	   the	   roles	   of	   all	   these	   genes	   in	   preventing	   senescence,	   it	  will	   be	   necessary	   to	  
perform	  in-­‐depth	  biochemical	  studies.	  	  	  
Interestingly,	  CTH	  was	  the	  gene	  with	  the	  highest	  mRNA	  fold	  change	  found	  upon	  both	  MYC	  
overexpression	   and	  Miz-­‐1	   knockdown	   compared	   to	   EGF-­‐stimulated	   Hmhi	   cells.	   Moreover,	  
reports	   state	   CTH	   to	   be	   crucial	   for	   the	   supply	   of	   cellular	   glutathione	   and	   taurine	   270,	   thus	  
contributing	  to	  ROS	  detoxification.	  Since	  we	  have	  identified	  ROS	  to	  be	  a	  crucial	  senescence	  
mediator	   in	   our	   model	   230	   and	   ROS	   levels	   were	   found	   to	   be	   diminished	   upon	   MYC	  
overexpression	  and	  Miz-­‐1	  knockdown,	  CTH	  regulation	  by	  MYC	  and	  Miz-­‐1	  might	  be	  linked	  to	  
senescence.	  
7.14 CTH	   overexpression	   suppresses	   HERmrk-­‐induced	   senescence	   and	  
decreases	  melanocyte	  pigmentation	  
Thus,	  I	  transfected	  the	  parental	  cell	   line	  melan	  a	  as	  well	  as	  Hmhi	  cells	  with	  either	  an	  empty	  
pBabe	  control	  vector	  (ctrl.)	  or	  pBabe-­‐CTH	  resulting	  in	  CTH	  overexpression	  before	  performing	  
a	   long-­‐term	   stimulation	   assay	   (Figure	   44).	   Interestingly,	   CTH	   overexpression	   seemed	   to	  
enhance	  the	  proliferation	  potential	  of	  melan	  a	  as	  well	  as	  Hmhi	  cells	  after	  14	  days	  in	  culture	  
regardless	   of	   EGF	   treatment.	   In	   addition,	   CTH	   overexpression	   suppressed	   the	   HERmrk-­‐
induced,	   multinucleated	   phenotype	   observed	   for	   EGF-­‐stimulated	   Hmhi-­‐ctrl.	   cells.	   While	   a	  
large	  proportion	  of	  Hmhi-­‐ctrl.	  cells	  had	  become	  enlarged	  and	  multinucleated	  upon	  7	  days	  of	  
EGF	   treatment,	   only	   sporadic	   multinucleated	   melanocytes	   were	   observed	   when	   CTH	   was	  
overexpressed.	  	  




Figure	  44:	  CTH	  overexpression	  suppresses	  Xmrk-­‐induced	  melanocyte	  senescence	  
Phase	   contrast	   images	   (100-­‐fold	  magnification)	   of	  melan	   a	   and	   Hmhi	   cells	   stably	   transfected	  with	   an	   empty	  
pBabe	   control	   vector	   (ctrl.)	   or	   the	   CTH	   overexpression	   plasmid	   pBabe-­‐CTH	   (CTH)	   upon	   3,	   7	   and	   14	   days	   in	  
culture.	  Where	  indicated,	  cells	  were	  cultured	  in	  starving	  medium	  alone	  (-­‐)	  or	  stimulated	  with	  EGF	  (EGF).	  
Wanting	  to	  compare	  the	  senescence	  extent	  after	  14	  days	  in	  culture,	  I	  performed	  a	  long-­‐term	  
senescence	  assay.	  SA-­‐β-­‐Gal	  stainings	  showed	  that	  senescence	  was	  largly	  suppressed	  by	  CTH	  
overexpression	   in	   EGF-­‐treated	   Hmhi	   cells	   (Figure	   45a).	   Hmhi	   control	   (ctrl.)	   cells	   became	  
multinucleated	  and	  SA-­‐β-­‐Gal-­‐positive	  upon	  long-­‐term	  EGF	  stimulation,	  while	  concurrent	  CTH	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overexpression	   limited	   the	   multinucleated	   phenotype.	   Besides,	   no	   SA-­‐β-­‐Gal	   staining	   was	  
detected	  in	  serum-­‐starved	  (-­‐)	  Hmhi	  cells	  regardless	  of	  CTH’s	  expression	  status.	  	  	  
Interestingly,	   CTH	   overexpression	   decreased	   the	   pigmentation	   of	   melan	   a	   cells	   in	   both	  
absence	  and	  presence	  of	  EGF	   (Figure	  45b).	   Since	  Hmhi	   cells	   show	  hardly	  any	  pigmentation	  
when	   cultured	   in	   starving	   medium,	   no	   difference	   in	   pigmentation	   intensity	   upon	   CTH	  
overexpression	  became	  evident	  (data	  not	  shown).	  	  
 
Figure	  45:	  CTH	  overexpression	  suppresses	  HERmrk-­‐induced	  melanocyte	  senescence	  and	  	  decreases	  melanocyte	  
pigmentation	  
(a)	  Brightfield	  images	  (100-­‐fold	  magnification)	  of	  SA-­‐β-­‐Gal-­‐stained	  Hmhi	  cells	  stably	  transfected	  with	  an	  empty	  
pBabe	   control	   vector	   (ctrl.)	   or	   the	   CTH	   overexpression	   plasmid	   pBabe-­‐CTH	   (CTH)	   upon	   14	   days	   in	   culture.	  
Where	  indicated,	  cells	  were	  cultured	  in	  starving	  medium	  alone	  (-­‐)	  or	  stimulated	  with	  EGF.	  (b)	  Pellets	  of	  melan	  a	  
cells	  stably	  transfected	  with	  an	  empty	  pBabe	  control	  vector	   (ctrl.)	  or	  the	  CTH	  overexpression	  plasmid	  pBabe-­‐
CTH	   (CTH)	   upon	   14	   days	   in	   culture.	   Where	   indicated,	   cells	   were	   cultured	   in	   starving	   medium	   alone	   (-­‐)	   or	  
stimulated	  with	  EGF	  (EGF).	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Taken	  together,	  it	  is	  safe	  to	  attribute	  CTH	  an	  important	  role	  in	  preventing	  ROS-­‐induced	  senescence	  of	  
Hmhi	  cells.	  	  
7.15 HERmrk-­‐induced	   senescent	   melanocytes	   are	   a	   source	   for	   highly	  
proliferative,	  anoikis-­‐resistant	  cells	  
Senescence	  is	  considered	  to	  be	  a	  tumour-­‐protective	  mechanism	  and	  some	  groups	  even	  aim	  
at	  senescence	  induction	  as	  a	  therapeutic	  target	  271–273.	  However,	  one	  should	  not	  neglect	  the	  
fact	   that	   senescent	   cells	   secrete	   factors	   that	   promote	   the	   tumourigenic	   effect	   of	  
neighbouring	  cells	  and	  cause	  inflammation	  274–277.	  
The	  interesting	  and	  at	  the	  same	  time	  surprising	  part	  of	  my	  observations	  described	  in	  the	  first	  
part	  of	  my	  thesis	  is	  the	  fact	  that	  I	  had	  found	  low	  and	  medium	  levels	  of	  the	  oncogene	  HERmrk	  
to	  result	  in	  enhanced	  proliferation	  and	  tumourigenic	  potential	  of	  melanocytes,	  whereas	  high	  
expression	   levels	   forced	   cells	   into	   senescence.	  However,	   in	   vivo	   the	  Xmrk	  expression	   level	  
directly	  correlates	  with	  malignancy	  and	  melanoma	  progression	  278.	  These	  differences	  could	  
either	   be	   attributed	   to	   in	   vitro-­‐in	   vivo	   discrepancies	   or	   tackled	   in	   a	   scientific	   manner.	   I	  
decided	   on	   the	   latter	   and	   investigated	   the	   effects	   of	   even	   longer	   oncogene	   activation	   on	  
melanocytes	   (Figure	   46).	   As	   expected,	   EGF-­‐treated	   Hmhi	   cells	   became	  multinucleated	   and	  
SA-­‐β-­‐Gal-­‐positive	  within	  14	  days	  of	  stimulation	  (Figure	  46a).	  However,	  upon	  sustained	  EGF	  
treatment,	   I	   observed	   nest-­‐like	   structures	   consisting	   of	   small	   cells,	   which	   divided	   rapidly,	  
overgrew	   the	   dish	   and	   finally	   formed	   3D-­‐structures	   (Figure	   46b).	   Interestingly,	   it	   seemed	  
that	   nests	   were	   found	   to	   arise	   predominantly	   in	   close	   proximity	   to	   a	   multinucleated	   cell	  
(data	  not	  shown).	  




Figure	  46:	  Sustained	  EGF	  treatment	  of	  multinucleated	  Hmhi	  cells	  results	  in	  “nest”	  formation	  	  
(a)	   Phase	   contrast	   (PH)	   and	   brightfield	   images	   (100-­‐fold	   magnification)	   of	   SA-­‐β-­‐Gal-­‐stained	   Hmhi	   cells	  
stimulated	  with	  EGF	  upon	  3	  and	  14	  days	  in	  culture.	  (b)	  Phase	  contrast	   images	  of	  EGF-­‐treated	  Hmhi	  cells	  (100-­‐
fold	  magnification)	  at	  indicated	  time	  points.	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7.16 Oncogene	   activation	   is	   the	   prerequisite	   for	   nest	   formation	   of	   Hmhi	  
melanocytes	  
To	   investigate	  whether	   long-­‐term	  cultivation	   in	   starving	  medium	  alone	   is	   sufficient	   for	   the	  
emergence	  of	  these	  nests,	  I	  performed	  further	  long-­‐term	  assays	  comparing	  EGF-­‐treated	  and	  
starved	   Hmhi	   cells	   (Figure	   47).	   In	   starved	   Hmhi	   cells,	   neither	   nest	   formation	   nor	   the	  
appearance	  of	  small	  cells	  could	  be	  observed.	  Upon	  EGF	  stimulation,	  however,	  Hmhi	  cells	  first	  
became	  multinucleated	  before	  nests	  emerged.	  Even	   though	  multinucleated	  cells	  were	   still	  
visible	  after	  32	  days	  in	  culture,	  the	  number	  and	  size	  of	  the	  nests	  steadily	  increased.	  	  
 
Figure	  47:	  Appearance	  of	  “nest”-­‐Hmhi	  cells	  
Phase	  contrast	   images	  (320-­‐fold	  magnification)	  of	  Hmhi	  cells	   in	  a	   long-­‐term	  senescence	  assay	  upon	  21,	  24,	  28	  
and	  32	  days	   in	  culture.	  Where	   indicated,	  cells	  were	  cultured	   in	  starving	  medium	  alone	   (-­‐)	  or	  stimulated	  with	  
EGF	  (EGF).	  The	  upper	  EGF	  panel	  shows	  multinucleated	  Hmhi	  cells	  and	  the	  lower	  one	  the	  smaller	  nest	  cells.	  	  
Taken	  together,	  HERmrk	  activation	  followed	  by	  multinucleation	  seems	  to	  be	  the	  prerequisite	  
for	  nest	  formation.	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7.17 In	  vitro	  transformation	  potential	  of	  Hmhi-­‐Neo	  cells	  
Since	   I	  wanted	   to	   further	  characterize	   these	   small,	  emerging	  cells,	   I	  picked	  different,	   large	  
nests	   and	   transferred	   them	   into	   a	   48-­‐well	   plate	   using	   a	   pipette	   tip.	   I	   cultured	   these	   cells	  
(Hmhi-­‐Neo-­‐Pool)	   in	   complete	  medium	  before	   generating	   and	   raising	   single	   cell	   clones.	   The	  
cells	   picked	   from	   a	   single	   nest	   were	   termed	   Hmhi-­‐Neo-­‐Pool,	   single	   cell	   clones	   were	  
numbered	   consecutively	   and	   the	   ones	   growing	   best	   in	   culture	   were	   chosen	   for	   further	  
experiments.	  To	  compare	   the	   transformation	  potential	  of	  Hmhi-­‐Neo	  cells	   in	  vitro,	   soft	  agar	  
assays	  were	  performed.	  Since	  Hmhi	  cells	  showed	  no	  or	  only	  limited	  colony	  forming	  capacity	  
in	  starving	  medium	  alone	  or	  supplemented	  with	  EGF,	  respectively,	  assays	  were	  performed	  in	  
complete	   medium	   containing	   the	   growth	   stimulus	   TPA.	   Even	   though	   Hmhi	   cells	   formed	  
colonies	  in	  complete	  medium,	  the	  ones	  observed	  for	  the	  Hmhi-­‐Neo-­‐Pools	  and	  the	  single	  cell	  
clones	  were	  not	  only	  bigger	  but	  also	  more	  numerous	  (Figure	  48).	   
 
Figure	  48:	  Hmhi-­‐Neo	   cells	   bear	   a	  higher	   transformation	  potential	   than	  Hmhi	   cells	   in	   TPA-­‐containing	   complete	  
medium	  	  




7.18 Colony	  forming	  capacity	  in	  relation	  to	  culture	  media	  
Since	  Hmhi-­‐Neo	  cells	  seem	  to	  bear	  a	  higher	  transformation	  potential	  than	  Hmhi	  cells	  in	  TPA-­‐
containing	  complete	  medium,	  I	  wanted	  to	  compare	  soft	  agar	  assays	  with	  serum-­‐starved	  cells	  
(Figure	   49).	   To	   check	   whether	   colony	   formation	   was	   also	   possible	   without	   any	   growth	  
stimulus,	   I	   performed	   assays	   using	   both	   starving	  medium	   and	  medium	   lacking	   TPA	   (D10).	  
Notably,	  starving	  medium	  was	  supplemented	  with	  10%	  dialyzed	  FCS,	  whereas	  D10	  contains	  
10%	   FCS.	   Compared	   to	   FCS,	   dialyzed	   FCS	   contains	   significantly	   lower	   amounts	   of	   small	  
molecules	   like	   amino	   acids,	   cytokines	   and	   hormones.	   The	   colony	   forming	   capacity	   of	   two	  
Hmhi-­‐Neo	   clones	   was	   compared	   to	   Hmhi	   and	   B16-­‐F1	   cells,	   a	   highly	   tumourigenic	   and	  
metastatic	  melanoma	  cell	  line	  279280,	  was	  used	  as	  positive	  control.	  	  	  
None	  of	   the	  analysed	  cell	   lines	   formed	  colonies	   in	   starving	  medium.	  Besides,	  even	   though	  
EGF	  treatment	  enabled	  colony	  formation	  in	  Hmhi	  and	  Hmhi-­‐Neo	  cells,	  both	  number	  and	  size	  
of	  the	  colonies	  observed	  was	  similar.	  When	  cells	  were	  cultured	  in	  D10-­‐soft	  agar	  lacking	  TPA,	  
colony	   formation	  was	   limited	   and	  no	  differences	   in	   colony	  number	  or	   size	  were	  observed	  
comparing	  Hmhi	  cells	  and	  the	  Hmhi-­‐Neo	  clones.	  Notably,	  the	  highly	  tumourigenic	  B16-­‐F1	  cells	  
formed	   surprisingly	   few	   colonies	   in	   both	   D10	   and	   complete	  medium	   even	   though	   B16-­‐F1	  
cells	   can	   be	   cultured	   in	   either	  medium.	   However,	   Hmhi-­‐Neo	   F#8	   cells	   showed	  many	   large	  
colonies	  in	  complete	  medium,	  whereas	  clone	  E#8	  formed	  fewer	  colonies	  than	  Hmhi	  cells.	  	  
Taken	  together,	  soft	  agar	  assays	  indicated	  that	  Hmhi-­‐Neo	  cells	  are	  not	  able	  to	  form	  colonies	  
in	  absence	  of	  growth	  stimuli.	  However,	  Hmhi-­‐Neo	  F#8	  cells	  appear	  to	  be	  more	  tumourigenic	  
than	  Hmhi	  cells.	  Interestingly,	  the	  highly	  tumourigenic	  B16-­‐F1	  melanoma	  cells	  formed	  hardly	  
any	  colonies.	  	  




Figure	  49:	  Increased	  transformation	  potential	  of	  Hmhi-­‐Neo	  compared	  to	  Hmhi	  cells	  	  
Phase	  contrast	   images	  (25-­‐fold	  magnification)	  of	  Hmhi,	  Hmhi-­‐Neo	  E#8	  and	  Hmhi-­‐Neo	  F#8	  cells	  upon	  14	  days	   in	  
soft	   agar.	   B16-­‐F1	   melanoma	   cells	   served	   as	   positive	   control.	   Where	   indicated	   cells	   were	   either	   cultured	   in	  
starving	  medium	   alone	   (-­‐)	   or	   supplemented	   with	   EGF	   (EGF)	   or	   with	   10%	   FCS	   in	   absence	   (D10)	   or	   presence	  
(complete)	  of	  TPA.	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7.19 Features	  of	  Hmhi-­‐Neo	  clones	  in	  culture	  
Apart	  from	  the	  difference	  in	  cell	  size	  compared	  to	  Hmhi	  cells,	  Hmhi-­‐Neo	  single	  cell	  clones	  also	  
varied	  in	  shape	  and	  growth	  behaviour	  in	  culture	  (Figure	  50a).	  Some	  clones	  had	  roundish	  cells	  
(e.g.	  Hmhi-­‐Neo	  C#2	  and	  Hmhi-­‐Neo	  E#9),	  others	  were	  spindle-­‐shaped	  (e.g.	  Hmhi-­‐Neo	  F#5)	  and	  
some	   grew	   in	   an	   extremely	   dense	   manner	   while	   cell	   borders	   became	   undistinguishable	  
(Hmhi-­‐Neo	  E#8).	  Besides,	  most	   clones	  grew	   in	  an	   island-­‐like	  manner	   (e.g.	  Hmhi-­‐Neo	  C#2	  or	  
Hmhi-­‐Neo	  E#8)	  whereby	  islands	  expanded	  outwards	  while	  island	  borders	  were	  rather	  even.	  	  	  
An	  even	  more	  fascinating	  observation	  was	  the	  rafts,	  an	  aggregate	  of	  two	  to	  several	  hundred	  
viable	  cells,	  floating	  on	  the	  surface	  of	  the	  culture	  medium	  of	  Hmhi-­‐Neo	  clones	  (Figure	  50b).	  
These	   rafts	   came	   in	   different	   shapes	   and	   sizes	   and	   were	   found	   in	   all	   Neo	   clones.	  
Interestingly,	  the	  rafts	  did	  not	  rely	  on	  high	  cell	  density	  on	  the	  dish,	  but	  were	  observed	  even	  
when	  cell	  confluency	  on	  the	  main	  dish	  had	  not	  even	  reached	  50%.	  Notably,	  these	  rafts	  could	  
be	  replated	  and	  cultured.	  	  
Since	  Hmhi-­‐Neo	  C#6	  cells	  grew	  rapidly	  in	  an	  island-­‐like	  manner	  in	  complete	  culture	  medium	  
while	  forming	  3D-­‐structures	  (Figure	  50c)	  and	  rafts,	  I	  decided	  to	  use	  this	  cell	  clone	  to	  further	  
scrutinize	   the	   cellular	   features	   of	   Hmhi-­‐Neo	   cells.	   Hence,	   from	   now	   on	  Hmhi-­‐Neo	   C#6	  was	  
termed	  Hmhi-­‐AR	  (anoikis	  resistant)	  and	  used	  for	  further	  experiments.	  




Figure	  50:	  Hmhi-­‐Neo	  clones	  come	  in	  different	  shapes	  and	  generate	  cell	  rafts	  
(a)	  Phase	  contrast	  images	  (100-­‐fold	  magnification)	  of	  different	  Hmhi-­‐Neo	  clones	  cultured	  in	  complete	  medium	  
and	  (b)	  of	  cell	  rafts	  floating	  on	  the	  surface.	  (c)	  Phase	  contrast	  images	  (50-­‐	  and	  100-­‐fold	  magnification)	  of	  Hmhi-­‐
Neo	  C#6	  cells	  cultured	  in	  complete	  medium.	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7.20 Hmhi-­‐AR	  cells	  do	  not	  senesce	  upon	  oncogene	  activation	  
To	   check	   whether	   Hmhi-­‐AR	   cells	   still	   senesce	   when	   the	   HERmrk	   receptor	   is	   activated,	   I	  
performed	  a	  long-­‐term	  stimulation	  assay	  comparing	  melan	  a	  cells	  to	  Hmhi	  and	  Hmhi-­‐AR	  cells.	  
As	   expected,	   both	   control	   cell	   lines	   that	   were	   carried	   through	   the	   full	   long-­‐term	   assay	  
behaved	   as	   expected:	   	   melan	   a	   cells	   were	   indifferent	   to	   EGF	   treatment	   and	   Hmhi	   cells	  
became	  multinucleated.	  In	  clear	  contrast	  to	  these	  controls,	  Hmhi-­‐AR	  cells	  (Figure	  51)	  showed	  
enhanced	   proliferation	   upon	   EGF	   stimulation,	   but	   no	   large,	   multinucleated	   cells	   were	  
observed.	  In	  addition,	  Hmhi-­‐AR	  cells	  also	  seemed	  to	  grow	  to	  a	  higher	  density	  than	  Hmhi	  cells	  
when	  cultured	  in	  starving	  medium	  alone	  (-­‐).	  
 
 
Figure	  51:	  Hmhi-­‐AR	  cells	  do	  not	  form	  multinucleated	  cells	  upon	  EGF	  treatment	  	  
Phase	   contrast	   images	   (100-­‐fold	  magnification)	   of	  melan	   a,	   Hmhi	   and	  Hmhi-­‐AR	   cells	   upon	   14	   days	   in	   culture.	  
Where	  indicated,	  cells	  were	  either	  cultured	  in	  starving	  medium	  alone	  (-­‐)	  or	  supplemented	  with	  EGF	  (EGF).	  
Hence,	  in	  contrast	  to	  Hmhi	  cells	  Hmhi-­‐AR	  cells	  do	  not	  seem	  to	  become	  multinucleated	  upon	  
EGF	  treatment.	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7.21 Lack	   of	   multinucleation	   for	   Hmhi-­‐AR	   cells	   cannot	   be	   overcome	   by	  
sustained	  oncogene	  stimulation	  
To	   check	  whether	   the	   lack	   of	   large,	  multinucleated	   cells	  was	   just	   a	  matter	   of	   stimulation	  
time,	  I	  continued	  the	  long-­‐term	  stimulation	  assay	  comparing	  Hmhi	  and	  Hmhi-­‐AR	  cells	  for	  up	  
to	  35	  days	  (Figure	  52).	  To	  illustrate	  the	  progression	  of	  cell	  growth	  behaviour	  throughout	  the	  
complete	  assay,	   the	   images	   shown	   in	  Figure	  51	  were	   included	   in	   the	   time-­‐series	   shown	   in	  
Figure	   52.	   Clearly,	   there	   were	   no	   senescing	   Hmhi-­‐AR	   cells	   even	   upon	   long-­‐term	   EGF	  
treatment.	  Instead,	  Hmhi-­‐AR	  cells	  seemed	  to	  steadily	  increase	  the	  cell	  density	  on	  the	  dish	  in	  
presence	   of	   EGF	   throughout	   the	   experiment,	   while	   their	   potential	   to	   grow	   in	   starving	  
medium	  alone	  (-­‐)	  appeared	  to	  be	  limited.	  Nevertheless,	  cell	  density	  seemed	  to	  be	  higher	  for	  
starved	  Hmhi-­‐AR	  cells	  compared	  to	  their	  Hmhi	  counterpart.	  EGF-­‐treated	  Hmhi	  cells	  once	  again	  
became	  multinucleated	  upon	  EGF	  stimulation	  (14	  days)	  before	  nests	   (21	  days)	   followed	  by	  
3D-­‐structures	  (35	  days)	  were	  formed.	   
Taken	   together,	   Hmhi-­‐AR	   cells	   did	   not	   become	   multinucleated	   upon	   EGF	   treatment,	   but	  
instead	   seemed	   to	   divide	   much	   faster	   than	   Hmhi	   cells.	   The	   lack	   of	   multinucleated	   cells	  





Figure	  52:	  Hmhi-­‐AR	  cells	  do	  not	  form	  multinucleated	  cells	  upon	  long-­‐term	  EGF	  treatment	  	  
Phase	   contrast	   images	   (100-­‐fold	   magnification)	   of	   Hmhi	   and	   Hmhi-­‐AR	   cells	   upon	   14,	   21,	   28	   and	   35	   days	   in	  




7.22 Hmhi-­‐AR	   cells	   show	  marker	   expression	   and	   nuclear-­‐cytoplasmic	   ratios	  
similar	  to	  those	  of	  stem	  cells	  
As	  the	  shape	  and	  size	  of	  Hmhi-­‐AR	  cells	  seemed	  to	  differ	  from	  that	  of	  Hmhi	  cells,	  I	  wanted	  to	  
quantify	   this	   phenomenon.	   Therefore,	   Dr.	   Toni	   Wagner	   (Department	   of	   Physiological	  
Chemistry	   I,	  University	   of	  Wuerzburg,	  Wuerzburg,	  Germany)	   performed	  3D	   confocal	   scans	  
thereby	   determining	   the	   total	   cell	   volume	   and	   the	   nuclear	   volume,	  which	   enabled	  me	   to	  
generate	  graphs	  and	  make	  the	  following	  figure	  (Figure	  53).	  Even	  though	  in	  2D	  images	  both	  
cytoplasm	   and	   nucleus	   appeared	   smaller	   in	   Hmhi-­‐AR	   compared	   to	  Hmhi	   cells	   (Figure	   53a),	  
measuring	  the	  compartment	  volumes	  disproved	  this	  assumption	  (Figure	  53b).	  	  Interestingly,	  
only	  cell	  and	  cytoplasm	  volume	  differed	  significantly	  when	  comparing	  Hmhi	  to	  Hmhi-­‐AR	  cells,	  
whereas	  the	  nuclear	  volumes	  of	  both	  cell	   lines	  were	  found	  to	  be	  very	  similar	   (Figure	  53b).	  
This	  fact	  results	  in	  a	  highly	  significant	  difference	  in	  the	  nuclear-­‐cytoplasmic	  ratios	  of	  both	  cell	  
clones,	  where	   Hmhi-­‐AR	   cells	   reached	   a	   50%	   increase	   compared	   to	   Hmhi	   cells	   (Figure	   53c).	  
Furthermore,	  we	  found	  Hmhi-­‐AR	  nuclei	  to	  be	  dome-­‐shaped	  compared	  to	  the	  rather	  flat	  Hmhi	  
nuclei	   (Figure	   53d).	   This	   finding	   explains	   the	   discrepancy	   between	   the	   apparently	   smaller	  
nuclei	  of	  Hmhi-­‐AR	  compared	  to	  Hmhi	  cells	  according	  to	  the	  2D	  pictures	  (Figure	  53a)	  and	  the	  
actual,	  highly	  similar	  nuclear	  volumes	  depicted	  in	  the	  compartment	  graph	  (Figure	  53b).	  




Figure	  53:	  Hmhi-­‐AR	  cells	  are	  smaller	  and	  have	  a	  higher	  nuclear-­‐cytoplasmic	  ratio	  than	  Hmhi	  cells	  
(a)	   False	   colour	   2D	   confocal	   snapshots	   (600-­‐fold	  magnification)	   of	   Hmhi	   and	   Hmhi-­‐AR	   cells	   plated	   onto	   glass	  
cover	  slips	  and	  cultured	  in	  complete	  medium.	  The	  cytoplasm	  was	  stained	  with	  cell	  mask	  deep	  red	  and	  DNA	  was	  
counterstained	  using	  Hoechst	  33342.	  (b)	  Bars	  display	  the	  mean	  compartment	  volumes	  of	  9	  Hmhi	  and	  Hmhi-­‐AR	  
cells	  each.	  Standard	  deviations	  are	  shown.	  Where	  indicated,	  statistical	  significance	  determined	  by	  Student´s	  t-­‐
test	  (paired,	  two-­‐tailed)	  was	  reached	  (*p<0.05).	  (c)	  Scatter	  plot	  displaying	  the	  nuclear-­‐cytoplasmic	  ratios	  for	  all	  
9	   single	   cells	   analysed	   for	   both	   Hmhi	   and	   Hmhi-­‐AR.	   Vertical	   bars	   represent	   the	   mean	   values.	   Statistical	  
significance	  determined	  by	   Student´s	   t-­‐test	   (paired,	   two-­‐tailed)	  was	   reached	   (**p<0.01).	   (d)	   Equally	   cropped	  
false	  colour	  3D	  stack	  images	  comparing	  the	  shape	  of	  Hmhi	  and	  Hmhi-­‐AR	  cells.	  Upper	  and	  lower	  panels	  show	  cells	  
at	  the	  same	  rotation	  point.	  Axes	  are	  shown	  in	  the	  lower	  left	  corner	  (x:	  green,	  y:	  red,	  z:	  blue).	  
Since	  high	  nuclear-­‐cytoplasmic	  ratios	  are	  not	  only	  a	  prominent	  feature	  for	  aggressive	  tumour	  
cells	  281–283,	  but	  also	  a	  hallmark	  of	  stem	  cells	  284–286,	  I	  was	  wondering	  whether	  Hmhi-­‐AR	  cells	  
expressed	  stem	  cell	  markers.	  Thus,	  I	  transiently	  transfected	  both	  Hmhi	  and	  Hmhi-­‐AR	  cells	  with	  
the	   Nanog-­‐driven	   PL-­‐SIN-­‐EOS-­‐S(4+)-­‐eGFP	   vector	   287,	   a	   gift	   from	   James	   Ellis	   (University	   of	  
Toronto,	   Canada)	   kindly	   provided	   by	   Dr.	   Toni	   Wagner	   (Department	   of	   Physiological	  
Chemistry	  I,	  University	  of	  Wuerzburg,	  Biocenter,	  Am	  Hubland,	  Wuerzburg,	  Germany).	  I	  found	  
Hmhi	   cells	   to	   lack	   Nanog	   expression,	   whereas	   a	   large	   fraction	   of	   Hmhi-­‐AR	   cells	   expressed	  
functional	  Nanog	  protein	  (Figure	  54a).	  Applying	  the	  antibiotic	  puromycin,	  I	  could	  even	  select	  
	  
102	  
and	  expand	  Nanog-­‐expressing	  Hmhi-­‐AR	  (Hmhi-­‐AR-­‐EOS)	  cells	  (Figure	  54b),	  while	  Hmhi	  cells	  did	  
not	   survive	   the	   selection	   procedure.	  Western	   blot	   analyses	   revealed	   that	   Hmhi-­‐AR	   clones	  
also	  expressed,	  apart	  from	  Nanog,	  the	  stem	  cell	  markers	  C-­‐Myc	  and	  Oct4	  at	  different	  levels,	  
whereas	  Hmhi	  cells	  lacked	  both	  Nanog	  and	  Oct4	  protein	  expression	  while	  showing	  low	  levels	  
of	   C-­‐Myc.	   Hmhi-­‐AR-­‐EOS	   cells	   expressed	   very	   high	   levels	   of	   C-­‐Myc	   and	   Nanog,	   but	   Oct4	  
protein	  was	  hardly	  detectable	  (Figure	  54c).	  
Nevertheless,	   it	   seems	   safe	   to	   conclude	   that	   Hmhi-­‐AR	   cells	   show	   marker	   expression	   and	  
nuclear-­‐cytoplasmic	  ratios	  similar	  to	  those	  of	  stem	  cells.	   
 
Figure	  54:	  Hmhi-­‐AR	  cells	  express	  stem	  cell	  markers	  
(a)	   Phase	   contrast	   and	   fluorescence	   images	   (200-­‐fold	   magnification)	   of	   Hmhi	   and	   Hmhi-­‐AR	   cells	   transiently	  
transfected	  with	  the	  Nanog-­‐driven	  PL-­‐SIN-­‐EOS-­‐S(4+)-­‐eGFP	  vector	  and	  (b)	  of	  Hmhi-­‐AR	  cells	  stably	  expressing	  the	  
PL-­‐SIN-­‐EOS-­‐S(4+)-­‐eGFP	   vector	   and	   therefore	   termed	   Hmhi-­‐AR-­‐EOS.	   (c)	   Western	   blot	   analyses	   of	   Hmhi,	   three	  
different	  Hmhi-­‐AR	  clones	  and	  Hmhi-­‐AR-­‐EOS	  cells	  cultured	  in	  complete	  medium.	  Cells	  were	  harvested	  and	  whole	  




7.23 HERmrk	  receptor	  and	  DNA	  damage	  level	  in	  Hmhi-­‐AR	  clones	  
To	  investigate	  whether	  the	  HERmrk	  receptor	  level	  correlates	  with	  the	  enhanced	  proliferation	  
observed	  for	  Hmhi-­‐AR	  compared	  to	  Hmhi	  cells,	  I	  performed	  Western	  blot	  analyses	  (Figure	  55).	  
I	  found	  some	  Hmhi-­‐AR	  clones	  to	  express	  extremely	  high	  Xmrk	  levels,	  whereas	  the	  third	  Hmhi-­‐
AR	  clone	  showed	  a	  weaker	  protein	  band	  compared	  to	  Hmhi	  cells	  (Figure	  55a).	  Furthermore,	  
for	  Hmhi-­‐AR-­‐EOS	  cells,	  a	  medium	  Xmrk	  protein	  level	  could	  be	  detected	  (Figure	  55a).	  	  
Interestingly,	   for	   the	   HERmrk	   high	   expressing	   Hmhi-­‐AR	   clones,	   the	   Xmrk	   expression	   level	  
directly	  correlated	  with	  the	  detected	  protein	  level	  of	  the	  DNA	  damage	  markers	  P-­‐p53	  and	  P-­‐
Chk2	  (Figure	  55b).	  Notably,	  the	  protein	  levels	  of	  both	  DNA	  damage	  markers	  were	  higher	  in	  
the	  Hmhi-­‐AR	  clone	  expressing	  low	  amounts	  of	  Xmrk	  compared	  to	  the	  DNA	  damage	  extent	  in	  
Hmhi	  control	  cells.	  
 
Figure	  55:	  Hmhi-­‐AR	  clones	  express	  variable	  levels	  of	  HERmrk	  and	  DNA	  damage	  markers	  
Western	  blot	  analyses	  of	  (a)	  HERmrk	  expression	  levels	  and	  (b)	  the	  DNA	  damage	  markers	  P-­‐p53	  and	  P-­‐Chk2	  for	  
Hmhi,	  three	  different	  Hmhi-­‐AR	  clones	  and	  Hmhi-­‐AR-­‐EOS	  cells	  cultured	  in	  complete	  medium.	  Cells	  were	  harvested	  
and	  whole	  cell	  lysates	  were	  separated	  using	  10%	  SDS	  gels.	  Protein	  weights	  are	  indicated	  in	  kDa.	  β-­‐actin	  served	  
as	  loading	  control.	  
Taken	   together,	   compared	   to	   Hmhi	   cells,	   all	   Hmhi-­‐AR	   clones	   investigated	   expressed	   higher	  




7.24 In	  vivo	  transformation	  potential	  of	  Hmhi	  and	  Hmhi-­‐AR	  cells	  
To	   see	   whether	   the	   enhanced	   proliferation	   and	   transformation	   capacity	   in	   vitro	   can	   be	  
confirmed	  in	  vivo,	  we	  decided	  to	  inoculate	  Hmhi-­‐AR	  and	  melan	  a	  control	  cells	  into	  nude	  mice.	  
Dr.	  Christoph	  Otto	  [Experimental	  Surgery,	  Experimental	  Transplantation	  Immunology,	  Clinic	  
of	   General,	   Visceral,	   Vascular	   and	   Pediatric	   Surgery	   (Surgical	   Clinic	   I),	   University	   of	  
Wuerzburg	  Hospital,	  Wuerzburg,	   Germany]	   and	   his	   technician	   Bettina	  Mühling	   performed	  
the	  experiments	  using	  five	  animals	  each	  and	  subcutanously	  inoculating	  equal	  cell	  numbers	  in	  
both	  flanks.	  
In	  melan	  a	  control	  (ctrl.)	  mice,	  the	  inoculated	  cells	  formed	  a	  nevus-­‐like	  structure	  visible	  as	  a	  
black	   dot	   at	   the	   site	   of	   inoculation	   (Figure	   56a).	   However,	   neither	   visible	   nevus-­‐like	  
structures,	  nor	  tumours	  had	  been	  formed	  in	  Hmhi-­‐AR	  mice	  when	  the	  animals	  were	  sacrificed	  
71	   days	   post	   inoculation	   (Figure	   56a).	   Notably,	   in	   contrast	   to	  melan	   a	   control	   (ctrl.)	   cells,	  
Hmhi-­‐AR	  cells	  showed	  no	  pigmentation.	  Nevertheless,	  within	  the	  final	  week	  prior	  to	  sacrifice,	  
all	   five	   Hmhi-­‐AR	  mice	   suffered	   from	   significant	  weight	   loss	   (Figure	   56b),	   showed	   a	   humpy	  
back	   and	   wrinkled	   skin,	   most	   likely	   due	   to	   the	   loss	   of	   subcutaneous	   fat,	   while	   behaving	  
normally	   [personal	   conversation	   with	   Bettina	  Mühling].	   Interestingly,	   when	   Hmhi-­‐AR	  mice	  
were	  opened	  up,	  we	   found	   the	   stomach	  of	   all	   animals	   to	  be	   strongly	  dilated	   (Figure	  56c).	  
Unfortunately,	  melan	  a	  control	  mice	  had	  already	  been	  sacrificed	  so	  we	  could	  only	  compare	  
the	  stomach	  size	  to	  the	  ones	  of	  N-­‐RAS*	  mice	  (N-­‐RAS*)	  which	  had	  been	  kept	  in	  the	  absence	  
of	   doxycycline	   and	   are	  discussed	  below	   (Figure	   56c).	   The	   stomach	  of	  N-­‐RAS*	  mice	   looked	  
unsuspicious	  (Figure	  56c).	  




Figure	  56:	  Hmhi-­‐AR	  cells	  do	  not	  induce	  rapid	  tumour	  growth	  in	  nude	  mice,	  but	  induce	  features	  of	  bad	  medical	  
condition	  
(a)	   Comparison	   of	   nude	  mice	   either	   bearing	  melan	   a	   control	   (ctrl.)	   or	  Hmhi-­‐AR	   (Hmhi-­‐AR)	   cells	   71	   days	   upon	  
inoculation.	  (b)	  Graph	  depicts	  the	  weight	  of	  melan	  a	  control	  (ctrl.)	  and	  Hmhi-­‐AR	  (Hmhi-­‐AR)	  mice	  over	  time.	  Bars	  
represent	   the	   mean	   weight	   of	   five	   animals	   each.	   Standard	   deviations	   are	   shown.	   Statistical	   significance	  
determined	   by	   Student´s	   t-­‐test	   (paired,	   two-­‐tailed)	   was	   reached	   71	   days	   upon	   inoculation	   (*p<0.05).	   (c)	  
Comparison	  of	  nude	  mice	  stomachs	  71	  days	  upon	  inoculation	  of	  Hmhi-­‐AR	  (Hmhi-­‐AR)	  or	  N-­‐RAS*	  (N-­‐RAS*)	  cells.	  
The	  N-­‐RAS*	  mouse	  had	  been	  kept	  without	  doxycycline.	  	  
Taken	   together,	  melan	  a	   control	   (ctrl.)	   cells	   formed	  nevus-­‐like	   structures	  upon	   inoculation	  
into	   nude	  mice,	  while	  Hmhi-­‐AR	   cells	   led	   to	   a	   significant	  weight	   loss	   and	  unhealthy-­‐looking	  




7.25 N-­‐RAS*-­‐induced	   senescent	   melanocytes	   are	   a	   source	   for	   highly	  
proliferative,	  anoikis-­‐resistant,	  tumourigenic	  and	  de-­‐differentiated	  cells	  
Since	   apart	   from	   HERmrk,	   we	   had	   identified	   N-­‐RAS*	   to	   induce	   senescence	   in	  	  
melanocytes	  230,	  I	  wanted	  to	  know	  whether	  sustained	  doxycycline	  treatment	  also	  resulted	  in	  
overgrowth	   of	   senescent	   cells	   and	   nest	   formation.	   Hence,	   I	   performed	   a	   long-­‐term	  
stimulation	   assay	   using	   N-­‐RAS*	   cells.	   As	   expected,	   just	   like	   EGF-­‐stimulated	   Hmhi	   cells,	  
doxycycline-­‐treated	   N-­‐RAS*	   cells	   became	   multinucleated	   and	   SA-­‐β-­‐Gal-­‐positive	   within	   14	  
days	  of	  stimulation	  (Figure	  57a).	  However,	  upon	  sustained	  doxycycline	  treatment,	  I	  observed	  
nest-­‐like	   structures	   consisting	   of	   small	   cells,	  which	   divided	   rapidly,	   overgrew	   the	   dish	   and	  
finally	  formed	  3D-­‐structures	  (Figure	  57b).	  Once	  again,	  all	  nests	  were	  found	  to	  arise	  in	  close	  
proximity	   to	   a	   multinucleated	   cell.	   Importantly,	   in	   doxycycline-­‐treated	   N-­‐RAS*	   cells,	   nest	  
formation	   occurred	  much	  more	   rapidly	   than	   in	   EGF-­‐stimulated	  Hmhi	   cells.	   Besides,	   the	  N-­‐
RAS*	   nest-­‐forming	   cells	   appeared	   to	   be	   even	   smaller	   than	   Hmhi-­‐AR	   cells	   and	   the	   3D	  
structures	  overgrowing	  the	  dish	  were	  much	  more	  impressive	  compared	  to	  those	  observed	  in	  
EGF-­‐treated	  Hmhi	  cells. 




Figure	  57:	  Sustained	  Dox	  treatment	  of	  multinucleated	  N-­‐RAS*	  cells	  results	  in	  “nest”	  formation	  	  
(a)	   Phase	   contrast	   (PH)	   and	   brightfield	   images	   (100-­‐fold	   magnification)	   of	   SA-­‐β-­‐Gal-­‐stained	   N-­‐RAS*	   cells	  
stimulated	  with	   doxycycline	   (Dox)	   upon	   3	   and	   14	   days	   in	   culture.	   (b)	   Phase	   contrast	   images	   of	   doxycycline-­‐
treated	  N-­‐RAS*	  cells	  (100-­‐fold	  magnification)	  at	  indicated	  time	  points.	  
Since	   I	   wanted	   to	   further	   characterize	   these	   small,	   emerging	   cells,	   I	   once	   again	   picked	  
different,	  large	  nests	  and	  transferred	  cells	  into	  a	  48-­‐well	  plate	  with	  the	  help	  of	  a	  pipette	  tip.	  I	  
cultured	   these	  cells	   (N-­‐RAS*-­‐Neo-­‐Pool)	   in	   complete	  medium	  before	  generating	  and	   raising	  
single	  cell	  clones.	  The	  cells	  picked	  from	  a	  single	  nest	  were	  termed	  N-­‐RAS*-­‐Neo-­‐Pool,	  single	  
cell	  clones	  were	  numbered	  consecutively	  and	  the	  ones	  growing	  best	  in	  culture	  were	  chosen	  
for	  further	  experiments.	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7.26 Features	  of	  N-­‐RAS*-­‐Neo	  single	  cell	  clones	  
These	  N-­‐RAS*-­‐Neo	  single	  cell	  clones	  either	  grew	  in	  an	   island-­‐like	  manner	  (e.g.	  N-­‐RAS*-­‐Neo	  
C#4	  or	  N-­‐RAS*-­‐Neo	  D#1)	  or	  formed	  nest-­‐like	  structures	  (e.g.	  N-­‐RAS*-­‐Neo	  E#2	  or	  N-­‐RAS*-­‐Neo	  
E#4)	  (Figure	  58a).	  	  
As	   N-­‐RAS*-­‐Neo-­‐Pool	   cells	   cultured	   in	   complete	   medium	   formed	   rafts	   similar	   to	   those	  
observed	   for	  Hmhi-­‐Neo	   cells,	   I	   replated	   the	   supernatant	   cells,	   expanded	   them	  and	   termed	  
the	   cells	   N-­‐RAS*-­‐AR-­‐Pool	   (for	   anoikis	   resistant)	   (Figure	   58b).	   N-­‐RAS*-­‐AR-­‐Pool	   cells	   again	  
formed	   rafts,	   cell	   clumps	   and	   single	   cells	   were	   floating	   in	   the	   supernatant.	   Once	   again,	   I	  
replated	   these	   cells,	   termed	   them	   supernatant	   of	   N-­‐RAS*-­‐AR-­‐Pool	   and	   cultured	   them	   in	  
complete	  medium	  (Figure	  58b).	   I	  generated	  single	  cell	  clones,	  which	  were	  termed	  N-­‐RAS*-­‐
AR#1-­‐#4.	  The	  ones	  growing	  best,	  namely	  N-­‐RAS*-­‐AR#2	  and	  N-­‐RAS*-­‐AR#3	  (Figure	  58b),	  were	  
chosen	   for	   further	  experiments.	  Notably,	   the	  supernatant	  cells	   seemed	  to	  become	  smaller	  
and	  increased	  their	  proliferation	  potential	  with	  every	  replating	  procedure.	  Moreover,	  N-­‐RAS-­‐
AR	  single	  cell	  clones	  again	  formed	  rafts	  even	  though	  the	  cell	  density	  on	  the	  culture	  dish	  was	  
low	  (Figure	  58c).	  	  
Taken	   together,	   sustained	   doxycycline	   treatment	   of	   multinucleated	   N-­‐RAS*	   melanocytes	  
resulted	   in	   nest	   formation	   followed	   by	   appearance	   of	   cell-­‐rafts	   and	   generation	   of	   3D	  
structures.	   The	   small,	   nest-­‐generating	   cells	   could	   be	   replated	   before	   forming	   rafts,	   which	  
again	  were	  viable	  and	  highly	  proliferative.	  




Figure	  58:	  N-­‐RAS*-­‐Neo	  cells	  generate	  rafts	  	  
(a)	   Phase	   contrast	   images	   (100-­‐fold	  magnification)	   of	  N-­‐RAS*-­‐Neo	   single	   cell	   clones	   and	   (b)	  N-­‐RAS*-­‐AR	   lines	  
cultured	  in	  complete	  medium.	  (c)	  Phase	  contrast	  images	  (100-­‐fold	  magnification	  of	  two	  rafts	  in	  the	  focus	  level	  
(raft)	  generated	  by	  N-­‐RAS*-­‐AR#2	  cells.	  The	  corresponding	  pictures	  of	  the	  attached	  cells	  in	  the	  focus	  level	  of	  the	  
culture	  dish	  (dish)	  were	  taken	  at	  the	  site	  of	  the	  respective	  raft.	  
7.27 In	  vitro	  tumourigenic	  potential	  of	  N-­‐RAS*-­‐Neo-­‐AR-­‐Pool	  cells	  
To	   investigate	   the	   transformation	  potential	   of	  N-­‐RAS*-­‐Neo-­‐AR-­‐Pool	   cells	   in	   vitro,	   soft	   agar	  
assays	  were	   performed	   (Figure	   59).	   I	   found	   N-­‐RAS*-­‐AR-­‐Pool	   cells	   to	   form	   fairly	   large	   and	  
numerous	  colonies	  in	  starving	  medium.	  Upon	  additional	  doxycycline	  treatment,	  the	  colonies	  
observed	   were	   larger	   and	   similar	   to	   those	   observed	   when	   N-­‐RAS*-­‐AR-­‐Pool	   cells	   were	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Figure	  59:	  N-­‐RAS*-­‐AR-­‐Pool	  cells	  bear	  in	  vitro	  transformation	  potential	  	  
Phase	   contrast	   images	   (25-­‐fold	   magnification)	   of	   N-­‐RAS*-­‐AR-­‐Pool	   cells	   upon	   14	   days	   in	   soft	   agar.	   Where	  
indicated,	   cells	  were	   kept	   in	   starving	  medium	  alone	   (-­‐)	   or	   supplemented	  with	  doxycycline	   (Dox)	  or	   agar	  was	  
supplied	  with	  10%	  serum	  (D10).	  	  
7.28 In	  vitro	  tumourigenic	  potential	  of	  melan	  a	  control,	  N-­‐RAS*	  and	  N-­‐RAS*-­‐
AR	  clones	  
Since	   N-­‐RAS*-­‐AR-­‐Pool	   cells	   proved	   to	   be	   tumourigenic	   in	   vitro,	   I	   wanted	   to	   compare	   the	  
transformation	  potential	  of	  serum-­‐starved	  N-­‐RAS*-­‐AR#2	  and	  N-­‐RAS*-­‐AR#3	  to	  those	  of	  melan	  
a	  control	   (ctrl.)	  and	  N-­‐RAS*	  melanocytes.	  Therefore,	  soft	  agar	  assays	  using	  different	  media	  
were	  performed	  (Figure	  60).	  Upon	  14	  days	  in	  soft	  agar	  I	  found	  melan	  a	  control	  cells	  (ctrl.)	  to	  
lack	  colony	  forming	  capacity	  regardless	  of	  culture	  conditions.	  Furthermore,	  N-­‐RAS*	  cells	  only	  
formed	   very	   few	   small	   colonies	   in	   presence	   of	   doxycycline	   (Dox).	   N-­‐RAS*-­‐AR#2	   and	   N-­‐
RAS*#3	   cells	   however,	   formed	   colonies	   irrespective	   of	  medium	   supply.	   Interestingly,	   even	  
though	  complete	  medium	  contained	  TPA	  in	  addition	  to	  the	  10%	  serum	  in	  D10,	  the	  N-­‐RAS*-­‐
AR#2	  and	  #3	  colonies	  observed	  upon	  culture	  in	  complete	  medium	  were	  much	  smaller	  than	  
those	   observed	   in	   D10.	   Notably,	   the	   number	   and	   size	   of	   N-­‐RAS*-­‐AR#2	   and	   #3	   colonies	  
observed	  in	  starving	  medium	  (-­‐)	  were	  not	  altered	  in	  presence	  of	  doxycycline	  (Dox),	  while	  #3	  
generally	  formed	  larger	  colonies.	  	  




Figure	  60:	  N-­‐RAS*-­‐AR#2	  and	  #3	  cells	  bear	  in	  vitro	  transformation	  potential	  	  
Phase	   contrast	   images	   (25-­‐fold	  magnification)	   of	   melan	   a	   control	   (ctrl.),	   N-­‐RAS*,	   N-­‐RAS*-­‐AR#2	   and	   #3	   cells	  
upon	  14	  days	  in	  soft	  agar.	  Where	  indicated,	  cells	  were	  kept	  in	  starving	  medium	  alone	  (-­‐)	  or	  supplemented	  with	  
doxycycline	  (Dox)	  or	  agar	  was	  supplied	  with	  10%	  serum	  in	  absence	  (D10)	  or	  presence	  of	  TPA	  (complete).	  	  
Taken	   together,	   serum-­‐starved	   N-­‐RAS*-­‐AR#2	   and	   #3	   cells	   showed	   a	   very	   high	   in	   vitro	  
transformation	   potential	   regardless	   of	   culture	   conditions,	   whereas	   N-­‐RAS*	   melanocytes	  
relied	  on	  doxycycline	  treatment	  to	  form	  very	  few,	  extremely	  small	  colonies,	  while	  melan	  a	  
control	  cells	  completely	  lacked	  transformation	  capacity.	  	  
Since	  serum-­‐starved	  N-­‐RAS*-­‐AR#3	  cells	   formed	  the	   largest	  and	  most	  numerous	  colonies	   in	  
soft	  agar	  and	  proliferated	  extremely	  well	  when	  cultured	   in	  complete	  medium,	   I	  decided	  to	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use	   this	   single	   cell	   clone	   to	   further	   scrutinize	   the	   features	   of	   N-­‐RAS*-­‐AR	   cells.	   Hence,	   I	  
termed	  N-­‐RAS*-­‐AR#3	  cells	  N-­‐RAS*-­‐AR	  and	  used	  them	  for	  further	  experiments.	  	  	  
7.29 N-­‐RAS*-­‐AR	  cells	  do	  not	  senesce,	  but	  proliferate	  
First	  of	  all,	  I	  wanted	  to	  check	  whether	  N-­‐RAS*-­‐AR	  cells	  still	  senesce.	  Therefore,	  I	  performed	  a	  
long-­‐term	  stimulation	  assay	  comparing	  melan	  a	  cells	  to	  Hmhi	  and	  Hmhi-­‐AR	  cells	  (Figure	  61a).	  
While	  melan	  a	  cells	  were	  indifferent	  to	  EGF	  treatment,	  N-­‐RAS*	  cells	  became	  multinucleated	  
as	   usual.	  N-­‐RAS*-­‐AR	   cells	   however,	   showed	   enhanced	   cell	   density	   upon	   doxycycline	   (Dox)	  
treatment,	   but	   no	   large,	  multinucleated	   cells	  were	   observed.	   In	   addition,	   N-­‐RAS*-­‐AR	   cells	  
grew	  to	  a	  much	  higher	  density	  than	  N-­‐RAS*melanocytes	  when	  cultured	  in	  starving	  medium	  
alone	  (-­‐).	  Notably,	  there	  was	  only	  a	  minor	  difference	  in	  cell	  density	  when	  comparing	  starved	  
(-­‐)	  and	  doxycycline-­‐treated	  (Dox)	  N-­‐RAS*-­‐AR	  cells.	  	  
This	  difference	  in	  cell	  density	  already	  became	  obvious	  when	  looking	  at	  the	  culture	  medium	  
in	   the	   6-­‐well	   plate	   used	   for	   the	   assay	   (Figure	   61b).	  While	   the	   red	   colour	   of	   the	  medium	  
remained	  throughout	  the	  experiment	  for	  melan	  a	  control	  (ctrl.)	  cells,	  N-­‐RAS*	  cells	  seemed	  to	  
have	  consumed	  more	  nutrients	  as	  indicated	  by	  the	  decrease	  in	  medium	  pH,	  which	  led	  to	  the	  
observed	   change	   of	   colour.	   Intriguingly,	   N-­‐RAS*-­‐AR	   cells	   appeared	   to	   have	   completely	  
metabolized	   and	   acidified	   the	  medium,	   which	   had	   turned	   yellow	   prior	   to	   the	   end	   of	   the	  
experiment.	  	  	  
To	   visualize	   the	   difference	   in	   proliferation	   as	   well	   as	   the	   3D	   structures	   formed	   upon	  
doxycycline	  treatment	   in	  N-­‐RAS*	  and	  N-­‐RAS*-­‐AR	  cells,	   I	  stained	  the	  cells	  with	  crystal	  violet	  
(Figure	  61c).	  While	  melan	  a	  control	  (ctrl.)	  cells	  showed	  only	  a	  very	  weak	  violet	  staining,	  the	  
3D	  structures	  in	  N-­‐RAS*	  cells	  stained	  dark	  purple.	  The	  colour	  intensity	  was	  even	  higher	  in	  the	  
densely	  packed	  N-­‐RAS*-­‐AR	  cells.	  
Taken	   together,	   in	   contrast	   to	   N-­‐RAS*	   melanocytes	   N-­‐RAS*-­‐AR	   cells	   do	   not	   become	  
multinucleated	   upon	   doxycycline	   treatment.	   Instead,	   N-­‐RAS*-­‐AR	   cells	   seem	   to	   bear	   an	  




Figure	  61:	  N-­‐RAS*-­‐AR	  cells	  do	  not	  form	  multinucleated	  cells	  upon	  doxycycline	  treatment	  	  
(a)	  Phase	  contrast	  images	  (100-­‐fold	  magnification)	  of	  melan	  a	  control	  (ctrl.),	  N-­‐RAS*	  and	  N-­‐RAS*-­‐AR	  cells	  upon	  
14	  days	   in	  culture.	  Where	  indicated,	  cells	  were	  either	  cultured	  in	  starving	  medium	  alone	  (-­‐)	  or	  supplemented	  
with	  doxycycline	  (Dox).	  (b)	  Equally	  cropped	  images	  of	  the	  6-­‐wells	  used	  for	  the	  senescence	  assay	  upon	  14	  days	  
in	   culture.	  Where	   indicated,	   cells	   were	   either	   cultured	   in	   starving	   medium	   alone	   (-­‐)	   or	   supplemented	   with	  
doxycycline	  (Dox).	  (c)	  Brightfield	  images	  (100-­‐fold	  magnification)	  of	  crystal	  violet-­‐stained	  melan	  a	  control	  (ctrl.),	  
N-­‐RAS*	  and	  N-­‐RAS*-­‐AR	  cells	  upon	  14	  days	  in	  culture.	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7.30 N-­‐RAS*-­‐AR	  cells	  seem	  to	  proliferate	  in	  a	  Dox-­‐independent	  manner	  and	  
lack	  density-­‐induced	  growth	  inhibition	  
Thus,	   I	   repeated	   the	   long-­‐term	   stimulation	   assay	   and	   also	   cultured	   the	   cells	   in	   medium	  
supplemented	   with	   10%	   serum	   (D10)	   (Figure	   62).	   I	   found	   melan	   a	   control	   (ctrl.)	   cells	   to	  
behave	   indifferent	   to	   culture	   conditions.	   N-­‐RAS*	   cells	   senesced	   upon	   doxycycline	   (Dox)	  
treatment	  and	  D10	  did	  not	  seem	  to	  enhance	  their	  proliferation	  potential	  compared	  to	  the	  
level	  observed	   in	  starving	  medium	  (-­‐).	   In	  contrast,	  N-­‐RAS*-­‐AR	  cells	  appeared	  to	  proliferate	  
equally	   well	   in	   all	   three	   culture	   conditions	   analysed.	   Strikingly,	   illustrated	   by	   the	   phase	  
contrast	  images,	  no	  density-­‐induced	  growth	  inhibition	  occured	  in	  N-­‐RAS*-­‐AR	  cells,	  while	  the	  
other	  cell	  lines	  kept	  flat,	  extended	  cell	  shapes.	  In	  stark	  contrast,	  N-­‐RAS*-­‐AR	  cells	  formed	  cell	  
clumps	  and	  continued	  to	  grow	  in	  a	  3-­‐dimensional	  fashion.	  
 
Figure	  62:	  N-­‐RAS*-­‐AR	  cells	  seem	  to	  proliferate	  in	  a	  doxycycline-­‐independent	  manner	  	  
Phase	  contrast	  images	  (100-­‐fold	  magnification)	  of	  melan	  a	  control	  (ctrl.),	  N-­‐RAS*	  and	  N-­‐RAS*-­‐AR	  cells	  upon	  14	  
days	  in	  culture.	  Where	  indicated,	  cells	  were	  either	  cultured	  in	  starving	  medium	  alone	  (-­‐)	  or	  supplemented	  with	  
doxycycline	  (Dox)	  or	  in	  medium	  containing	  10%	  FCS	  (D10).	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7.31 N-­‐RAS*-­‐AR	  cells	  grow	  regardless	  of	  culture	  conditions	  
Since	  N-­‐RAS*-­‐AR	  cells	  seemed	  to	  proliferate	  in	  a	  doxycycline-­‐independent	  manner	  and	  much	  
better	   than	   their	   N-­‐RAS*	   counterparts,	   I	   wanted	   to	   quantify	   this	   phenomenon.	   Hence,	  
proliferation	   assays	   using	   different	   culture	   conditions	   were	   performed	   to	   compare	   the	  
proliferation	  potential	  of	  melan	  a	  control	  (ctrl.),	  N-­‐RAS*	  and	  N-­‐RAS*-­‐AR	  cells	  (Figure	  63).	  	  
I	   found	  melan	   a	   control	   (ctrl.)	   cells	   to	   lack	   proliferation	   capacity	  when	   cultured	   in	  DMEM	  
supplemented	  with	  only	  2.5%	  dialyzed	  serum	  (-­‐)	  (Figure	  63a).	  As	  expected,	  doxycycline	  (Dox)	  
treatment	  could	  not	  induce	  proliferation	  of	  melan	  a	  control	  cells	  (ctrl.)	  (Figure	  63a).	  N-­‐RAS*	  
cells	   however,	   slightly	   proliferated	   after	   an	   initial	   proliferation	   lag	   in	   medium	   containing	  
2.5%	   dialyzed	   FCS	   even	   though	   stimulation	   with	   doxycycline	   did	   not	   alter	   the	   total	   cell	  
number	   (Figure	  63a).	  Unfortunately,	  N-­‐RAS*	  expression	  was	   found	   to	  be	   leaky	   resulting	   in	  
increased	   N-­‐RAS*	   protein	   levels	   compared	   to	   empty	   vector	   control	   melanocytes	   (Figure	  
65a).	  Interestingly,	  N-­‐RAS*-­‐AR	  cells	  only	  needed	  a	  3	  day	  period	  to	  recover	  their	  proliferation	  
capacity	  from	  the	  pre-­‐experiment-­‐starvation	  and	  replating	  in	  medium	  containing	  only	  2.5%	  
dialyzed	   FCS:	   N-­‐RAS*-­‐AR	   cells	   proliferated	   equally	   well	   in	   absence	   (-­‐)	   or	   presence	   of	   Dox	  
finally	   exceeding	  N-­‐RAS*	   cell	   numbers	  by	   a	   factor	  of	   4	   at	  day	  10	   (Figure	  63a).	   The	   results	  
were	   similar	   when	   cells	   were	   cultured	   in	   DMEM	   supplemented	   with	   10%	   dialyzed	   FCS	  
(Figure	   63b).	   Melan	   a	   control	   (ctrl.)	   cells	   hardly	   proliferated	   irrespective	   of	   doxycycline	  
status,	  while	  N-­‐RAS*	  melanocytes	   responded	   to	  Dox	   stimulation	   reaching	   higher	   total	   cell	  
numbers	  despite	  multinucleation	  compared	  to	  cells	  cultured	  in	  starving	  medium	  alone	  (-­‐).	  In	  
addition,	   N-­‐RAS*-­‐AR	   cells	   proliferated	   about	   10	   times	   faster	   than	   Dox-­‐treated	   N-­‐RAS*	  
melanocytes	   and	   similarly	  well	   in	   absence	   and	   presence	   of	   Dox	  with	   total	   numbers	   being	  
slightly	  higher	  when	  cells	  were	  stimulated	  with	  Dox.	  Total	  cell	  numbers	  increased	  once	  again	  
when	   cells	  were	   cultured	   in	  DMEM	  containing	  10%	  FCS	   in	   absence	   (-­‐)	   or	   presence	  of	   TPA	  
(TPA)	   (Figure	   63c).	  While	  melan	   a	   control	   (ctrl.)	   cells	   hardly	   and	  N-­‐RAS*	   cells	   only	   slightly	  
proliferated	   in	   absence	   of	   TPA	   (-­‐),	   N-­‐RAS*-­‐AR	   cells	   proliferated	   really	   well	   with	   total	   cell	  
numbers	   increasing	  by	  about	  40%	  compared	  to	  Dox-­‐stimulated	  cells	   in	  medium	  containing	  
10%	  of	  dialyzed	  FCS.	  Interestingly,	  the	  addition	  of	  TPA	  did	  not	  alter	  N-­‐RAS*-­‐AR	  cell	  number.	  
However,	  only	   in	  presence	  of	  TPA	  and	  10%	  FCS	  did	  melan	  a	  control	   (ctrl.)	  cells	  proliferate,	  
even	   though	   total	   cell	   number	  was	  higher	   for	  N-­‐RAS*	   cells.	  Nevertheless,	  melan	  a	   control	  
(ctrl.)	  and	  N-­‐RAS*	  cells	  only	  reached	  about	  30%	  and	  60%	  of	  the	  total	  N-­‐RAS*-­‐AR	  cell	  number	  
in	  complete	  medium	  in	  presence	  of	  TPA.	  




Figure	  63:	  N-­‐RAS*-­‐AR	  cells	  bear	  an	  increased	  proliferation	  potential	  independent	  of	  TPA	  
Graphs	  depict	  the	  total	  cell	  number	  (mean	  values	  of	  three	  independent	  experiments)	  of	  melan	  a	  control	  (ctrl.),	  
N-­‐RAS*	  and	  N-­‐RAS*-­‐AR	  cells	  over	  time	  in	  DMEM	  containing	  (a)	  2.5%	  dialyzed	  FCS,	  (b)	  10%	  dialyzed	  FCS	  or	  (c)	  
10%	   FCS	   in	   absence	   (-­‐)	   or	   presence	   of	   doxycycline	   (Dox)	   and	   TPA	   (TPA).	   Standard	   deviations	   are	   shown.	  
Student´s	   t-­‐test	   (paired,	   2-­‐tailed)	   revealed	   statistical	   significance	   comparing	   N-­‐RAS*	   and	   N-­‐RAS*-­‐AR	   cells	   at	  
each	  time	  point	  indicated	  by	  asterisks	  (*p<0.05,	  **p<0.01,	  ***p<0.001).	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Taken	   together,	   N-­‐RAS*-­‐AR	   cells	   grow	   regardless	   of	   culture	   conditions	   as	   they	   proliferate	  
best	  in	  presence	  of	  10%	  FCS,	  but	  also	  in	  starving	  medium	  supplemented	  with	  either	  2.5%	  or	  
10%	  dialyzed	  FCS.	  
7.32 Lack	   of	   multinucleation	   for	   N-­‐RAS*-­‐AR	   cells	   cannot	   be	   overcome	   by	  
sustained	  oncogene	  stimulation	  
In	   the	   following,	   I	  wanted	   to	   exclude	  both,	   a	   possible	   delayed	  onset	   of	   raft	   formation	   for	  
melan	  a	  and	  N-­‐RAS*	  cells	  as	  well	  as	  multinucleation	  for	  N-­‐RAS*-­‐AR	  cells.	  Thus,	  I	  performed	  a	  
long-­‐term	  stimulation	  assay	  comparing	  melan	  a	  control	   (ctrl.),	  N-­‐RAS*	  and	  N-­‐RAS*-­‐AR	  cells	  
for	  up	  to	  28	  days	  (Figure	  64)	  instead	  of	  the	  usual	  14	  days.	  I	  did	  not	  find	  N-­‐RAS*-­‐AR	  cells	  to	  
senesce	   upon	   long-­‐term	   doxycycline	   (Dox)	   treatment.	   Instead,	   N-­‐RAS*-­‐AR	   cells	   steadily	  
proliferated	  throughout	  the	  experiment	  irrespective	  of	  doxycycline	  (Dox)	  status.	  Intriguingly,	  
N-­‐RAS*-­‐AR	  cells	  even	  detached	  from	  the	  culture	  dish	  after	  cell	  density	  had	  become	  too	  high	  
prior	   to	   the	   end	   of	   the	   experiment.	   N-­‐RAS*	   cells	   first	   became	   multinucleated	   (14	   days)	  
before	   the	   appearance	   of	   nests	   and	   3D	   structures	   (21	   days)	   upon	   doxycycline	   (Dox)	  
treatment.	   Notably,	   N-­‐RAS*	   cells	   also	   became	   multinucleated	   and	   formed	   nests	   and	   3D	  
structures	  when	  cultured	  in	  starving	  medium	  alone	  (-­‐),	  even	  though	  the	  onset	  was	  delayed	  
compared	   to	   Dox-­‐stimulated	   cells.	   This	   observation	   indicates	   leaky	   N-­‐RAS*	   expression.	  
Importantly,	   melan	   a	   control	   (ctrl.)	   melanocytes	   neither	   formed	   nests,	   nor	   rafts	   nor	   3D	  
structures	  irrespective	  of	  doxycycline	  status.	  	  	  
Taken	  together,	  N-­‐RAS*-­‐AR	  cells	  do	  not	  senesce	  upon	  sustained	  doxycycline	  treatment	  and	  
melan	   a	   control	   cells	   did	   neither	   form	  nests	   nor	   rafts	   nor	   3D	   structures	  within	   28	  days	   in	  
culture.	  




Figure	  64:	  N-­‐RAS*-­‐AR	  cells´	  lack	  of	  senescence	  cannot	  be	  overcome	  by	  sustained	  doxycycline	  treatment	  	  
Phase	  contrast	  images	  (100-­‐fold	  magnification)	  of	  melan	  a	  control	  (ctrl.),	  N-­‐RAS*	  and	  N-­‐RAS*-­‐AR	  cells	  upon	  14,	  
21	   and	   28	   days	   in	   culture.	   Where	   indicated,	   cells	   were	   either	   cultured	   in	   starving	   medium	   alone	   (-­‐)	   or	  
supplemented	  with	  doxycycline	  (Dox).	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7.33 N-­‐RAS*-­‐AR	  clones	  express	  high	  levels	  of	  N-­‐Ras	  and	  show	  DNA	  damage	  
To	  investigate	  whether	  the	  N-­‐Ras	  expression	  level	  correlates	  with	  the	  enhanced	  proliferation	  
observed	   for	  N-­‐RAS*-­‐AR	   compared	   to	  N-­‐RAS*	   cells,	   I	   performed	  Western	   blot	   analyses	   of	  
cells	  cultured	  in	  complete	  medium	  (Figure	  65).	  I	  found	  all	  N-­‐RAS*-­‐AR	  clones	  investigated	  to	  
express	   enhanced	   N-­‐Ras	   protein	   levels	   compared	   to	   those	   of	   N-­‐RAS*	   cells	   (Figure	   65a).	  
Furthermore,	  only	  a	  faint	  N-­‐Ras	  band	  was	  detected	  for	  melan	  a	  control	  (ctrl.)	  melanocytes.	  
Interestingly,	   the	  N-­‐Ras	  expression	   level	  directly	  correlated	  with	  the	  detected	  protein	   level	  
of	   the	   DNA	   damage	   markers	   P-­‐p53	   and	   P-­‐Chk2	   (Figure	   65b).	   Notably,	   the	   P-­‐p53	   protein	  
levels	   were	   very	   low	   in	   melan	   a	   control	   (ctrl.)	   and	   N-­‐RAS*	   cells	   while	   P-­‐Chk2	   was	  
undetectable	  in	  either	  cell	  line	  (Figure	  65b).	   
 
Figure	  65:	  N-­‐RAS*-­‐AR	  clones	  express	  high	  levels	  of	  N-­‐Ras	  and	  DNA	  damage	  markers	  
Western	  blot	  analyses	  of	   (a)	  N-­‐Ras	  expression	   levels	  and	   (b)	   the	  DNA	  damage	  markers	  P-­‐p53	  and	  P-­‐Chk2	   for	  
melan	  a	  control	  (ctrl.),	  N-­‐RAS*	  cells	  and	  three	  different	  N-­‐RAS*-­‐AR	  clones	  cultured	  in	  complete	  medium.	  Cells	  
were	  harvested	  and	  whole	  cell	  lysates	  were	  separated	  using	  10%	  SDS	  gels.	  Protein	  weights	  are	  indicated	  in	  kDa.	  
β-­‐actin	  served	  as	  loading	  control.	  
Taken	  together,	  N-­‐RAS*-­‐AR	  clones	  not	  only	  express	  higher	  N-­‐Ras	  protein	  levels	  than	  N-­‐RAS*	  
cells	  but	  also	  bear	  an	  enhanced	  DNA	  damage	  level.	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7.34 N-­‐RAS*-­‐AR	  cells	  show	  higher	  in	  vitro	  transformation	  potential	  than	  B16-­‐
F1	  melanoma	  cells	  
Prior	   to	   planned	   in	   vivo	   assays	   analyzing	   the	   tumour-­‐forming	   potential	   of	   N-­‐RAS*	   and	   N-­‐
RAS*-­‐AR	   cells,	   I	   wanted	   to	   compare	   their	   in	   vitro	   transformation	   potential	   to	   that	   of	   the	  
highly	  metastatic	  B16-­‐F1	  melanoma	  cell	  line	  frequently	  used	  as	  positive	  control	  in	  nude	  mice	  
assays.	   I	   found	   N-­‐RAS*-­‐AR	   cells	   to	   form	   much	   more	   and	   larger	   colonies	   in	   agar	  
supplemented	  with	  10%	  FCS	  than	  B16-­‐F1	  cells.	  As	  previously	  observed	  (Figure	  60),	  N-­‐RAS*	  
cells	  were	  unable	  to	  form	  colonies.	   
 
Figure	  66:	  N-­‐RAS*-­‐AR	  cells	  bear	  a	  higher	  in	  vitro	  transformation	  potential	  than	  B16-­‐F1	  cells	  	  
Phase	   contrast	   images	   (25-­‐fold	  magnification)	   of	  N-­‐RAS*,	  N-­‐RAS*-­‐AR	  melanocytes	   and	   the	   highly	  metastatic	  
B16-­‐F1	  melanoma	  cells	  upon	  14	  days	  in	  soft	  agar.	  Agar	  was	  supplied	  with	  10%	  FCS.	  	  
7.35 In	   vivo	   transformation	   potential	   of	   melan	   a	   control,	   N-­‐RAS*	   and	   N-­‐
RAS*-­‐AR	  cells	  
Since	   N-­‐RAS*-­‐AR	   cells	   demonstrated	   a	   high	   transformation	   potential	   in	   vitro,	   we	   were	  
wondering	  whether	  these	  cells	  could	  also	  be	  tumourigenic	  in	  vivo.	  Hence,	  Dr.	  Christoph	  Otto	  
[Experimental	   Surgery,	   Experimental	   Transplantation	   Immunology,	   Clinic	   of	   General,	  
Visceral,	  Vascular	  and	  Pediatric	  Surgery	  (Surgical	  Clinic	  I),	  University	  of	  Wuerzburg	  Hospital,	  
Wuerzburg,	  Germany]	  and	  his	  technician	  Bettina	  Mühling	  inoculated	  nude	  mice	  with	  melan	  
a	   control	   (ctrl.),	  N-­‐RAS*	  or	  N-­‐RAS*-­‐AR	   cells.	  Upon	   subcutaneous	   cell	   application	   into	  both	  
flanks,	   N-­‐RAS*	  mice	   were	   either	   supplied	   with	   common	   drinking	   water	   (-­‐)	   or	   with	   water	  
supplemented	  with	  doxycycline	  (Dox).	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7.36 N-­‐RAS*-­‐AR	  cells	  induce	  rapid	  tumour	  growth	  in	  nude	  mice	  
As	   already	   described	   (Figure	   56),	   melan	   a	   control	   (ctrl.)	   cells	   formed	   black,	   nevus-­‐like	  
structures	  upon	  inoculation	  in	  nude	  mice	  (Figure	  67a).	  These	  nevus-­‐like	  structures	  formed	  at	  
every	  single	  injection	  site	  and	  were	  limited	  to	  the	  skin.	  In	  some	  mice	  the	  duct	  generated	  by	  
the	   injection	   needle	   was	   found	   to	   be	   colonized	   (Figure	   67a).	   Interestingly,	   N-­‐RAS*	   cells	  
formed	  highly	  similar	  black,	  nevus-­‐like	  structures	  in	  both	  absence	  (-­‐)	  and	  presence	  (Dox)	  of	  
doxycycline.	  	  Notably,	  the	  nevus-­‐like	  structures	  generated	  by	  N-­‐RAS*	  cells	  did	  neither	  differ	  
in	   size	   nor	   in	   shape	   and	   appearance	   from	   those	   formed	   by	   melan	   a	   control	   (ctrl.)	  
melanocytes	   (Figure	   67a).	   All	   melan	   a	   control	   (ctrl.)	   and	   N-­‐RAS*	   mice	   behaved	   normally	  
throughout	  the	  experiment	  [personal	  conversation	  with	  Bettina	  Mühling]	  and	  seemed	  to	  be	  
healthy	  when	  sacrificed	  71	  days	  upon	  inoculation.	  
In	  contrast	  to	  melan	  a	  control	  (ctrl.)	  and	  N-­‐RAS*	  melanocytes,	  N-­‐RAS*-­‐AR	  cells	  formed	  large	  
and	   aggressive	   tumours	   in	   absence	  of	   doxycycline	   (Figure	   67b)	   at	   all	   injection	   sites	  within	  
one	  week	  upon	  inoculation.	  The	  tumours	  grew	  so	  rapidly	  (Figure	  67c)	  that	  N-­‐RAS*-­‐AR	  mice	  
had	  to	  be	  sacrificed	  at	  day	  28	  due	  to	  extensive	  tumour	  load	  (Figure	  67b).	  Notably,	  N-­‐RAS*-­‐
AR	  cells	  had	  already	  metastasized	  to	  the	  lung	  (data	  not	  shown).	  
Importantly,	   in	  contrast	   to	  Hmhi-­‐AR	  mice	   (Figure	  56),	  weight	  development	  was	  not	  altered	  
over	   the	   course	   of	   the	   experiment	  when	   comparing	   all	   three	   cell	   lines	   inoculated	   (Figure	  
67d). 
Taken	   together,	   in	   contrast	   to	  melan	  a	  control	   (ctrl.)	   and	  N-­‐RAS*	  melanocytes,	  N-­‐RAS*-­‐AR	  
cells	   proved	   to	   be	   highly	   tumourigenic	   in	   vivo	   inducing	   very	   aggressive,	   fast-­‐growing	   and	  
metastasizing	  tumours	  at	  every	  injection	  site.	  	  




Figure	  67:	  N-­‐RAS*-­‐AR	  cells	  induce	  rapid	  tumour	  growth	  in	  nude	  mice	  	  
(a)	  Comparison	  of	  nude	  mice	  either	  bearing	  melan	  a	  control	  (ctrl.)	  or	  N-­‐RAS*	  cells	  in	  absence	  (-­‐)	  or	  presence	  of	  
doxycycline	   (Dox)	   71	   days	   upon	   inoculation.	   (b)	   Representative	   nude	   mouse	   bearing	   N-­‐RAS*-­‐AR-­‐induced	  
tumours	  on	  both	  flanks	  28	  days	  upon	   inoculation.	   (c)	  Graph	  depicts	  the	  mean	  N-­‐RAS*-­‐AR	  tumour	  weight	  per	  
flank	  over	  time.	  Standard	  deviations	  are	  shown.	  (d)	  Graph	  depicts	  the	  weight	  of	  melan	  a	  control	  (ctrl.),	  N-­‐RAS*-­‐
AR	  and	  N-­‐RAS*	  mice	  in	  absence	  (-­‐)	  or	  presence	  (Dox)	  of	  doxycycline	  over	  time.	  Bars	  represent	  the	  mean	  weight	  
of	  five	  animals	  each.	  Standard	  deviations	  are	  shown.	  	  
7.37 N-­‐RAS*-­‐AR	  cells	  show	  increased	  nuclear-­‐cytoplasmic	  ratio	  
Since	  the	  highly	  tumourigenic	  N-­‐RAS*-­‐AR	  cells	  also	  seemed	  to	  be	  much	  smaller	  than	  N-­‐RAS*	  
cells,	   I	   again	  quantified	   the	  phenomenon	  with	  help	   from	  Dr.	   Toni	  Wagner	   (Department	  of	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Physiological	   Chemistry	   I,	   University	   of	  Wuerzburg,	  Wuerzburg,	   Germany)	  who	   performed	  
3D	  confocal	  scans	  thereby	  determining	  the	  total	  cell	  volume	  and	  the	  nuclear	  volume	  (Figure	  
68,	   3D	  pictograms	  68d	  by	  Dr.	   Toni	  Wagner,	   figure	   by	   Claudia	   Leikam).	  Even	   though	   in	   2D	  
images	  both	  cytoplasm	  and	  nucleus	  seem	  to	  be	  smaller	  in	  N-­‐RAS*-­‐AR	  compared	  to	  N-­‐RAS*	  
cells	   (Figure	  68a),	  measuring	   the	  compartment	  volumes	  disproved	   this	  assumption	   (Figure	  
68b).	  Interestingly,	  only	  cell	  and	  cytoplasm	  volume	  differed	  significantly	  when	  comparing	  N-­‐
RAS*	  to	  N-­‐RAS*-­‐AR	  cells,	  whereas	  the	  nuclear	  volumes	  of	  both	  cell	   lines	  were	  found	  to	  be	  
highly	  similar	  (Figure	  68b).	  Notably,	  N-­‐RAS*	  cells	  were	  more	  than	  four	  times	  bigger	  than	  N-­‐
RAS*-­‐AR	  cells	  and	  the	  cytoplasm	  differed	  by	  a	   factor	  of	  almost	  6.	  These	  data	  resulted	   in	  a	  
highly	   significant	   difference	   in	   the	   nuclear-­‐cytoplasmic	   ratios	   of	   both	   cell	   clones,	   since	   N-­‐
RAS*-­‐AR	   cells	   reached	   a	   6-­‐fold	   higher	   ratio	   compared	   to	   N-­‐RAS*	   cells	   (Figure	   68c).	  
Furthermore,	   the	  3D	  scans	  proved	  N-­‐RAS*-­‐AR	  nuclei	   to	  be	  dome-­‐shaped	  compared	   to	   the	  
rather	   flat	   N-­‐RAS*	   nuclei	   (Figure	   68d).	   This	   finding	   explains	   the	   discrepancy	   between	   the	  
apparently	   smaller	   nuclei	   of	   N-­‐RAS*-­‐AR	   compared	   to	   N-­‐RAS*	   cells	   according	   to	   the	   2D	  
pictures	   (Figure	   68a)	   and	   the	   actual,	   highly	   similar	   nuclear	   volumes	   depicted	   in	   the	  




Figure	  68:	  N-­‐RAS*-­‐AR	  cells	  are	  much	  smaller	  and	  have	  a	  significantly	  higher	  nuclear-­‐cytoplasmic	  ratio	  than	  N-­‐
RAS*	  melanocytes	  
(a)	   False	   colour	   2D	   confocal	   snapshots	   (600-­‐fold	  magnification)	   of	   N-­‐RAS*	   and	   N-­‐RAS*-­‐AR	   cells	   plated	   onto	  
glass	   cover	   slips	  and	  cultured	   in	   complete	  medium.	  The	  cytoplasm	  was	   stained	  with	   cell	  mask	  deep	   red	  and	  
DNA	  was	  counterstained	  using	  Hoechst.	  (b)	  Bars	  display	  the	  mean	  compartment	  volumes	  of	  6	  N-­‐RAS*	  and	  N-­‐
RAS*-­‐AR	   cells	   each.	   Standard	   deviations	   are	   shown.	  Where	   indicated,	   statistical	   significance	   determined	   by	  
Student´s	  t-­‐test	  (paired,	  two-­‐tailed)	  was	  reached	  (**p<0.01).	  (c)	  Scatter	  plot	  displaying	  the	  nuclear-­‐cytoplasmic	  
ratios	  for	  all	  6	  single	  cells	  analysed	  for	  each	  cell	  line,	  N-­‐RAS*	  and	  N-­‐RAS*-­‐AR.	  Vertical	  bars	  represent	  the	  mean	  
values.	  Statistical	  significance	  determined	  by	  Student´s	  t-­‐test	  (paired,	  two-­‐tailed)	  was	  reached	  (***p<0.001).	  (d)	  
Equally	  cropped	  false	  colour	  3D	  stack	  images	  comparing	  the	  shape	  of	  N-­‐RAS*	  and	  N-­‐RAS*-­‐AR	  cells.	  Upper	  and	  
lower	  panel	  show	  cells	  at	  the	  same	  rotation	  point.	  Axes	  are	  shown	  in	  the	  lower	  left	  corner	  (x:	  green,	  y:	  red,	  z:	  
blue).	  	  
7.38 Microarray	   analyses	   comparing	   Dox-­‐treated	   N-­‐RAS*	   and	   N-­‐RAS*-­‐AR	  
cells	  
Wanting	   to	   further	   scrutinize	   the	   features	   of	   N-­‐RAS*-­‐AR	   cells	   to	   eventually	   identify	   the	  
molecular	  players	  underlying	  the	  high	  tumourigenicity,	  an	  mRNA	  expression	  microarray	  was	  
performed	  by	  Susanne	  Kneitz	  [Microarray	  Core	  Unit,	  IZKF	  (Interdisciplinary	  Center	  for	  Clinical	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Research),	   University	   of	   Wuerzburg,	   Wuerzburg,	   Germany],	   who	   compared	   doxycycline-­‐
treated	  N-­‐RAS*	  cells	  that	  had	  undergone	  senescence	  (6-­‐14	  days)	  before	  evading	  senescence	  
(28	  days)	  to	  N-­‐RAS*-­‐AR	  cells	  cultured	  in	  presence	  of	  doxycycline.	  Cells	  from	  a	  standard	  long-­‐
term	  senescence	  assay	  were	  harvested	  at	  indicated	  time	  points	  and	  pellets	  were	  stored	  at	  -­‐
80°C	  prior	  to	  mRNA	  preparation.	   
7.39 N-­‐RAS*-­‐AR	  cells	  express	  stem	  cell	  markers	  
We	   wanted	   to	   identify	   genes	   that	   were	   clearly	   regulated	   when	   comparing	   doxycycline-­‐
treated	  and	  multinucleated	  N-­‐RAS*	  cells	   (6	  days	  of	  doxycycline)	   to	   the	   intermediate	  state,	  
when	  N-­‐RAS*	  cells	  were	  multinucleated	  and	  SA-­‐β-­‐Gal-­‐positive	  even	  though	  first	  nests	  were	  
observed	  (14	  days	  of	  doxycycline)	  and	  multinucleated	  N-­‐RAS*	  melanocytes	  overgrown	  with	  
small	   nest	   cells	   (28	   days	   of	   doxycycline)	   and	   finally	   to	   anoikis-­‐resistant	   and	   highly	  
tumourigenic	   N-­‐RAS*-­‐AR	   cells	   (Figure	   69a).	   Since	   N-­‐RAS*-­‐AR	   cells	   showed	   a	   massively	  
increased	   nuclear-­‐cytoplasmic	   ratio	   and	   were	   so	   tiny	   while	   growing	   similarly	   well	   in	   any	  
culture	  medium,	   the	  microarray	   data	  was	   filtered	   to	   only	   contain	   stem	   cell	  marker	   genes	  
(Figure	   69a).	  Nanog,	   Pdpn	   and	  Abcb1	   (mouse	   homologue	   of	   human	   CD133)	  mRNA	   levels	  
were	  much	  higher	  in	  N-­‐RAS*-­‐AR	  cells	  than	  in	  doxyclycline-­‐treated	  N-­‐RAS*	  cells	  regardless	  of	  
stimulation	   time.	   Notably,	   the	   pluripotency	   markers	   Pdpn	   and	   Nanog	   were	   exclusively	  
expressed	   in	   N-­‐RAS*-­‐AR	   cells,	   whereas	   doxycycline-­‐treated	   N-­‐RAS*	   melanocytes	   did	   not	  
express	  these	  genes	  at	  any	  time	  point	  investigated	  (Figure	  69a).	  
Western	   blot	   analyses	   further	   supported	   the	   microarray	   data	   since	   N-­‐RAS*-­‐AR	   clones	  
cultured	  in	  complete	  medium	  were	  found	  to	  express	  KLF4,	  C-­‐Myc,	  Nanog	  and	  Oct4	  protein.	  
While	  C-­‐Myc	  and	  Nanog	  protein	   levels	  were	  high,	   the	  Oct4	  protein	  band	  was	   rather	   faint.	  
Nevertheless,	   N-­‐RAS*	   cells	   exclusively	   expressed	   low	   levels	   of	   C-­‐Myc	   while	   the	   band	  
observed	   for	   melan	   a	   control	   cells	   (ctrl.)	   was	   even	   weaker.	   None	   of	   the	   other	   stem	   cell	  
markers	  investigated	  could	  be	  detected	  in	  either	  melan	  a	  control	  (ctrl.)	  or	  N-­‐RAS*	  cells.	  
In	  accordance	  with	  these	  data	  were	  my	  observations	  upon	  transient	  transfection	  of	  both	  N-­‐
RAS*	  and	  N-­‐RAS*-­‐AR	  cells	  with	  the	  Nanog-­‐driven	  PL-­‐SIN-­‐EOS-­‐S(4+)-­‐eGFP	  vector	  287.	   I	   found	  
N-­‐RAS*	  cells	  to	  lack	  Nanog	  expression,	  whereas	  a	  large	  fraction	  of	  N-­‐RAS*-­‐AR	  cells	  expressed	  
functional	  Nanog	  protein	  (Figure	  69c).	  Unfortunately,	  I	  could	  not	  select	  Nanog-­‐expressing	  N-­‐
RAS*-­‐AR	   cells	   as	   they	   were	   already	   puromycin-­‐resistant	   prior	   to	   transfection	   with	   the	  
Nanog-­‐driven	  vector.	  	  




Figure	  69:	  N-­‐RAS*-­‐AR	  cells	  express	  stem	  cell	  markers	  
(a)	  Heat	  plot	   illustrating	  the	  mRNA	  expression	  of	  various	  stem	  cell	  marker	  genes	  investigated.	  The	  color	  code	  
ranges	  from	  green	  (not	  expressed)	  to	  red	  (highly	  expressed).	  (b)	  Western	  blot	  analyses	  of	  melan	  a	  control	  (ctrl.)	  
melanocytes,	   N-­‐RAS*	   cells	   and	   three	   different	   N-­‐RAS*-­‐AR	   clones	   cultured	   in	   complete	   medium.	   Cells	   were	  
harvested	  and	  whole	  cell	  lysates	  were	  separated	  on	  10-­‐12%	  SDS	  gels.	  Protein	  weights	  are	  indicated	  in	  kDa.	  β-­‐
actin	  served	  as	  loading	  control.	  (c)	  Phase	  contrast	  and	  fluorescence	  images	  (200-­‐fold	  magnification)	  of	  N-­‐RAS*	  
and	  N-­‐RAS*-­‐AR	  cells	  transiently	  transfected	  with	  the	  Nanog-­‐driven	  PL-­‐SIN-­‐EOS-­‐S(4+)-­‐eGFP	  vector.	  	  
Taken	   together,	   in	   contrast	   to	   N-­‐RAS*	   cells,	   N-­‐RAS*-­‐AR	   cells	   express	   several	   stem	   cell	  
markers	  on	  RNA	  and	  protein	  level.	  
7.40 N-­‐RAS*-­‐AR	   cells	   lack	   melanocyte	   expression	   markers	   but	   show	  
neuronally-­‐expressed	  genes	  
Another	  interesting	  result	  obtained	  from	  the	  microarray	  analyses	  was	  the	  fact	  that	  N-­‐RAS*-­‐
AR	  cells	   lacked	  melanocyte	  expression	  markers	   such	  as	  Tyrp1,	  Mlana,	  Dct	   and	  Sox10	   even	  
though	   doxycycline-­‐treated	   N-­‐RAS*	   cells	   expressed	   these	   markers	   at	   any	   time	   point	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investigated	   (Figure	   70a).	   Mitf	   was	   the	   only	   melanocyte	   differentiation	   marker	   still	  
expressed	   in	  N-­‐RAS*-­‐AR	  cells	  even	  though	  expression	   levels	  were	  not	  as	  high	  as	   in	  N-­‐RAS*	  
cells	   treated	   with	   doxycycline	   for	   14	   or	   28	   days.	   Notably,	   expression	   of	   melanocyte	  
expression	   markers	   was	   highest	   in	   multinucleated	   N-­‐RAS*	   melanocytes	   upon	   14	   days	   of	  
doxycycline	  treatment	  (Figure	  70a).	  	  
While	  melanocyte	  differentiation	  gene	  expression	  levels	   in	  N-­‐RAS*	  cells	  decreased	  after	  14	  
days	  of	  doxycycline	  treatment,	  neuronal	  markers	  were	  found	  to	  be	  up-­‐regulated	  with	  mRNA	  
levels	  peaking	  at	  day	  28	  (Figure	  70b).	  Interestingly,	  even	  though	  most	  neuronal	  markers,	  e.g.	  
Efna1,	  Nefl,	  Areg	  or	  Smarca1,	  were	  still	   induced	   in	  N-­‐RAS*-­‐AR	  cells,	   some	  seemed	  to	  have	  
been	  silenced	  (e.g.	  Id4,	  Sema6a	  or	  Chl1)	  (Figure	  70b).	   
Taken	   together,	   the	   lack	   of	   melanocyte	   differentiation	   marker	   expression	   and	   the	   up-­‐
regulation	  of	  neuronal	  genes	  further	  supports	  the	  de-­‐differentiation	  process	  that	  N-­‐RAS*-­‐AR	  
cells	  had	  apparently	  undergone.	  
 
Figure	  70:	  N-­‐RAS*-­‐AR	  cells	  lack	  melanocyte	  differentiation	  markers	  and	  express	  neuronally-­‐expressed	  genes	  	  
Heat	  plots	   illustrating	   the	  mRNA	  expression	  of	   (a)	   the	  melanocyte	  differentiation	  markers	  and	   (b)	  neuronally	  
expressed	  genes	  investigated.	  The	  color	  code	  ranges	  from	  green	  (not	  expressed)	  to	  red	  (highly	  expressed).	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Another	   interesting	   gene	   set	   found	   to	   be	   up-­‐regulated	   in	   our	   microarray	   analyses	   were	  
proliferation	  markers.	   A	   broad	   range	   of	   positive	   regulators	   of	   proliferation	   including	  Gli2,	  
Btc,	  Ptgs2	  and	  Kitl	  were	  induced	  in	  N-­‐RAS*-­‐AR	  cells,	  whereas	  their	  mRNA	  levels	  were	  low	  in	  
N-­‐RAS*	  melanocytes	  throughout	  the	  course	  of	  sustained	  doxycycline	  treatment	  (Figure	  71a).	  
This	   finding	  underscored	  and	  explained	   the	  enhanced	  proliferation	  potential	  of	  N-­‐RAS*-­‐AR	  
compared	  to	  N-­‐RAS*	  cells	  when	  cultured	  in	  different	  media	  (Figure	  63).	  	  
Apart	   from	   the	   up-­‐regulation	   of	   proliferation	   markers,	   the	   microarray	   analyses	   also	  
identified	  several	  meiosis	  marker	  genes	  like	  Cyp26b2,	  Tex15,	  Suv39h2	  and	  Spo11	  to	  be	  highly	  
expressed	  in	  N-­‐RAS*-­‐AR	  cells	  (Figure	  71b).	  	  
 
Figure	  71:	  N-­‐RAS*-­‐AR	  cells	  express	  proliferation	  and	  meiosis	  markers	  
Heat	  plots	  illustrating	  the	  mRNA	  expression	  of	  (a)	  proliferation	  and	  (b)	  meiosis	  marker	  genes	  investigated.	  The	  
color	  code	  ranges	  from	  green	  (not	  expressed)	  to	  red	  (highly	  expressed).	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Taken	   together,	   microarray	   analyses	   revealed	   an	   induction	   of	   stem	   cell,	   neuronal,	  
proliferation	   and	   meiosis	   markers	   in	   N-­‐RAS*-­‐AR	   cells	   while	   melanocyte	   differentiation	  
markers	  were	  down-­‐regulated.	   
7.41 Multinucleated	  N-­‐RAS*	  melanocytes	  bud	  off	  tiny,	  viable	  cells	  
Having	  observed	  nests	  emerge	  upon	  sustained	  doxycycline	  treatment	  of	  multinucleated	  N-­‐
RAS*	  melanocytes,	  I	  was	  wondering	  where	  the	  tiny	  cells	  forming	  these	  structures	  originated	  
from.	  Thus,	  I	  subcloned	  the	  MN	  [EF1a-­‐red	  membrane	  and	  green	  nucleus]-­‐2A	  sequence	  kindly	  
provided	  by	  Dr.	  Toni	  Wagner	   into	  the	  pBabe	  vector	  before	  transiently	   transfecting	  N-­‐RAS*	  
cells	   with	   pBabe-­‐MN	   [EF1a-­‐red	   membrane	   and	   green	   nucleus]-­‐2APuro,	   which	   labels	   cell	  
membranes	   red	  and	  nuclei	   green.	  Upon	   long-­‐term	  doxycycline	   treatment	  of	   these	  N-­‐RAS*	  
cells,	  time-­‐lapse	  analyses	  were	  performed.	  I	  found	  N-­‐RAS*	  cells	  to	  bud	  off	  tiny	  cells	  (Figure	  
72),	  while	  both	  the	  multinucleated	  mother	  and	  the	  newly-­‐generated	  small	  cell	  were	  viable.	  	  
Figure	  72:	  Multinucleated	  N-­‐RAS*	  cells	  give	  rise	  to	  small	  cells	  	  	  
N-­‐RAS*	  transiently	   transfected	  with	  pBabe-­‐MN	  [EF1a-­‐red	  membrane	  and	  green	  nucleus]-­‐2APuro	  were	  plated	  
onto	   glass	   cover-­‐slips	   and	   cultured	   in	   starving	   medium	   supplemented	   with	   doxycycline.	   Upon	   16	   days	   of	  
treatment,	  the	  glass	  cover	  slips	  were	  transferred	  into	  the	  heatable,	  CO2-­‐supplied	  incubation	  chamber	  built	  for	  
this	  purpose	  and	  monitored	  at	  100-­‐fold	  magnification	  for	  17	  hours	  with	  pictures	  being	  taken	  every	  15	  minutes.	  
Equally	  cropped	   images	  are	  shown	  and	  time	  points	  are	   indicated.	  Scale	  bars	   represent	  50µm. A	  white	  arrow	  
highlights	  the	  budding	  cell.	  
Importantly,	   the	  cells	  budded	  off	  by	  multinucleated	  N-­‐RAS*	  cells	  were	  not	  only	  viable,	  but	  
also	   capable	   of	   undergoing	   mitosis	   (Figure	   73)	   as	   some	   of	   them	   quickly	   divided	   upon	  
budding.	  I	  claim	  these	  cells	  to	  be	  N-­‐RAS*-­‐AR	  progenitors.	  




        
Figure	  73:	  Multinucleated	  N-­‐RAS*	  cells	  bud	  off	  small	  cells	  capable	  of	  dividing	  	  
N-­‐RAS*	  cells	  were	  transiently	  transfected	  with	  pBabe-­‐puro-­‐H2-­‐eGFP	  before	  being	  plated	  onto	  glass	  cover-­‐slips.	  
Upon	   27	   days	   of	   continuous	   doxycycline	   treatment,	   the	   cells	   were	   monitored	   for	   28	   hours	   at	   100-­‐fold	  
magnification	  with	  pictures	  being	  taken	  every	  15	  minutes.	  Equally	  cropped	  (a)	  GFP	  fluorescence	  images	  alone	  
or	   (b)	   merged	   with	   the	   phase	   contrast	   counterparts	   are	   shown	   and	   time	   points	   are	   indicated.	   Scale	   bars	  
represent	  50µm.	  (a)	  White	  or	  (b)	  dark	  grey	  arrows	  highlight	  the	  budding	  and	  dividing	  cell.	  
Taken	  together,	  sustained	  doxycycline	  treatment	  of	  senescent	  N-­‐RAS*	  melanocytes	  enables	  
multinucleated	   cells	   to	   bud	   off	   viable,	   small	   cells,	   which	   are	   anoikis-­‐resistant,	   have	   lost	  
addiction	   to	   their	  original	  oncogene,	   are	  highly	   tumourigenic	   in	   vitro	   and	   in	   vivo	   and	  bear	  
stem-­‐like	  features.	  	  
Having	   gained	   all	   this	   knowledge	   from	   a	   murine	   cell	   culture	   model,	   we	   were	   wondering	  





7.42 Long-­‐term	   N-­‐RAS*	   expression	   induces	   binucleation	   in	   human	  
melanocytes,	   followed	   by	   the	   emergence	   of	   tiny,	   highly	   proliferative	  
and	  anoikis-­‐resistant	  cells	  
Thus,	   I	   analyzed	   normal	   human	   epidermal	   melanocyte	   (NHEM)	   cells	   which	   had	   been	  
transfected	   with	   the	   pCDH-­‐CMV-­‐N-­‐RAS61K-­‐EF1-­‐copGFP	   vector	   (kind	   gift	   by	   Dr.	   Roland	  
Houben,	  Department	  of	  Dermatology,	  University	  Hospital	  Wuerzburg,	  Wuerzburg,	  Germany)	  
allowing	  constitutive	  expression	  of	  oncogenic	  N-­‐RAS	  as	  well	  as	  GFP.	  Thanks	  to	  this	  N-­‐RAS61K	  
expression	  plasmid,	  NHEM	  cells	  bearing	   the	  vector	   (NHEM-­‐N-­‐RAS*	  or	  GFP/N-­‐RAS61K)	   could	  
easily	  be	  identified	  due	  to	  the	  concomitant,	  fluorescent	  GFP	  signal.	  
NHEM-­‐N-­‐RAS*	   cells	  were	   cultured	   at	   a	   very	   low	   cell	   density	   in	   standard	   growth	  medium.	  
Upon	  one	  week	  in	  culture,	   I	  observed	  several	  enlarged	  NHEM	  cells,	  all	  of	  which	  were	  GFP-­‐
positive	   (data	   not	   shown).	   A	   few	   days	   later,	   I	   found	   several	   enlarged	   NHEM-­‐N-­‐RAS*	   cells	  
containing	  multiple	  nuclei	  in	  the	  dish	  (Figure	  74a	  and	  b).	  After	  three	  weeks	  in	  culture,	  nest-­‐
like,	   GFP-­‐positive	   colonies	   were	   observed	   (Figure	   74c)	   which	   rapidly	   grew	   in	   a	   three-­‐
dimensional	  (3D)	  manner	  (Figure	  74d).	  Concomitantly,	  I	  found	  a	  steadily	  increasing	  number	  
of	  floating,	  green-­‐fluorescing	  NHEM-­‐N-­‐RAS*	  cell	  rafts	  on	  the	  surface	  of	  the	  culture	  medium	  
(Figure	  74e).	  Notably,	  these	  rafts	  could	  be	  replated	  and	  cultured	  (Figure	  74f).	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Figure	  74:	  N-­‐RAS61K	  expression	  induces	  multinuclear	  cells	  and	  subsequent	  anoikis	  in	  human	  melanocytes	  	  
(a),	   (b)	  Prolonged	  N-­‐RAS61K	  expression	   in	  human	  NHEM	  melanocytes	   resulted	   in	   the	  appearance	  of	  enlarged,	  
multinucleated	  cells.	  The	  white	  arrows	  highlight	   the	   two	  nuclei	  within	  a	  single	  GFP/N-­‐RAS61K	  positive	  cell.	   (c)	  
Upon	   three	   weeks	   in	   culture,	   GFP/N-­‐RAS61K	   cells	   formed	   nest-­‐like	   colonies	   which	   (d)	   grew	   rapidly	   into	   3D	  
structures.	  (e)	  Concomitantly,	  rafts	  of	  floating	  GFP/N-­‐RAS61K	  cells	  were	  observed.	  (f)	  These	  anoikis-­‐resistant	  raft	  
cells	  could	  be	  replated	  and	  cultured.	  Scale	  bars	  represent	  100µm.	  




7.43 Nest	  variations	  observed	  for	  NHEM-­‐N-­‐RAS*	  melanocytes	  
The	  nest-­‐like	   colonies	   observed	  upon	   sustained	  GFP/N-­‐RAS61K	   expression	   in	   human	  NHEM	  
melanocytes	  came	  in	  various	  shapes	  and	  sizes	  (Figure	  75).	  Notably,	  the	  cells	  forming	  these	  
colonies	  seemed	  to	  be	  much	  smaller	  than	  normal	  NHEM-­‐N-­‐RAS*	  cells.	  
 
Figure	  75:	  N-­‐RAS61K-­‐expressing	  NHEM	  cells	  form	  nest-­‐like	  3D	  colonies	  
(a),	  (b)	  Images	  of	  three	  different	  3D	  structures	  which	  arose	  from	  nests	  made	  of	  small	  cells	  in	  close	  proximity	  to	  
multinucleated	  GFP/N-­‐RAS61KNHEM	  cells	  at	  (a)	  50-­‐fold	  and	  (b)	  100-­‐fold	  magnification.	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7.44 NHEM-­‐N-­‐RAS*	   cells	   form	   3-­‐dimensional,	   anoikis-­‐resistant	   and	   viable	  
cell	  rafts	  	  
To	  this	  point,	  I	  had	  only	  proven	  that	  2-­‐dimensional	  rafts	  were	  viable	  when	  plated	  onto	  fresh	  
dishes.	  However,	  NHEM-­‐N-­‐RAS*	  cells	  added	  another	  dimension	  to	   this	  phenomenon.	  They	  
not	  only	  formed	  floating	  sheets	  of	  cells,	  but	  ball-­‐like,	  3-­‐dimensional	  aggregates	  of	  cells	  that	  
detached	  from	  the	  plastic	  surface	  and	  remained	  viable,	  as	  demonstrated	  by	  their	  ability	  to	  
reattach	   and	   expand	   when	   replated	   into	   fresh,	   empty	   dishes	   (Figure	   76).	   I	   termed	   the	  
replated	   cells	   NHEM-­‐N-­‐RAS*-­‐AR	   as	   they	   were	   anoikis-­‐resistant	   and	   appeared	   to	   have	   an	  
increased	  proliferation	  potential	  compared	  to	  NHEM-­‐N-­‐RAS*	  cells.	  
 
Figure	  76:	  NHEM-­‐N-­‐RAS*-­‐AR	  cells	  can	  be	  replated	  
Merge	   images	   (100-­‐fold	  magnification)	   of	   replated	   NHEM-­‐N-­‐RAS*-­‐AR	  melanocytes.	   Cells	   started	   to	   reattach	  
and	   divide	   as	   soon	   as	   the	   aggregate	   had	   been	   transferred	   to	   a	   new	  well	   even	   though	   the	   colony	   also	   kept	  
growing	   in	   a	   3D	  manner.	  One	  day	   after	   trypsinization	   (post	   trypsinization)	   single	   cells	   remained	   and	  divided	  
normally.	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7.45 Similarities	  between	  murine	  N-­‐RAS*-­‐AR	  and	  human	  NHEM-­‐N-­‐RAS*-­‐AR	  
cells	  	  
Since	  murine	  N-­‐RAS*-­‐AR	  cells	  proved	  to	  be	  highly	  tumourigenic	  upon	  inoculation	  into	  nude	  
mice,	   I	   was	   of	   course	  wondering	   about	   the	   impact	   human	  NHEM-­‐N-­‐RAS*-­‐AR	  might	   have.	  
However,	  due	  to	  lack	  of	  time,	  I	  only	  managed	  to	  compare	  their	  phenotypes,	  while	  including	  
the	  respective	  parental	  cell	  line	  (Figure	  77).	  	  
When	  comparing	  the	  cultured	  NHEM-­‐N-­‐RAS*-­‐AR	  cells	  to	  N-­‐RAS*-­‐AR	  cells	  with	  murine	  origin,	  
I	  noticed	  a	  similar	  cell	  shape	  and	  growth	  behavior.	  Both	  AR	  lines	  grew	  in	  a	  net-­‐like	  manner	  
when	  cultured	  in	  their	  respective	  complete	  medium.	  Furthermore,	  NHEM-­‐N-­‐RAS*-­‐AR	  as	  well	  
as	   N-­‐RAS*-­‐AR	   cells	   were	   found	   to	   be	   much	   smaller	   than	   NHEM	   or	   N-­‐RAS*	   melanocytes,	  
respectively.	  	  
 
Figure	  77:	  Similar	  features	  of	  N-­‐RAS*-­‐AR	  and	  NHEM-­‐N-­‐RAS*-­‐AR	  cells	  in	  culture	  	  
Phase	  contrast	   images	   (100-­‐fold	  magnification)	  of	  N-­‐RAS*	  and	  NHEM-­‐N-­‐RAS*	  cells	  and	  their	  anoikis-­‐resistant	  
(AR)	  counterparts	  cultured	  in	  the	  respective	  complete	  medium	  
Unfortunately,	  due	  to	  lack	  of	  time,	  no	  further	  experiments	  could	  be	  performed	  to	  scrutinize	  
the	  features	  of	  NHEM-­‐N-­‐RAS*	  cells.	  
In	   summary,	   oncogene-­‐induced	   senescence	   followed	   by	   the	   generation	   of	   small,	   highly	  
proliferative	  cells	  was	  not	  restricted	  to	  the	  murine	  cell	  culture	  model,	  but	  also	  holds	  true	  for	  




Nevi	   are	   common,	   benign,	   melanocytic	   lesions	   frequently	   harbouring	   the	   oncogenic	  
BRAFV600E	  mutation	  17,	  but	  rarely	  develop	  into	  malignancies	  289.	  Michaloglou	  et	  al.	  were	  the	  
first	   to	   show	   that	   BRAFV600E	   expression	   initially	   enhanced	  melanocyte	   proliferation	   before	  
cells	  arrested	  in	  a	  p16INK4A-­‐dependent	  manner	  and	  became	  SA-­‐β-­‐Gal-­‐positive	  and	  therefore	  
senescent	   290.	   	   Our	   cell	   culture	   model	   for	   oncogene-­‐induced	   senescence	   was	   the	   first	   to	  
explicitly	   recapitulate	   the	   occurrence	   of	   multinucleated	   cells,	   a	   well-­‐known	   hallmark	   of	  
human	  nevi	  291,292.	  Intriguingly,	  two	  independent	  oncogenes,	  namely	  HERmrk	  and	  N-­‐RAS61K,	  
induced	  this	  multinucleated	  phenotype	  in	  the	  murine	  melanocyte	  cell	  line	  melan	  a.	  Notably,	  
these	   multinucleated	   melanocytes	   had	   an	   increased	   cell	   size	   and	   were	   SA-­‐β-­‐Gal-­‐positive.	  
More	   importantly,	   the	  dosage-­‐dependent	   response	  of	  murine	  melanocytes	  observed	  upon	  
HERmrk	  activation	  states	  the	  first	  link	  between	  proliferation	  rates	  and	  oncogene	  expression	  
level	   in	   this	   cell	   type:	   when	   low	   levels	   of	   the	   oncogene	   are	   expressed	   melanocytes	  
proliferate	   well,	   whereas	   high	   oncogene	   expression	   levels	   limit	   proliferation	   and	   cells	  
senesce.	  	  
Prior	  to	  our	  study,	  a	  dosage-­‐dependent	  effect	  on	  proliferation	  and	  cell	  cycle	  arrest	  had	  been	  
reported	   for	   B-­‐	   and	   C-­‐Raf	   expression	   in	   murine	   fibroblasts	   293,294.	   Furthermore,	   high	   H-­‐
RasGV12	   expression	   in	  mice	   first	   led	   to	   hyperplasia	   followed	   by	   senescence	   295.	  Moreover,	  
human	  primary	  melanocyte	  cultures	  only	  senesced	  at	  high	  H-­‐RASG12V	  expression	  levels,	  but	  
the	   cellular	   features	   in	   a	   low	  oncogene	  dosage	  background	  has	   not	   been	   investigated	   296.	  
Sometimes,	   oncogene	   expression	   levels	   directly	   correlate	   with	   proliferation	   potential	   and	  
malignancy.	  C-­‐Myc	  overexpression,	  for	  example,	  can	  alter	  the	  protein	  expression	  profiles	  of	  
hamster	  ovary	   cells	   thereby	  enhancing	   their	  proliferation	  potential	   297.	   In	   accordance	  with	  
these	   findings,	  proliferation	  of	  nasopharyngeal	   carcinoma	  cells	   is	   suppressed	  by	  microRNA	  
let	   7	   via	   down-­‐regulation	   of	   C-­‐Myc	   expression	   298.	   Interestingly,	   oncogenes,	   such	   as	  
PML/RARalpha	  and	  TEL/ABL,	  only	  efficiently	  induced	  leukemia	  in	  mice	  when	  expressed	  at	  a	  
low	  level	  or	  close	  to	  pathophysiological	  level	  299.	  These	  studies	  together	  with	  our	  findings	  on	  
HERmrk-­‐induced	  senescence	  in	  melanocytes	  stress	  the	  importance	  of	  studying	  oncoprotein	  
function	  in	  a	  dosage-­‐dependent	  manner.	  
Most	  senescent	  cells	  have	  undergone	  a	  cell	  cycle	  block	  in	  G0	  300,301	  or	  in	  G0-­‐G1	  302,303,	  which	  
prevents	   endomitosis	   and	   multinucleation.	   However,	   a	   G0	   arrest	   can	   be	   excluded	   in	   our	  
system,	  since	  multinucleation	  precedes	  the	  senescence	  phenotype.	  Previously,	  p21-­‐	  or	  p53-­‐
mediated	  cell	  cycle	  blocks	  in	  G2	  were	  observed	  in	  endothelial	  cells	  and	  fibroblasts	  304–307	  as	  
well	   as	   in	   several	   yeast	   strains	   308.	   Besides,	   lung	   and	   bladder	   cancer	   cells	   were	   found	   to	  
arrest	  in	  G2	  upon	  overexpression	  of	  the	  mitotic	  kinase	  Nek6	  309.	  However,	  the	  endomitosis	  
observed	  for	  our	  senescent	  melanocytes	  rather	  suggests	  a	  cytokinesis	  failure.	  Rare	  cases	  of	  
premature	   senescence,	   e.g.	   upon	   treatment	   of	   HT1080	   fibrosracoma	   cells	   with	   the	   DNA-­‐
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damaging	   agent	   adriamycin,	   go	   along	   with	   multinucleation	   of	   the	   cells	   310.	   In	   addition,	  
treatment	   of	   NIH3T3	   fibroblasts	   with	   the	   histone	   deacetylase	   inhibitor	   sodium	   butyrate	  
blocked	  cells	   in	  G0/G1,	  thereby	  featuring	  flat,	  enlarged,	  senescent-­‐like	  cells	  some	  of	  which	  
showed	   multiple	   nuclei	   311.	   Furthermore,	   polyamine	   depletion	   in	   MALME-­‐3M	   melanoma	  
cells	   led	   to	   a	   p21-­‐dependent	   G1	   arrest	   and	   polyamine	   inhibition	   release	   led	   to	   bi-­‐	   or	  
mutinucleation	   in	   25%	   of	   the	   cells	   312.	   Moreover,	   mice	   bearing	   mutations	   in	   ERCC1,	   an	  
endonuclease	   involved	   in	   nucleotide	   excision	   repair,	   show	  multinucleated,	   senescent	   liver	  
and	  kidney	  cells	  313.	  Besides,	   inactivating	  the	  transgenic	  SV40	  large	  T	  antigen	  drives	  human	  
fibroblasts	  into	  ROS-­‐mediated	  senescence	  with	  more	  than	  half	  the	  cells	  bearing	  two	  or	  more	  
nuclei	   314.	   In	   these	  studies,	  elevated	  ROS	   levels	  activated	  protein	  kinase	  C	  δ,	  which	   in	   turn	  
further	  increased	  ROS	  levels.	  This	  positive	  feedback	  loop	  finally	  resulted	  in	  cytokinesis	  failure	  
and	  multinuclear	  cells	  314.	  In	  accordance	  with	  our	  findings,	  concomitant	  treatment	  with	  the	  
ROS	   scavenger	   NAC	   rescued	   the	   senescence	   phenotype	   and	   allowed	   fibroblasts	   to	  
proliferate	  normally	  314.	  Supporting	  these	  studies,	  both	  hepatocyte	  growth	  factor	  315	  and	  the	  
neurotransmitter	  calcitonin	  gene-­‐related	  peptide	  316	  limited	  the	  intracellular	  ROS	  levels	  and	  
thus	   attenuated	   angiotensin-­‐II-­‐mediated	   senescence	   in	   endothelial	   progenitor	   cells.	   These	  
data	  reinforce	  our	  finding	  of	  ROS	  being	  the	  crucial	  senescence-­‐mediator	  in	  HERmrk-­‐induced	  
melanocyte	  senescence.	  
Hence,	   with	   multinuclear	   cells	   being	   a	   commonly	   observed	   feature	   of	   some	   human	  	  
nevi	  317,318,	  our	  data	  propose	  that	  HERmrk	  signalling	  might	  resemble	  the	  aberrant	  oncogene	  
signal	  found	  in	  those	  nevi,	  thereby	  correlating	  the	  occurrence	  of	  multinuclear	  melanocytes	  
with	   the	   senescence	   phenotype.	   However,	   due	   to	   a	   DNA	   content	   of	   more	   than	   8n	   FACS	  
analyses	   failed	   to	   ascertain	   in	  which	   phase	   of	   the	   cell	   cycle	  multinuclear	  Hmhi	   cells	   finally	  
arrest.	  Hence,	   introducing	   the	   FUCCI	   (fluorescent	   ubiquitination-­‐based	   cell	   cycle	   indicator)	  
construct	   into	  Hmhi	  melanocytes	  would	   circumvent	   the	  DNA	   content	   problem	   as	   it	   allows	  
colour-­‐coded	   (red	   in	   G1,	   yellow/light	   green	   in	   S	   and	   green	   in	   G2/M)	   cell	   phase	  	  
determination	   319.	   With	   pRB	   and	   p53,	   two	   major	   pathways	   are	   usually	   causative	   for	   the	  
induction	   of	   senescence	   78.	   We	   found	   no	   difference	   in	   hyopohosphorylated,	   active	   RB	  
protein	  levels,	  but	  instead	  a	  marked	  decrease	  in	  the	  ratio	  of	  hyper-­‐	  to	  hypophosphorylated	  
pRB	  and	  minor	  differences	  for	  the	  overall	  amount	  of	  p53,	  when	  comparing	  senescing	  Hmhi	  
cells	  with	  non-­‐senescing	  Hmme	  and	  Hmlo	  melanocytes.	  In	  addition,	  we	  only	  observed	  a	  weak	  
increase	  of	  p16INK4A	  and	  p15INK4B	  and	  no	  consistent	  increase	  of	  ARF	  in	  senescent	  versus	  non-­‐
senescent	  cells.	  Notably,	   the	   loss	  of	  p16INK4A	  and	  ARF	  was	  reported	  to	  be	  a	  prerequisite	  of	  
most	   mouse	   melanocyte	   cell	   lines,	   including	   melan	   a	   81.	   However,	   these	   studies	   were	  
performed	  under	  standard	  growth	  conditions.	  We	  found	  melan	  a	  cells	   to	   lack	  p16INK4A	  and	  
ARF	   expression	   under	   standard	   culture	   conditions,	   but	   both	   proteins	   were	   expressed	   in	  
starved	  cells.	  Since	  we	  found	  no	  mutation	  in	  the	  Cdkn2a	  cDNA,	  we	  concluded	  that	  melan	  a	  
cells	  are	  capable	  of	  producing	  functional	  INK4A	  and	  ARF	  when	  stressed.	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For	  human	  cells,	  it	  has	  been	  shown	  that	  neither	  p16INK4A	  nor	  p14ARF	  were	  necessary	  to	  induce	  
senescence	  in	  human	  melanocytes	  upon	  N-­‐RASQ61K	  expression	  320.	  Besides,	  oncogenic	  Raf-­‐1	  
was	   shown	   to	   induce	   senescence	   in	   human	   mammary	   epithelial	   cells	   (HMEC),	   which	   is	  
independent	   of	   	   p16INK4A,	   p21Cip1,	   p14ARF,	   p27Kip1	   and	   p57Kip2	   321.	   One	   feature	   exclusively	  
observed	   in	   senescing	   Hmhi	   cells	   was	   the	   dramatic	   increase	   in	   protein	   levels	   of	   the	   DNA	  
damage	  markers	  P-­‐p53	  (Ser18)	  and	  P-­‐Chk2.	  Ser18-­‐phosphorylated	  p53	  is	  a	  target	  of	  ATR	  and	  
ATM	   kinases.	   Interestingly,	   p53	   stability	   remains	   unaffected	   in	   mice	   bearing	   a	   Ser18-­‐Ala	  
mutation	  thereby	  lacking	  phosphorylation	  of	  this	  residue	  322.	  Likewise,	  DNA	  damage-­‐induced	  
P-­‐p53	  (Ser15),	  the	  P-­‐p53	  (Ser18)	  equivalent	  in	  humans,	  leads	  to	  reduced	  interaction	  of	  p53	  
with	  its	  ubiquitin	   ligase	  MDM2	  both	   in	  vitro	  and	   in	  vivo	  323.	  These	  data	  are	  in	   line	  with	  our	  
observation	  that	  the	  protein	  levels	  of	  P-­‐Ser18-­‐p53	  do	  not	  parallel	  the	  overall	  amount	  of	  p53.	  
However,	   P-­‐Ser15-­‐p53	   augments	   p53-­‐mediated	   recruitment	   of	   CBP/p300	   resulting	   in	   an	  
increase	  in	  C-­‐terminal	  p53	  acetylation	  and	  enhanced	  target	  gene	  activation	  324.	  Thus,	  rather	  
than	  comparing	  total	  p53	  protein,	  we	  consider	  P-­‐Ser18-­‐p53	  levels	  to	  be	  the	  gauge	  of	  choice	  
as	  it	  nicely	  parallels	  the	  senescence	  extent	  in	  our	  melanocyte	  system.	  
Apart	  from	  the	  induction	  of	  DNA	  damage	  markers,	  we	  found	  ROS	  levels	  to	  correlate	  with	  the	  
senescence	   extent	   observed	   in	   Hm	   cells.	   Even	   though	   both	   premature	   and	   replicative	  
senescence	  have	  formerly	  been	  associated	  with	  increased	  ROS	  generation	  325–327,	  the	  origin	  
of	  oxidative	  stress	  observed	  upon	  oncogene	  activity	  remains	  a	  matter	  of	  extensive	  debate.	  
The	   GTPases	   and	   HERmrk	   downstream	   effectors	   RAC1	   and	   RAS	   65	   were	   reported	   to	   be	  
essential	   for	   the	   generation	   of	   ROS	   in	   various	   cell	   culture	   models	   328,329.	   We	   found	   the	  
treatment	  with	   the	  ROS	   scavenger	  NAC	   to	   limit	   the	   formation	   of	  multinuclear	   cells,	  while	  
enhancing	   the	   proliferation	   potential	   of	   Hmhi	   cells.	   Similar	   observations	   were	   made	   in	  
primary	   rat	   hepatocytes,	  where	   oxidative	   stress	   in	   presence	   of	   growth	   factors	   resulted	   in	  
polyploidy	   and	   decreased	   proliferation	   330.	   Furthermore,	   NAC	   treatment	   reversed	   H2O2-­‐
induced	  generation	  of	  polyploidy	  in	  human	  lymphoid	  cells	  331.	  
Apart	   from	  activation	  of	  HERmrk,	   a	  positive	   regulator	  of	   the	  RAS/RAF/MAPK	  pathway,	  we	  
determined	   oncogenic	   N-­‐RAS	   to	   resemble	   ROS	   generation	   followed	   by	   the	   occurrence	   of	  
multinuclear	   cells	   and	   SA-­‐β-­‐Gal	   activity	   when	   expressed	   in	   our	   melanocyte	   system.	  
Nonetheless,	   whether	   this	   phenotype	   is	   also	   expression	   level-­‐dependent	   has	   not	   been	  
determined	   in	   our	   system.	  However,	   tumours	   progressing	   to	   higher	   grades	   of	  malignancy	  
have	   been	   reported	   to	   increase	   RAS	   expression	   levels	   which	   in	   turn	   lead	   to	  	  
senescence	   295,332,333.	   Besides,	   RAS-­‐induced	   OIS	   has	   been	   attributed	   to	   either	   increased	  
oxygen	   levels	   328,334	  or	  exertion	  of	   the	  DNA	  damage	  response	  pathway	  due	  to	  DNA	  double	  
strand	   breaks	   235,335,	   both	   of	   which	   were	   also	   observed	   in	   our	   model	   system.	   Besides,	  
overexpression	  of	  MTH1,	  the	  cellular	  8-­‐oxodGTPase	  human	  MuT	  homolog	  1,	  suppressed	  H-­‐
RASV12-­‐induced	   senescence	   in	   BJ	   fibroblasts	   even	   though	   ROS	   levels	   were	   unaffected	  
compared	  to	  senescing	  control	  cells	  only	  expressing	  H-­‐RASV12.	  Further	  experiments	  revealed	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that	  MTH1	   overexpression	   conveyed	   its	   senescence-­‐protective	   effect	   through	   limiting	   the	  
RAS-­‐mediated	  DNA	  damage	  extent.	  Hence,	  the	  guanine	  nucleotide	  pool	  was	  suggested	  to	  be	  
a	  critical	  target	  for	  oncogenic	  RAS-­‐induced	  ROS	  336.	  Another	  way	  to	  counteract	  RAS-­‐induced	  
senescence	   is	   to	   diminish	   ROS	   directly.	   RAS	   signalling	   was	   shown	   to	   activate	   superoxide	  
radical-­‐generating	   NADPH	   oxidases	   337	   including	   NOX4	   338.	   The	   H-­‐RASV12-­‐mediated	  
senescence	  response	  of	  non-­‐tumoural	  thyroid	  cells	  could	  be	  limited	  by	  siRNA-­‐knockdown	  of	  
NOX4	   338.	   Furthermore,	   cells	   cultured	   in	   low	  oxygen	   conditions	   or	   in	   presence	  of	   the	  ROS	  
scavenger	  NAC	  did	  not	  undergo	  RAS-­‐mediated	  senescence	  244.	  Hence,	  in	  summary,	  our	  data	  
provide	   evidence	   that	   oncogenic	   RAS-­‐induced	   senescence	   in	   melanocytes	   relies	   on	   the	  
generation	  of	  ROS	  followed	  by	  DNA	  damage.	  
Taken	   together,	   we	   established	   a	   model,	   which	   mimics	   the	   multinuclear	   phenotype	   of	  
human	  nevus	  cells	  in	  vitro	  by	  overexpressing	  a	  powerful	  melanoma	  oncogene,	  namely	  either	  
HERmrk	  or	  N-­‐RAS61K.	  As	  we	  proved	   for	   the	  HERmrk	  model,	   senescence	   induction	  relied	  on	  
oncogene-­‐dependent	  ROS	  generation,	  concomitant	  DNA	  damage	  and	  increased	  p53	  activity.	  
Our	  data	   for	   the	   first	   time	  adduce	  a	   connection	  between	  oxidative	   stress,	  multinucleation	  
and	  senescence	  in	  melanocytes.	  
Intriguingly,	   I	   found	   the	   tumour	   marker	   Survivin	   to	   be	   exclusively	   up-­‐regulated	   in	   the	  
senescing	  melanocyte	  cell	  line	  Hmhi,	  whereas	  no	  Survivin	  expression	  could	  be	  detected	  in	  the	  
non-­‐senescing,	   proliferating	   and	   more	   tumourigenic	   clones	   Hmme	   and	   Hmlo.	   This	   up-­‐
regulation	   in	   mRNA	   was	   paralleled	   by	   an	   increase	   in	   survivin	   protein	   in	   EGF-­‐treated,	  
multinuclear	  Hmhi	  melanocytes.	  In	  addition,	  Survivin	  mRNA	  expression	  appeared	  to	  correlate	  
with	   the	   proportion	   of	   multinuclear	   cells	   as	   levels	   went	   down	   upon	   NAC	   treatment.	  
Interestingly,	   shRNA	   knockdown	   of	   Survivin	   expression	  was	   not	   followed	   by	   the	   expected	  
decrease	  in	  survivin	  protein,	  but	  instead	  resulted	  in	  an	  increased	  survivin	  level	  even	  though	  
multinuclear	   melanocytes	   were	   observed	   when	   cells	   were	   cultured	   in	   complete	  medium.	  
The	  occurrence	  of	  multinuclear	  cells	  upon	  Survivin	  knockdown	  was	  not	  surprising	  as	  survivin	  
enables	   correct	   cytokinesis	   222,224	  and	   its	  ablation	  was	   shown	   to	   result	   in	  polyploidy	   224,226,	  
while	  survivin	  expression	   is	   thought	   to	  play	  a	   role	   in	  endomitosis	   225.	   It	  might	  well	  be	   that	  
shRNA	  knockdown	  of	  Survivin	  initially	  resulted	  in	  multinucleated	  Hmhi	  cells,	  while	  activating	  
counter-­‐regulatory	   feedback	  mechanisms.	   Another	   explanation	   could	   be	   a	   stabilization	   of	  
remaining	   survivin	   protein.	   Taken	   together,	   at	   first	   sight	   it	   seems	   contradictory	   that	   the	  
prognostic	  tumour	  marker	  Survivin,	  which	  is	  associated	  with	  poor	  prognosis	  in	  several	  cancer	  
types	   including	   melanoma	   339–341,	   is	   highly	   expressed	   in	   our	   senescent	   melanocytes.	  
However,	  survivin	  might	  play	  an	  important	  role	  in	  the	  budding	  of	  tiny,	  tumourigenic	  and	  de-­‐
differentiated	   cells	   from	   multinucleated	   Hmhi	   cells.	   Unfortunately,	   I	   did	   not	   have	   the	  
opportunity	  to	  investigate	  this	  possibility.	  
Even	  though	  I	  could	  not	  identify	  the	  molecular	  mediator	  crucial	  for	  senescence	  induction	  in	  
our	   melanocyte	   system,	   two	   protective	   setups,	   namely	   MYC	   overexpression	   and	   Miz-­‐1	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knockdown,	   were	   validated.	   In	   addition	   to	   antioxidants	   such	   as	   N-­‐acetylcysteine,	   I	   found	  
both	  MYC	  overexpression	  and	  Miz-­‐1	  knockdown	  to	  diminish	  ROS	  levels,	  multinucleation	  and	  
senescence	   in	   Hmhi	   cells,	   while	   enhancing	   their	   tumourigenic	   potential	   and	   proliferation	  
capacity.	  Notably,	  all	  three	  MYC	  overexpression	  constructs	  (MYC-­‐wt,	  MYC-­‐VD	  and	  MYC-­‐TA)	  
were	   capable	   of	   suppressing	   HERmrk-­‐induced	   senescence	   of	   Hmhi	   cells	   while	   conveying	  
tumourigenicity,	   but	   the	   effects	  were	  most	   impressive	   for	   the	  more	   stable	  MYC-­‐TA	   form.	  
This	   is	  not	   surprising	  as	  MYC	   is	   an	  unstable	  protein	  with	  a	  half-­‐life	  of	  only	  20-­‐30	  minutes,	  
which	   has	   been	   reported	   to	   be	   stabilized	   in	   several	   tumour	   types	   including	   Burkitt´s	  
lymphoma	   342.	   Interestingly,	   even	   though	   MYC	   overexpression	   slightly	   enhanced	  
proliferation	  in	  starved	  Hmhi	  cells,	  MYC´s	  impact	  became	  much	  more	  obvious	  when	  HERmrk	  
was	  active	   in	  presence	  of	   EGF.	  Besides,	   the	  dramatic	   increase	   in	   soft	   agar	   growth	  of	  Hmhi	  
cells	   upon	  MYC	   overexpression	   exclusively	   occurred	   in	   presence	   of	   EGF.	   Hence,	   our	   data	  
provide	  compelling	  evidence	  that	  MYC	  and	  HERmrk	  act	  synergistically.	  These	  findings	  are	  in	  
accordance	   with	   the	   observation	   that	   MYC	   expression	   suppresses	   RAS-­‐	   and	   RAF-­‐induced	  
senescence	   in	   melanoma	   cells	   159.	   Besides,	   MYC´s	   potential	   to	   de-­‐differentiate	   cells	   and	  
increase	  their	  proliferation	  capacity	  becomes	  evident	  when	  used	  for	  generating	  pluripotent	  
cells	   from	   fully	   differentiated	   adult	   fibroblasts	   314.	   The	   expression	   of	   four	   transcription	  
factors,	   namely	  MYC	   together	  with	  Oct3/4,	   Sox2	   and	   Klf4	   reprograms	   differentiated	   adult	  
fibroblasts	   back	   to	   a	   pluripotent	   state	   314.	   The	   resulting	   induced	   pluripotent	   stem	   cells	  
(iPSCs)	  resemble	  embryonic	  stem	  cells.	  Further	  analyses	  showed	  that	  three	  of	  these	  genes,	  
Oct4,	   Sox2,	   and	   Klf4,	   are	   critical	   to	   the	   reprogramming	   process,	   but	   MYC	   enhances	   the	  
reprogramming	  efficiency	  343–345.	  	  
In	  addition,	  MYC	  also	  regulates	  several	  microRNAs	  346,347.	  MYC	  primes	  breast	  cancer	  cells	  for	  
epithelial-­‐mesenchymal	  transition	  (EMT)	  and	  stimulates	  angiogenesis	  by	  inducing	  miR-­‐9	  348.	  
Moreover,	   MYC	   represses	   the	   expression	   of	   miR23a	   and	   miR23b	   allowing	   for	   enhanced	  
glutaminase	   expression	   in	   lymphoma	   and	   prostate	   cancer	   cells	   349.	   Glutaminase	   converts	  
glutamine	  to	  glutamate,	  which	  also	  serves	  as	  substrate	  for	  the	  synthesis	  of	  the	  antioxidant	  
glutathione	  350.	  
Hence,	  bearing	  all	  these	  MYC	  features	  in	  mind,	  it	  is	  not	  surprising	  that	  MYC	  is	  deregulated	  in	  
the	   vast	  majority	   of	   human	   cancers	   351,352.	   Notably,	  MYC	   suppression	   induces	   senescence	  
and	  tumour	  regression	   in	  several	   tumour	  types	   including	   lymphoma	  154,	  osteosarcoma	  and	  
hepatocellular	   carcinoma	   353,354.	   Besides,	   several	   years	   ago	   MYC	   overexpression	   was	  
demonstrated	   to	   be	   prevalent	   in	   both	   primary	   and	   secondary	   malignant	   melanoma	   and	  
hence	  suggested	  to	  be	  a	  prognostic	  marker	  355.	  More	  importantly,	  MYC	  knockdown	  in	  human	  
BRAFV600E	  and	  N-­‐RASQ61R	  melanoma	  lines	  sensitized	  cells	  for	  oncogene-­‐induced	  senescence,	  
while	   MYC	   overexpression	   suppressed	   OIS	   induction	   in	   melanocytes	   159.	   Interestingly,	  
senescence	   suppression	   was	  more	   efficient	   in	   a	   BRAFV600E	   background	   than	   in	   N-­‐RASQ61R-­‐
expressing	  melanocytes	  159.	  This	  finding	  might	  explain	  why	  MYC	  overexpression	  diminished	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senescence	   in	   Hmhi	   cells	   and	   only	   limited	   the	   senescence	   extent	   in	   N-­‐RAS61Q-­‐expressing	  
melan	   a	   cells.	   In	   addition,	   down-­‐regulation	   of	   MYC	   forced	   M14	   melanoma	   cells	   into	  
senescence	  and	   cellular	   crisis	   157.	   Interestingly,	   cells	  were	  not	  only	  enlarged	  and	  SA-­‐β-­‐Gal-­‐
positive,	   but	   also	   contained	  multiple	   nuclei,	   while	   an	   increase	   in	   reactive	   oxygen	   species	  
accompanied	  by	  glutathione	  depletion	  was	  observed	   157.	  Besides,	   concurrent	   treatment	  of	  
those	  M14	  melanoma	  cells	  that	  were	  manipulated	  to	  express	  reduced	  levels	  of	  MYC	  with	  the	  
ROS	  scavenger	  NAC	  (N-­‐acteyl-­‐cysteine)	  suppressed	  the	  growth	  arrest	  157.	  These	  data	  nicely	  
go	   along	   with	   our	   findings	   that	  MYC	   overexpression	   diminished	   the	   presence	   of	   reactive	  
oxygen	  species	  in	  EGF-­‐treated	  Hmhi	  cells.	  Hence,	  these	  data	  suggest	  MYC	  to	  counteract	  the	  
intrinsic	  ROS	   levels,	  which	  are	   likely	   to	  be	  an	   important	  player	   in	   senescence	   induction	  of	  
melanocytes	   and	  melanoma	   cells.	   In	   this	   context,	   the	   allocation	   of	   cysteine	   seems	   to	   be	  
crucial	   for	   ROS	   suppression.	   In	   accordance	   with	   this	   finding,	   our	   microarray	   analysis	  
identified	   a	   novel	   MYC	   target	   gene,	   CTH,	   which	   allows	   cysteine	   production	   via	   the	  
transsulfuration	   pathway	   269.	   Cysteine	   is	   therefore	   required	   to	   synthesize	   cellular	   redox-­‐
controlling	  molecules	  like	  glutathione	  and	  taurine	  270.	  
Intriguingly,	  MYC	  expression	  not	  only	  facilitates	  cells	  to	  overcome	  senescence,	  but	  can	  also	  
induce	  senescence.	   In	  absence	  of	  cyclin-­‐dependent	  kinase	  2	   (Cdk2)	   long-­‐term	  activation	  of	  
MYC	  led	  to	  senescence	  in	  mouse	  embryo	  fibroblasts	  356.	  Similarly,	  MYC	  overexpression	  upon	  
depletion	  of	  WRN,	  the	  Werner	  Syndrome	  and	  DNA	  repair	  gene,	  in	  human	  fibroblasts	  rapidly	  
induced	  senescence	  357.	  	  
Thus,	  in	  a	  nutshell,	  MYC	  is	  on	  the	  one	  hand	  capable	  of	  exerting	  the	  senescence	  programme	  
in	   a	   defined	   genetic	   background,	   but	   on	   the	   other	   hand	   suppresses	   oncogene-­‐induced	  
senescence	  in	  various	  cell	  lines	  and	  tumour	  types.	  The	  MYC-­‐mediated	  OIS	  suppression	  in	  our	  
model	   system	   is	   likely	   to	  be	  at	   least	  partly	  mediated	  by	   increased	  CTH	  expression	   thereby	  
allowing	   for	   increased	  detoxification	  of	   intracellular	  stress.	  Furthermore,	  MYC	  and	  HERmrk	  
act	  synergistically	  since	  both	  the	  proliferation	  potential	  and	  the	  in	  vitro	  tumourigenicity	  were	  
greatly	   enhanced	   when	   both	   oncogenes	   were	   active.	   Likewise,	   MYC	   expression	   limited	  
senescence	  and	  led	  to	  an	  increased	  proliferation	  capacity	  in	  N-­‐RAS*-­‐expressing	  melanocytes.	  
Apart	   from	   MYC	   overexpression,	   we	   also	   found	   Miz-­‐1	   knockdown	   to	   diminish	   HERmrk-­‐
mediated	   ROS	   levels,	   DNA	   damage	   and	   senescence,	   while	   enhancing	   the	   proliferation	  
potential	   and	   in	   vitro	   tumourigenicity,	   but	   to	   a	   lesser	   extent	   than	   MYC	   overexpression.	  
Similarly,	  Miz-­‐1	  knockdown	  limited	  the	  senescence	  extent	  and	  enhanced	  proliferation	  in	  N-­‐
RAS*-­‐expressing	   melanocytes.	   When	   cells	   are	   stressed,	   MYC	   binds	   to	   Miz-­‐1	   thereby	  
preventing	  induction	  of	  Miz-­‐1	  target	  genes	  like	  p15INK4B	  or	  p21	  141.	  Besides,	  only	  when	  MYC	  
permanently	  represses	  Miz-­‐1,	  lymphoma	  cells	  can	  be	  kept	  from	  undergoing	  TGFβ-­‐mediated	  
senescence	   358.	   Surprisingly,	  we	   found	   neither	   p15INK4B	   nor	   p21	   protein	   levels	   to	   correlate	  
with	   senescence	   suppression	   in	   Hmhi	   cells	   upon	  Miz-­‐1	   knockdown.	   However,	   microarray	  
analysis	   also	   revealed	   Hmhi-­‐pS-­‐Miz-­‐1	   melanocytes	   to	   express	   slightly	   elevated	   Cth	   levels,	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suggesting	   that	   the	   senescence-­‐protective	   effect	   upon	   Miz-­‐1	   knockdown	   also	   relies	   on	  
enhanced	  ROS	  detoxification,	  probably	  via	  CTH.	  	  
The	  majority	   of	   cellular	   antioxidant	   systems,	   including	   GSH	   and	   taurine,	   require	   cysteine.	  
Under	   normal	   conditions,	  most	   cells	   are	   able	   to	   accommodate	   their	   need	   for	   cysteine	   by	  
importing	  extracellular	  cystine	   359.	  Cells	  with	  particularly	  high	  ROS	   loads,	  e.g.	   tumour	  cells,	  
additionally	   rely	   on	   the	   CTH-­‐dependent	   transsulfuration	   pathway	   for	   the	   biosynthesis	   of	  
cysteine	  from	  methionine	  270.	  However,	  increased	  H2S,	  a	  byproduct	  generated	  in	  a	  cysteine-­‐
degrading	   step	   also	   mediated	   by	   CTH,	   	   allows	   for	   antiproliferative	   effects	   when	   CTH	   is	  
overexpressed	   360,361.	   Besides,	   CTH	   has	   been	   associated	   with	   tumour-­‐protective	   activities	  
since	   mutations	   decreasing	   CTH	   activity	   have	   been	   reported	   to	   cause	   cystathioninuria,	  
hypercystathioninemia	  and	  increased	  risk	  of	  developing	  atherosclerosis	  and	  bladder	  cancer	  
362.	  Moreover,	  treatment	  of	  gastric	  cancer	  cells	  with	  the	  H2S	  donor	  and	  potential	  anti-­‐cancer	  
agent	  S-­‐propargyl-­‐cysteine	  suppressed	  proliferation	  and	  migration	  and	  reduced	  the	  tumour	  
volume	  in	  nude	  mice.	  These	  phenomena	  could	  be	  attributed	  to	  enhanced	  CTH	  expression	  as	  
concomitant	   treatment	  with	   the	   CTH	   inhibitor	   PAG	   reversed	   the	   effects	   363.	   Nevertheless,	  
due	  to	  its	  cysteine-­‐generating	  properties,	  only	  low	  CTH	  levels	  are	  detected	  in	  normal	  tissue,	  
whereas	   expression	   is	   elevated	   in	   tumours	  
(http://www.proteinatlas.org/ENSG00000116761).	  However,	  information	  on	  CTH	  regulation	  
in	   tumours	   is	   scarce.	  Notably,	   the	   	   pro-­‐tumourigenic	   functions	  of	  CTH	  are	   associated	  with	  
high	   glutathione	   levels,	   which	   have	   been	   connected	   to	   different	   tumour	   types	   including	  
melanoma	   364–368.	  Moreover,	   CTH	  expression	  was	   found	   to	  be	   vital	   for	   cancer	   cell	   survival	  
since	   glutathione	   depletion	   in	   glioma	   cells	   up-­‐regulated	   CTH	   369	   and	   so	   did	   butyrate	  
expression	   in	   colon	   cancer	   cells	   370,	   but	   the	   responsible	   transcription	   factors	   remain	  
unidentified.	  Besides,	  our	  studies	  identified	  the	  first	  tumour-­‐associated	  transcription	  factors,	  
namely	  MYC	  and	  MIZ-­‐1,	  which	  regulate	  CTH	  expression.	  Furthermore,	  the	  finding	  that	  CTH	  
overexpression	  diminished	  HERmrk-­‐induced	  senescence	  and	  enhanced	  proliferation	  in	  Hmhi	  
cells	  suggests	  a	  possible	  role	  for	  CTH	  in	  senescence	  evasion.	  Additionally,	  together	  with	  the	  
enhanced	   proliferation	   potential,	   the	   loss	   of	   pigmentation	   in	   melan	   a	   cells	   upon	   CTH	  
overexpression	  points	  to	  a	  possible	  dedifferentiation,	  which	  might	  go	  along	  with	  an	  increase	  
in	  tumourigenicity.	  However,	  further	  experiments	  are	  necessary	  to	  test	  this	  hypothesis.	  
Interestingly,	  deregulation	  of	  CTH	  expression	  seems	  to	  have	   little	  effect	  on	  developmental	  
processes.	   Cth-­‐/-­‐	   mice	   show	   normal	   development	   and	   only	   suffer	   from	   hypertension	   in	  
adulthood	   371.	  Moreover,	   the	   inhibitory	  mechanisms	   of	   DL-­‐propargylglycine	   (PAG)	   on	   CTH	  
function	  is	  well-­‐documented	  372,373.	  H2S	  produced	  by	  CTH	  causes	  cardiovascular	  and	  nervous	  
system-­‐related	   diseases	   in	   mice,	   the	   symptoms	   of	   which	   are	   efficiently	   relieved	   applying	  	  
PAG	   374.	   Nonetheless,	   due	   to	   PAG´s	   limited	   membrane	   permeability,	   designing	   improved	  
inhibitors	  should	  be	  considered.	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Taken	  together,	  we	  identified	  CTH	  as	  a	  novel	  MYC/MIZ-­‐1	  target	  gene,	  and	  thus	  provide	  the	  
first	  direct	  link	  between	  tumour-­‐associated	  transcription	  factors	  and	  CTH.	  Furthermore,	  our	  
experiments	  proved	  that	  CTH	  is	  important	  for	  intracellular	  stress	  reduction,	  a	  vital	  feature	  of	  
tumour	   cells.	   Hence,	   it	   is	   safe	   to	   attribute	   CTH	   the	   role	   of	   a	   possible	   player	   in	   the	  
demonstrated	  senescence-­‐protective	  effects	  upon	  MYC	  overexpression	  or	  Miz-­‐1	  knockdown	  
in	  Hmhi	  cells.	  	  
Even	   though	   oncogene-­‐induced	   senescence	   is	   considered	   a	   major	   barrier	   in	   cancer	  
progression,	   we	   were	   surprised	   to	   find	   Hmhi	   cells	   senesce	   while	   Hmlo	   and	   Hmme	   cells	  
proliferated	   considering	   that	   high	   Xmrk	   expression	   levels	   are	   related	   to	   highly	   malignant	  
melanoma	  in	  fish,	  while	  low	  Xmrk	  levels	  cause	  pigment	  spots	  and	  minor	  tumours	  278.	  
Likewise,	   expression	   of	   oncogenic	   RAS	   in	   mice	   resulted	   in	   stimulated	   proliferation	   and	  
mammary	  hyperplasia	  when	  H-­‐RASV12	  levels	  were	  low,	  while	  high	  RAS	  activity	  induced	  ARF-­‐
p16INK4A-­‐independent	   senescence	   295.	   Thus,	   a	   three	   step	  model	   for	   RAS-­‐mediated	   tumour	  
development	   was	   proposed:	   (1)	   an	   activating	   RAS	   mutation,	   (2)	   RAS	   overexpression	   (3)	  
senescence	  evasion	   295.	  Occasionally	  melanomas	  develop	   from	  pre-­‐existing	  nevi	   composed	  
of	   senescent	   melanocytes	   375,376.	   However,	   information	   on	   senescence	   evasion	   on	   the	  
cellular	  level	  is	  lacking.	  	  
I	  could	  show	  that	  sustained	  oncogene	  expression	  of	  either	  N-­‐RAS*	  or	  HERmrk	  initially	  leads	  
to	   OIS	   induction	   followed	   by	   the	   generation	   of	   nest-­‐like	   colonies.	   Similar	   structures	   have	  
previously	   been	   described	   to	   occur	   six	   weeks	   upon	   carcinogenic	   exposure	   of	   non-­‐
tumourigenic	  C3H10T1/2	  mouse	  embryo	  cells	  with	  polycyclic	  hydrocarbons	  377.	  Notably,	  the	  
small	  cells	  were	  only	  observed	  once	  the	  cell	  culture	  had	  reached	  confluency.	  The	  generation	  
of	  clones	  isolated	  from	  these	  nests	  followed	  by	  inoculation	  led	  to	  late	  tumour	  formation	  in	  
immunocompromised	  mice	  377.	  However,	  only	  50-­‐80%	  of	  mice	  showed	  tumours,	  which	  were	  
observed	   after	   2-­‐6	   months	   upon	   inoculation	   377.	   These	   findings	   are	   in	   line	   with	   our	  
observations,	   but	   in	   our	   system	   N-­‐RAS*-­‐AR	   cells	   were	   highly	   tumourigenic	   and	   formed	  
aggressive	  tumours	  at	  every	  single	  injection	  site	  within	  only	  one	  week	  post	  inoculation.	  Since	  
the	   origin	   of	   the	   tumourigenic	   cells	   remained	   unclear	   377	  with	   a	  minimum	  of	   13	   passages	  
upon	  carcinogenic	  treatment	  claimed	  to	  be	  necessary	  prior	  to	  neosis	  378,	  Sundaram	  et	  al	  took	  
out	   to	   perform	   time-­‐lapse	   imaging	   379.	   They	   found	   irradiated	   and	   carcinogen-­‐treated	  
C3H10T1/2	   mouse	   embryo	   fibroblasts	   to	   become	   multinucleated	   before	   tiny,	  
mononucleated	  cells,	  capable	  of	  dividing,	  were	  generated,	  presumably	  from	  multinucleated	  
mother	  cells.	  The	  mother	  cells	  were	  claimed	  to	  die	  due	  to	  mitotic	  crisis	  379.	  In	  addition,	  giant	  
p53-­‐/-­‐	   mouse	   embryonic	   fibroblasts	   and	   human	   metastatic	   neuroblastoma-­‐derived	   HTB11	  
have	   been	   shown	   to	   develop	   tiny	   daughter	   cells	   either	   spontaneously	   or	   after	   carcinogen	  
treatment,	   respectively	   379.	   Even	   though	   the	   tiny	   daughter	   cells	   look	   similar	   to	   those	  
observed	  in	  N-­‐RAS*	  and	  HERmrk-­‐expressing	  melanocytes	  upon	  long-­‐term	  oncogenic	  stress,	  
the	  actual	  budding	  process	  was	  discussed,	  but	  not	  shown.	  Thanks	  to	  nuclear	  and	  cytoplasmic	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fluorescent	  labelling,	  our	  time-­‐lapse	  analyses	  revealed	  multinucleated	  N-­‐RAS*	  and	  Hmhi	  cells	  
to	  bud	  off	  tiny,	  mononucleated	  cells,	  which	  undergo	  mitosis	  while	  the	  mother	  cells	  survived.	  
Notably,	   a	   large	   proportion	   of	  multinucleated	  melanocytes	   had	   undergone	   senescence	   by	  
that	   time.	   In	   addition,	   microarray	   analyses	   demonstrated	   N-­‐RAS*-­‐AR	   cells	   to	   differ	   from	  
multinucleated	  N-­‐RAS*	   cells	   in	   their	   gene	   expression	   profile.	   Even	   though	   Sundaram	  et	   al	  
found	   differences	   in	   autoradiograms	   of	   RT-­‐PCR-­‐differential	   display	   analyses	   comparing	  
untreated	  C3H10T1/2	  cells	   to	  etoposide-­‐treated	  and	  neotic	   counterparts,	  gene	  names	  and	  
further	   studies	   are	   lacking	   379.	   Our	   microarray	   data,	   however,	   proved	   N-­‐RAS*-­‐AR	   cells	   to	  
have	   largely	   lost	   melanocyte	   differentiation	   markers,	   which	   had	   been	   induced	   during	  
senescence	  initiation.	  Mitf	  was	  the	  only	  typical	  marker	  for	  mature	  melanocytes	  still	  found	  to	  
be	   expressed	   at	   reasonable	   levels	   in	   N-­‐RAS*-­‐AR	   cells.	   Interestingly,	   MITF	   is	   not	   only	  
important	   for	   melanocyte	   proliferation	   and	   survival,	   but	   is	   also	   sustained	   in	   human	  
melanoma	  380.	  Nevertheless,	  in	  accordance	  with	  the	  gene	  expression	  signature	  of	  N-­‐RAS*-­‐AR	  
cells,	  highly	   invasive	  melanoma	  cells	  have	  been	  shown	  to	  express	   lower	   levels	  of	   the	  MITF	  
target	   genes	  Tyrp1,	  Mlana	   and	  Dct.	   These	   cells	   as	  well	   as	   N-­‐RAS*-­‐AR	   cells	   rather	   express	  
members	  of	   the	  Wnt	  pathway	  as	  well	  as	  certain	  matrix	   components	   56.	  More	   importantly,	  
inhibition	  of	  Mitf	  not	  only	  increased	  the	  tumourigenic	  potential	  of	  melanoma	  cells,	  but	  also	  
up-­‐regulated	  the	  stem	  cell	  markers	  Oct4	  and	  Nanog	  381.	  This	  finding	  supports	  the	  increased	  
stem	  cell	  marker	  expression	  including	  Nanog	  on	  both	  mRNA	  and	  protein	  levels	  observed	  for	  
Hmhi-­‐AR	   as	   well	   as	   N-­‐RAS*-­‐AR	   clones.	   Furthermore,	   both	   Hmhi-­‐AR	   and	   N-­‐RAS*-­‐AR	   cells	  
exhibited	   a	   significantly	   higher	   nuclear/cytoplasmic	   ratio	   than	   Hmhi	   and	   N-­‐RAS*	   cells,	  
respectively.	  High	  nuclear/cytoplasmic	  are	  a	  hallmark	  of	  stem	  cells	   284–286	  and	  a	  prominent	  
feature	   of	   aggressive	   tumour	   cells	   281–283.	   Cells	   in	   malignant	   tumours	   usually	   have	   a	  
nuclear/cytoplasmic	  ratio	  of	  about	  0.5,	  whereas	  cells	  in	  benign	  lesions	  bear	  a	  close	  to	  normal	  
ratio	  of	   0.17	   283.	   The	   ratios	  observed	   for	  Hmhi-­‐AR	  and	  N-­‐RAS*-­‐AR	   cells	  were	  0.35	   and	  1.2,	  
respectively,	   going	   along	  with	   the	   trend	  observed	   for	   cells	  with	  enhanced	   tumourigenicity	  
and	  de-­‐differentiation	  potential.	  Notably,	  3D	  volume	  analyses	  of	  stem	  cell	  compartments	  to	  
determine	  the	  nuclear/cytoplasmic	  ratio	  are	  lacking	  and	  figures	  referring	  to	  the	  ratio	  often	  
only	  show	  2D	  images	  285,382,	  which	  is	  unfit	  to	  exactly	  and	  reliably	  determine	  the	  ratio	  284,383.	  
Concurrent	   with	   the	   decrease	   of	   melanocyte	   differentiation	   markers	   and	   the	   increase	   in	  
some	  pluripotency-­‐associated	  genes,	  several	  neuronal	  markers	  were	   induced	  in	  N-­‐RAS*-­‐AR	  
cells.	   Since	   melanocytes	   originate	   from	   the	   neural	   crest	   lineage,	   this	   change	   in	   gene	  
expression	   points	   to	   a	   de-­‐differentiation	   process,	   which	   might	   accompany	   N-­‐RAS*-­‐AR	  
generation.	  Intriguingly,	  human	  melanoma	  cells	  have	  also	  been	  associated	  with	  neuronally-­‐
expressed	   genes	   47,384.	   In	   addition,	   melanoma	   cells	   often	   express	   high	   levels	   of	   meiosis-­‐
related	  genes	  and	  are	  susceptible	   to	  meiomitosis,	  an	  abnormal	  cell	  division	  through	  which	  
cancer	   daughter	   cells	   inherit	   partially	   expressed	   meiotic	   machinery	   upon	   mitosis	   385.	   The	  
budding	   observed	   in	   N-­‐RAS*-­‐AR	   cells	   bears	   resemblance	   to	   the	   asymmetric	   division	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described	   to	   occur	   in	   tetra-­‐	   or	   polyploid	   tumour	   cells.	   In	   a	   process	   termed	  
depolyploidisation,	  aneuploid	  cancer	  cells	  give	  rise	  to	  para-­‐diploid	  cells	  in	  order	  to	  re-­‐enter	  a	  
normal	  cell	   cycle.	  Depolyploidisation	  allows	   the	  cells	   to	   limit	   the	   risk	  of	  accumulating	  DNA	  
damage,	  which	  might	  otherwise	  result	   in	  cell	  death	  386,387.	  A	  shared	  phenomenon	  between	  
cells	   undergoing	   depolyploidisation	   and	   N-­‐RAS*-­‐AR	   cells	   is	   the	   up-­‐regulation	   of	   meiotic	  
genes	  such	  as	  Spo11,	  which	  is	  associated	  with	  depolyploidisation	  387–389.	  Apart	  from	  Spo11,	  
depolyploidisation	  has	  been	  linked	  to	  re-­‐expression	  of	  additional	  meiosis-­‐related	  genes	  and	  
the	  clonogenic	  re-­‐growth	  of	  tumour	  cells	  after	  genotoxic	  treatment	  388,390.	  In	  addition,	  these	  
tumour	   cells	   were	   found	   to	   up-­‐regulate	   the	   key	   self-­‐renewal	   transcription	   factors	   OCT4,	  
NANOG	  and	  SOX2	  391.	  Interestingly,	  ploidy	  has	  been	  reported	  to	  be	  a	  valuable	  parameter	  in	  
the	   assessment	   of	   cancers	   and	   for	   the	   majority	   of	   tumours	   aneuploidy	   was	   found	   to	  
correlate	   with	   further-­‐progressed	   tumour	   stage	   and	   poor	   prognosis	   184,185,392.	   Besides,	  
mounting	   evidence	   suggests	   that	   polyploid	   cells	   are	   genetically	   unstable	   and	   can	   act	   as	  
intermediates	  on	   the	   road	   to	  aneuploidy	  and,	  ultimately,	   cancer	   178,181.	   Further	   supporting	  
this	   argument,	   genes	   involved	   in	   maintaining	   chromosome	   stability	   are	   frequently	  
deregulated	  in	  human	  tumours	  186.	  	  
Multinucleated	   so-­‐called	   “starburst	   cells”	   were	   also	   found	   in	   the	   vast	   majority	   of	   lentigo	  
maligna	   patient	   samples	   393.	   This	  melanoma	   type	   has	   been	   causally	   linked	   to	   chronic	   sun	  
exposure	  394,395.	  This	  observation	  points	  to	  a	  connection	  between	  UV-­‐induced	  DNA	  damage	  
and	   the	   generation	   of	   starburst	   cells.	   Furthermore,	   not	   only	   melanoma	   samples	   exhibit	  
polyploid	   cells,	   but	   multinuclear	   melanocytes	   are	   also	   found	   in	   premalignant	   nevi	   396,397.	  
Notably,	  even	  though	  the	  majority	  of	  melanomas	  arises	  de	  novo,	  malignant	  lesions	  can	  also	  
emerge	   from	   nevi	   398–402.	   Multinuclear	   cells	   are	   also	   found	   in	   other	   cancer	   types,	   e.g.	   in	  
malignant	  mammary	   cancers.	  Here,	   only	   tetraploid	   p53-­‐/-­‐	  mouse	  mammary	   epithelial	   cells	  
induced	  malignant	   tumours	   in	   nude	  mice,	   whereas	   their	   diploid	   counterparts	   did	   not	   199.	  
Interestingly,	   a	   small	   fraction	   of	   tetraploid	   human	   IMR90	   fibroblasts	   started	   to	   re-­‐express	  
Nanog	  and	  Oct4	  together	  with	  DNA	  damage	  and	  senescence	  markers	  before	  some	  of	  them	  
became	   octaploid	   and	   even	   divided	   prior	   to	   undergoing	   replicative	   senescence	   403.	   In	  
addition,	  PROb	  rat	  colon	  carcinoma	  cells,	  which	  had	  adopted	  apolyploid	  and	  multinucleated	  
senescence-­‐like	  phenotype	  upon	  cisplatin	  treatment,	  have	  been	  observed	  to	  give	  rise	  to	  tiny,	  
diploid,	   rapidly	   dividing	   and	   colony-­‐forming	   cells	   404.	   Notably,	   both	   the	   appearance	   and	  
endoreplication	   process	   generating	   the	   multinuclear	   cells	   described	   here	   as	   well	   as	   the	  
features	  of	  the	  tiny,	  emerging	  cells	  404	  strongly	  resemble	  the	  emergence	  of	  N-­‐RAS*-­‐AR	  and	  
Hmhi-­‐AR	  cells.	  However,	  experiments	  to	  scrutinize	  the	  gene	  and	  protein	  expression	  patterns	  
and	   verify	   the	   origin	   of	   PROb-­‐derived	   AR	   cells	   are	   lacking.	   Nevertheless,	   the	   high	  
proliferation	   potential	   of	   PROb-­‐AR	   cells	   is	   in	   line	   with	   that	   of	   N-­‐RAS*-­‐AR	   cells,	   which	  
emphasizes	   their	   tumourigenic	   features.	   Our	   N-­‐RAS*-­‐AR	   microarray	   analysis	   revealed	   an	  
induction	  of	   proliferation-­‐associated	   genes	   such	  as	   the	   growth	   factors	  Kitl,	  Vegfa,	  Btc	   and	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Areg	   and	   growth	   factor	   receptors	   like	   Pdgfra	   or	   Flt1as	   well	   as	   molecules	   involved	   in	  
transmitting	  growth-­‐promoting	  signals	  e.g.	  Ptgs2	  or	  Fabp4.	  In	  addition,	  we	  found	  N-­‐RAS*-­‐AR	  
cells	  to	  proliferate	  very	  well	  under	  all	  tested	  culture	  conditions.	  Neither	  did	  N-­‐RAS*-­‐AR	  cells	  
require	   the	   growth	   stimulus	   of	   TPA,	   nor	   normal	   FCS.	   More	   importantly,	   N-­‐RAS*-­‐AR	   cells	  
proliferated	   equally	   well	   in	   absence	   and	   presence	   of	   doxycycline	   and	   formed	   aggressive,	  
metastasizing	   tumours	   in	   absence	   of	   Dox	   in	   nude	  mice.	   Hence,	   N-­‐RAS*-­‐AR	   cells	   have	   lost	  
their	   oncogene	   addiction.	   Besides,	   time-­‐lapse	   imaging	   of	   longterm-­‐activated	   N-­‐RAS*	   cells	  
clearly	   demonstrated	   the	   budding	   of	   N-­‐RAS*-­‐AR	   cells	   from	   multinucleated	   N-­‐RAS*	   cells	  
frequently	   followed	  by	   subsequent	  mitosis	  of	  N-­‐RAS*-­‐AR	  cells.	  Apart	   from	  HERmrk	  and	  N-­‐
RAS*	   in	   melan	   a	   mouse	   melanocytes,	   I	   also	   found	   N-­‐RAS*	   expression	   in	   primary	   human	  
NHEM	   melanocytes	   to	   induce	   the	   generation	   of	   giant,	   binuclear	   cells.	   In	   addition,	   the	  
occurrence	   of	   bi-­‐nucleated	   NHEM-­‐N-­‐RAS*	   cells	   was	   also	   followed	   by	   the	   emergence	   of	  
three-­‐dimensional	  cell	  nests	  made	  up	  of	   tiny	  cells	   that	  appeared	  to	  proliferate	  rapidly	  and	  
generated	   floating	   cell	   rafts.	   These	  NHEM-­‐N-­‐RAS*-­‐AR	   raft	   cells	   could	   be	   sub-­‐cultured	   and	  
cells	  showed	  no	  sign	  of	  senescence.	  Notably,	  the	  mono-­‐nucleated,	  untransfected	  NHEM	  cells	  
remaining	   on	   the	   dish	   either	   arrested	   or	   died.	   To	   my	   knowledge,	   binuclear	   cells	  
accompanied	  by	   the	  emergence	  of	  highly	  proliferative	  offspring,	  have	  not	  been	  previously	  
reported	   for	   NHEM	   cells,	   even	   though	   B-­‐RAFV600E	   expression	   was	   found	   to	   induce	   OIS	   in	  
primary	  human	  melanocytes	  233,405–407.	  Hence,	  the	  budding	  of	  tiny,	  de-­‐differentiated,	  highly-­‐
proliferative	   and	  aggressive	   tumour	   cells	   from	  bi-­‐	   or	  multinucleated	   cells	   is	   likely	   to	  occur	  
not	  only	  in	  murine,	  but	  also	  in	  human	  melanocytes.	  Nevertheless,	  further	  experiments	  need	  
to	  be	  performed	  to	  verify	  this	  assumption.	  	  	  
Summarizing	   our	   data,	  which	   could	   be	   underpinned	   by	   a	   diversity	   of	   findings	   from	   fellow	  
researchers,	   we	   suggest	   the	   following	   model	   for	   oncogene-­‐induced,	   ROS-­‐dependent	  
senescence	  in	  melanocytes	  (Figure	  78):	  Aberrant	  oncogene	  signalling,	  in	  our	  case	  caused	  by	  
HERmrk	  or	  N-­‐RAS*,	  leads	  to	  enhanced	  levels	  of	  reactive	  oxygen	  species	  (ROS),	  which	  in	  turn	  
results	  in	  the	  accumulation	  of	  DNA	  damage	  as	  detected	  by	  an	  induction	  of	  P-­‐Chk2	  and	  P-­‐p53.	  
Melanocytes	  eventually	  become	  enlarged,	  multinucleated	  and	  SA-­‐β-­‐Gal-­‐positive.	  Concurrent	  
N-­‐acetylcysteine	   (NAC)	   treatment	  of	  EGF-­‐stimulated	  Hmhi	   cells	   limited	  both	  ROS	   levels	  and	  
senescence	   extent.	   Besides,	   MYC	   overexpression	   and	   Miz-­‐1	   knockdown	   diminished	   the	  
senescence	   extent	   in	   Hmhi	   and	   limited	   that	   of	   melan	   a-­‐N-­‐RAS*	   cells,	   respectively,	   while	  
enhancing	  the	  proliferation	  potential	  of	  both	  cell	   lines.	  Microarray	  analyses	  suggested	  CTH	  
induction	  to	  be	  a	  factor	  involved	  in	  senescence	  prevention.	  This	  idea	  could	  be	  verified	  since	  
CTH	  overexpression	  diminished	  the	  senescence	  extent	  in	  EGF-­‐treated	  Hmhi	  cells.	  Moreover,	  
senescence	  appears	  not	  to	  be	  inert,	  because	  multinucleated	  Hmhi	  and	  N-­‐RAS*	  melanocytes	  
budded	   off	   tiny,	  mononuclear	   cells,	  which	  were	   de-­‐differentiated,	   anoikis-­‐resistant,	   highly	  
proliferative	  and	  induced	  early-­‐metastasizing	  tumours	  in	  nude	  mice.	  Most	  likely,	  this	  finding	  
is	   not	   restricted	   to	   murine	   melanocytes.	   Hence,	   our	   model	   might	   match	   melanoma	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development	  from	  pre-­‐existing	  senescent	  melanocytes	  and	  could	  possibly	  also	  hold	  true	   in	  
other	  senescence	  models.	  
 
Figure	  78:	  Proposed	  model	  for	  ROS-­‐dependent	  oncogene-­‐induced	  senescence	  in	  melanocytes	  	  
Prolonged	  HERmrk	   or	  N-­‐RAS*	   expression	   in	  mouse	  melanocytes	   led	   to	   enhanced	  ROS	   levels	   and	   concurrent	  
DNA	   damage,	   both	   of	  which	   could	   be	   limited	   by	   NAC	   treatment	   and	   diminished	   by	  MYC	   overexpression	   or	  	  
Miz-­‐1	   knockdown.	   Notably,	   CTH	   overexpression	   is	   likely	   to	   be	   a	   mediator	   for	   senescence	   suppression.	   The	  
appearance	   of	   enlarged,	   multinucleated,	   senescent	   cells	   was	   followed	   by	   budding	   of	   tiny,	   mononucleated,	  
highly	  proliferative,	  de-­‐differentiated,	  anoikis-­‐resistant	  and	  tumourigenic	  cells.	  The	  appearance	  of	  similar	  cells	  
was	  also	  observed	  upon	  N-­‐RAS*	  expression	  in	  human	  NHEM	  melanocytes.	  
The	   notion	   that	   induction	   of	   senescence	   is	   a	   prerequisite	   for	   tumour	   development	   seems	  
paradoxical	  at	  first.	  However,	  several	  reports	  underpin	  our	  data.	  Mice	  expressing	  oncogenic	  
RAS	   in	   their	   lungs	   develop	   malignant	   adenocarcinomas	   from	   benign	   and	   senescent	  
adenomas	  408.	  In	  addition,	  p53	  expression	  was	  found	  to	  correlate	  with	  previous	  UV	  exposure	  
and	   invasion	   status	   of	   human	   melanoma	   395.	   With	   p53	   being	   an	   important	   senescence	  
mediator,	  this	  finding	  might	  point	  to	  a	  possible	  re-­‐activation	  of	  the	  senescence	  programme	  
in	   melanoma.	   Most	   importantly,	   we	   identified	   multinuclear,	   polyploid	   cells	   frequently	  
observed	   in	  cancer	  as	   the	  source	  of	   the	  malignant	  offspring.	  Besides,	   senescent	  cells	  have	  
been	   implicated	   in	   promoting	   cancer	   by	   secreting	   factors	   associated	   with	   senescence	  
induction,	   inflammation	  (e.g.	   the	  chemokines	   IL-­‐6	  and	   IL-­‐8)	  and	  tumour	  development.	  This	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so-­‐called	  senescence-­‐associated	  phenotype	  (SASP)	  not	  only	  occurs	  in	  cultured	  cells,	  but	  also	  
in	   vivo	   upon	   DNA-­‐damage,	   e.g.	   chemotherapy	   4,409,410.	   The	   factors	   secreted	   by	   senescent	  
cells	  include	  chemokines	  including	  the	  CXC	  family	  members	  usually	  involved	  in	  inflammation	  
response	  signalling.	  CXCL-­‐8	  (also	  termed	  interleukin	  8,	  IL-­‐8)	  expression	  has	  been	  associated	  
with	   enhanced	   migration,	   angiogenesis	   and	   tumour	   growth	   in	   melanoma	   and	   other	  
malignancies	  411–415.	  Besides,	  CXCL-­‐8	  expression	  has	  been	  shown	  to	  positively	  correlate	  with	  
melanoma	  progression	   416,417.	   Intriguingly,	   the	  expression	  of	   either	  CXCL-­‐8	  or	   its	   receptors	  
CXCR1	  and	  CXCR2	  has	  been	  associated	  with	  melanoma	  aggressiveness	   418.	   In	  addition,	   the	  
observation	   that	   knocking	   down	   the	   chemokine	   receptor	   CXCR2	   in	   primary	   human	  
fibroblasts	   diminishes	   the	   DNA	   damage	   response	   and	   senescence	   extent	   419,	   while	   CXCR1	  
and	  CXCR2	  overexpression	  boosts	  the	  tumourigenic	  potential	  of	  human	  melanoma	  cells	  420	  
further	  supports	  the	  dual	  role	  of	  SASP	  in	  senescence	  and	  cancer	  progression.	  	  
Intriguingly,	   even	   though	   chemotherapy	   frequently	   induces	   complete	   tumour	   regression,	  
relapses	  months	  or	  years	  upon	  treatment	  are	  common	  and	  observed	  in	  more	  than	  half	  of	  all	  
advanced	   cervical	   cancer	   patients	   421.	  Moreover,	  DNA	  damaging	   agents	   applied	   in	   tumour	  
therapy	   either	   induce	   apoptosis	   or	   limit	   cancer	   cell	   proliferation	   via	   senescence	   induction	  
422–425	   or	   drive	   cells	   into	   aberrant	   mitosis	   termed	   mitotic	   catastrophe	   426–428.	   More	  
importantly,	  tumours	  formed	  upon	  inoculation	  of	  rat	  colon	  carcinoma	  cells	  in	  syngeneic	  rats	  
regressed	  within	  ten	  days	  in	  response	  to	  short-­‐term	  cisplatin	  treatment,	  but	  tumour	  growth	  
resumed	   three	   weeks	   later.	   Intriguingly,	   regressed	   tumours	   displayed	   enlarged,	   SA-­‐β-­‐Gal-­‐
positive	  cells,	  whereas	  relapse	  malignancies	  contained	  an	  abundance	  of	  small,	  cohesive,	  SA-­‐
β-­‐Gal-­‐negative	  cells	  404.	  	  
Taken	  together,	  even	  though	  senescence	  is	  considered	  a	  major	  barrier	  to	  tumour	  induction	  
and	  has	  been	  proposed	   to	  be	  a	   favourable	  approach	   for	   the	  development	  of	  novel	   cancer	  
therapeutics	  in	  general	  429	  and	  in	  melanoma	  in	  particular	  430,	  our	  data	  prove	  that	  oncogene-­‐
induced,	  multinuclear,	  senescent	  melanocytes	  are	  not	  inert,	  but	  provide	  a	  source	  for	  highly	  
malignant	   progeny.	   These	   daughter	   cells	   are	   characterized	   by	   a	   de-­‐differentiated,	  
proliferation-­‐promoting	  gene	  expression	  pattern	  and	  an	  increased	  nuclear/cytoplasmic	  ratio	  
accompanied	  by	  re-­‐established	  NANOG	  protein	  levels.	  Intriguingly,	  the	  anoikis-­‐resistant	  cells	  
exhibit	   rapid,	  excessive	  tumour	  growth	  and	  metastasis	   in	  nude	  mice.	  Thus,	  chemotherapy-­‐
induced	  polyploidy	  and	  senescence	  might	   lead	  to	  the	  emergence	  of	  a	  tumour	  that	   is	  more	  




For	   decades,	   senescence	   has	   been	   considered	   to	   be	   a	   potent	   barrier	   against	   tumour	  
progression.	   The	   fact	   that	   cancer	   cells	   have	  maintained	   the	   ability	   to	   senesce	   in	   vivo	   has	  
raised	   hope	   for	   novel	   cytostatic	   drugs.	   Temozolomide	   (TMZ),	   a	   DNA-­‐alkylating	   agent	   and	  
chemotherapeutic	  drug	  used	  to	  fight	  metastatic	  melanoma	  with	  a	  response	  rate	  of	  only	  10-­‐
20%,	   induces	   a	   p21CIP1-­‐mediated	  G2/M	  arrest	   accompanied	  by	   senescence-­‐like	   features	   in	  
some	  melanoma	  cells	  431.	  Besides,	  a	  subset	  of	  human	  melanoma	  cell	  lines	  bearing	  activating	  
BRAF	   or	   N-­‐RAS	   mutations	   also	   adopt	   senescence-­‐like	   phenotypes	   in	   response	   to	   the	  
diterpene	  ester	  and	  anti-­‐cancer	  agent	  PEP005	  432.	  Treatment	  with	  PEP005	  induces	  SA-­‐β-­‐Gal	  
reactivity,	   Rb	   activation,	   p21CIP1	   up-­‐regulation	   and	   induction	   of	   an	   irreversible	   G2/M	   cell	  
cycle	   arrest	   in	   a	  MAPK-­‐dependent	  manner	   432.	  Moreover,	   researchers	   and	   companies	   are	  
screening	  for	  more	  senescence-­‐inducing	  agents	  using	  various	  melanoma	  cell	   lines,	  because	  
they	  consider	  senescence	  induction	  as	  the	  future	  melanoma	  therapy	  of	  choice.	  However,	  our	  
data	  strongly	  argue	  against	  this	  idea.	  Even	  though	  senescence	  induction	  seems	  favourable	  at	  
first	   sight,	   our	   observations	   of	   de-­‐differentiated,	   highly	   tumourigenic	   and	   anoikis-­‐resistant	  
cells	   generated	   from	   senescent	   ones	   might	   be	   a	   possible	   and	   noteworthy	   side-­‐effect.	  
Furthermore,	   recent	   observations	   have	   demonstrated	   that,	   although	   growth	   stopped,	  
senescent	   cells	   display	   secretory	   capacity	   known	   as	   the	   senescence-­‐associated	   secretory	  
phenotype	   (SASP).	   The	   SASP	   comprises	  metalloprotease	   (MMP1,	  MMP3	   or	  MMP10),	   pro-­‐
inflammatory	  chemokines	  (CXCL2,	  IL6,	  IL8	  and	  TGF-­‐β)	  and	  growth	  factors	  (GROα,	  HGF,	  VEGF)	  
with	   auto-­‐	   and	   paracrine	   effects,	   which	   might	   favour	   tumourigenesis	   in	   nearby	   non-­‐
senescent	  cells	   433,434.	  Whether	  senescent	  melanoma	  cells	  develop	  a	  SASP	   is	  still	  unknown.	  
Nevertheless,	   one	   should	   also	   consider	   the	  high	   level	   of	   heterogeneity	   in	  melanomas	   and	  
the	  micro-­‐environments	   of	   the	   tumours,	   both	   of	   which	   influence	   the	   features	   of	   tumour	  
cells.	  In	  addition,	  in	  all	  studies	  mentioned,	  the	  senescence	  arrest	  has	  only	  been	  investigated	  
over	   a	   one	   or	   two-­‐week	   period.	   Thus,	   it	   remains	   unclear,	   whether	   this	   growth	   arrest	   is	  
irreversible.	   Furthermore,	   the	   causal	   role	   and	   requirement	   of	   most	   of	   the	   biomarkers	  
investigated	   in	   senescence	   induction	   remains	   to	   be	   elucidated	   in	   greater	   detail.	   The	  
senescence-­‐related	  data	  collected	  over	  the	  last	  decades	  suggest	  the	  existence	  of	  a	  complex	  
and	  overlapping	   regulatory	  network	  of	   senescence-­‐inducing	   stimuli.	  Thus,	   it	   remains	   to	  be	  
elucidated	   how	   the	   senescence	   programmes	   induced	   by	   modulation	   of	   these	   factors	   are	  
connected.	  Taken	  together,	  future	  insights	  gained	  from	  the	  molecular	  events	  of	  senescence	  
induction	  and	   follow-­‐up	  events	   in	  melanocytes	  and	  melanoma	  cells	  might	  help	  us	   identify	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